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Abstract 
Malaria causes around 2 million deaths per year, and the mortality appears to 
be rising. A prophylactic vaccination is urgently needed. A viral vectored vaccination 
regimen has been developed in Oxford to induce T cell responses reactive to pre-
erythrocytic antigens of Plasmodium Jalciparum malaria. I conducted a series of 
studies to evaluate the clinical outcome and immunological response to the vaccine. I 
analysed peR data from experimental sporozoite challenge studies in the UK, and 
showed that vaccination reduced the numbers of parasites completing their pre-
erythrocytic development. I conducted preliminary studies to explore the safety and 
immunogenicity of vaccination in adults and then children in Kilifi, Kenya. 
Antigen insert, multiple versus single priming, different batches of vaccine (in 
one instance) and pre-vaccination immunity influenced the reactogenicity and 
immunogenicity of vaccination. Enhanced memory responses were seen with novel 
alternating vector regimens. 
Having established immunogenicity, safety, and preliminary evidence of 
efficacy, I then conducted a large efficacy trial in the field, randomizing 406 children 
to either active vaccination or control. The primary outcome was time to first episode 
of febrile malaria. Although the regimen was immunogenic, the magnitude of T cell 
responses was lower than in previous studies. 346 children were vaccinated according 
to protocol. Episodes of febrile malaria were more frequent in the FFM ME-TRAP 
group (52/171 vs 401175 among controls), but this was not statistically significant 
(95% confidence interval 0.83 to 2.08, P=0.55 by logrank). Among children 
vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity 
and malaria incidence. 
v 
I examined factors in the cohort of children that may have influenced 
immunogenicity. Malaria was more immunosuppressive than other parasitic 
infections, and is therefore the factor most likely to impact the development of 
investigational T cell inducing vaccines in malaria endemic areas. 
vi 
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1 Introduction 
The worldwide mortality and morbidity from Plasmodium Jalciparum malaria is 
high, and has risen over the last 20 years (Hay et al. 2004; Snow et al. 1999; Snow et al. 
2005). There is evidence that Insecticide Treated Nets (Lengeler 2004) and newer anti-
malarials (White & Olliaro 1998) might reduce this mortality, but these are not yet 
adequately implemented (White et al. 2004) and it seems unlikely that these measures 
alone will halt the rising mortality of the disease. It has been argued that a malaria 
vaccine is required in order to bring about a lasting improvement in public health (Malkin 
et al. 2006). 
1.1 Vaccine Development. 
The traditional approach to vaccines development was to attenuate or inactivate 
the organism or toxin against which immunity is desired. Although irradiated sporozoites 
generate protective immunity in humans, this is laborious and does not currently appear 
to be feasible on a large scale (Herrington et al. 1991; Hoffman et al. 2002). 
Molecular technology allows cloned falciparum antigens and epitopes to be manufactured 
on a large scale, and delivered by a variety of vectors; as particulate protein with 
adjuvant, recombinant bacteria, recombinant viruses or as naked DNA (Moore & Hill 
2004). This approach has resulted in licensed vaccines to Hepatitis B and A (Peetermans 
1992; Peetermans 1987) and Streptococcus pneumoniae (Eskola et al. 2001). 
Vaccines designed to protect against Plasmodium Jalciparum malaria can be divided into 
3 main groups, according to which life cycle stage the chosen antigen is derived. This 
thesis concerns an approach to generate immunity against the pre-erythrocytic stage. 
Other approaches attempt to generate blood stage immunity, or transmission blocking 
immunity designed to prevent gametocytes from infecting mosquitoes. 
The sequenced malaria genome offers a large choice of antigens for inclusion in a 
candidate malaria vaccine (Gardner et a1. 2002). The choice of antigen is influenced by 
expression, the degree of antigenic variation in field isolates, and data from field studies 
suggesting that responses directed against it are protective in the field, and recent 
advances in proteomics might facilitate rational choices of antigens (Hall et al. 2005). 
Exposure necessarily correlates with the immunological responses measured and with 
protection against malaria, perhaps as a consequence of a number of protective responses 
(Marsh & Kinyanjui 2006). This means that observational studies are difficult to 
interpret, since exposure is a confounding factor. 
Having selected an antigen, animal models are generally used to measure 
immunogenicity and protection against infective challenge. This allows the vector 
delivery and vaccination regimen to be optimised. Animal studies are often poorly 
predictive of human responses, and given that the correlates of natural immunity in the 
field are not clearly understood (Marsh & Kinyanjui 2006), a safe challenge model for 
human subjects is highly desirable. Exposure of human volunteers to mosquito bites 
infective for Plasmodium Jalciparum consistently results in infection in non-immune 
volunteers, and is safe when carried out under strict clinical supervision (Herrington et a1. 
1988). This allows valuable preliminary evidence of efficacy in studies of small numbers 
of volunteers in countries that are not endemic for malaria. 
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1.2 Blood Stage Vaccines 
Blood stage parasitisation IS associated with clinical disease and chronic 
parasitisation of the host. Early studies in monkeys with Plasmodium knowlesi 
demonstrated antibody dependent protection against challenge with malaria (Mitchell et 
al. 1974). Most approaches to replicate immunity in humans use merozoite antigens. 
Antibody responses to MSP -1 (merozoite surface protein 1), MSP-2, MSP-3 and AMA-l 
(apical membrane antigen 1) have been associated with protection in field studies 
(Cavanagh et al. 2004; Polley et al. 2006; Polley et al. 2004; Polley et al. 2007). Vaccines 
based on all these antigens are in clinical development. 
The "Combination B" vaccine combined MSP-l, MSP-2 and a third antigen, RESA 
(ring-stage erythrocyte surface antigen). Partial efficacy was observed in a fall in parasite 
density. However, there was no reduction in the frequency of episodes of malaria after 
vaccination. (Genton et al. 2002) 
A fragment of the MSP-l antigen, MSP-l 42, has been formulated with a novel 
lipid adjuvant (AS02). This formulation appears to be safe and immunogenic, but a recent 
field trial has not demonstrated efficacy (Stoute et al. 2007). The AMA-l antigen has also 
been the subject of Phase 1 trials, but efficacy trials in the field have not been conducted. 
MSP-3 has been developed as a long synthetic peptide (Druilhe P 2002). 
Vaccination raises antibodies which interact with monocytes in an in vitro assay, and sera 
from vaccinated volunteers inhibits the growth of parasites in vitro (Druilhe et al. 2005). 
However, in vivo efficacy data is still lacking. 
3 
Schizont derived antigens that are expressed on the surface of red blood cells, and 
so accessible to host immunity, are typically very polymorphic, and so difficult targets for 
vaccination. However, a vaccination approach targeting the Glutamate Rich Protein 
(GLURP) using synthetic peptides is in phase 1 trials (Sauerwein R 2002), and sera from 
vaccinated volunteers also inhibits parasite growth in vitro. 
None of these approaches have been associated with efficacy against experimental 
or natrurally acquired malaria in human volunteers. It has been argued that sporozoite 
challenge is not appropriate in the clinical development of blood stage vaccines, since 
efficacy in the field might be seen at higher parasitaemias despite absence of efficacy in 
experimental infection. However, given the large number of vaccines now in 
development, it seems highly desirable to select the most promising candidate vaccines 
prior to large field trials. 
1.3 Sexual stage vaccines. 
Transmission blocking vaccines aim to elicit an antibody response capable of 
neutralizing the oocyst stage in the mosquito. Unusually, this vaccination would not 
benefit the individual, but would prevent transmission to others. Proof of principal has 
been achieved in vitro and in animal models (Stowers et al. 2000), and Phase 1 trials in 
human volunteers are underway. 
4 
1.4 Pre-erythrocytic vaccines. 
1.4.1 SPj66 
This synthetic vaccme, derived from the sequences of the circumsporozoite 
protein and 2 other blood stage proteins, has been the subject of 4 randomized trials in 
Africa, and 5 outside. In metanalysis, efficacy against clinical infection was not 
demonstrable in Africa (OR 0.96, CI 0.81 to 1.14) (Graves & Gelband 2003). Limited 
protection was demonstrable outside Africa (OR 0.77, CI 0.67 to 0.88). The vaccine is 
unlikely to be the subject of further large field trials. 
1.4.2 Circumsporozoite protein 
The circumsporozite protein is a logical choice of antigen, since it is present on 
the surface of sporozoites (Nussenzweig & Nussenzweig 1985), and therefore a target for 
antibody mediated immunity, as well as highly expressed during intracellular hepatocytic 
development (and so a target for T cell mediated immunity), and has conserved antibody 
and T cell epitopes (Aidoo et al. 1995). The circumsporozoite protein contains a 
conserved N terminal section, a central region with NANP repeats and a C terminal 
section with a relatively conserved region, and a highly polymorphic region, divided into 
the TH2R and TH3 R sections. 
Individuals in malaria endemic areas acqUIre antibody responses to the 
circumsporozoite protein, but these do not appear to be protective (Nussenzweig & 
Nussenzweig 1985). However, studies in mice (Egan et al. 1987) confirmed that some 
degree of protection could be induced by antibody responses to the circumsporozoite 
protein. Studies in humans showed that a synthetic peptide of the NANP repeat was 
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immunogenic, and when the highest responders were exposed to infective mosquito bites, 
some limited protection was seen (Herrington et al. 1987). 
1.4.3 Thrombospondin Related Adhesion Peptide 
TRAP is the second most abundant pre-erythrocytic protein (Robson et al. 1988). 
Although it has an important role in hepatocyte invasion, the molecule is not accessible to 
antibody mediated immunity at the sporozoite stage (John et al. 2005). However, it is 
highly expressed during intra-hepatocytic development, and so is accessible to T cell 
mediated immunity (Robson et al. 1995). The molecule consists of a small extra-cellular 
domain, with adhesive modules. Naturally acquired T cell responses are distributed along 
the length of the molecule, and single nucleotide polymorphisms are distributed along the 
length of the molecule (Flanagan et al. 1999). 
1.4.4 RTS,S 
Greater efficacy has been obtained with a formulation of the circumsporozoite 
antigen called RTS,S. RTS,S contains the carboxyl terminal (a.a. 207-395) of the 307 
circumsporozoite protein fused to the hepatitis B surface antigen, co-expressed in yeast 
with the non-fused hepatitis B surface antigen. The co-expression with hepatitis B surface 
antigen results in particle formation, and this strategy is designed to enhance the 
immunogenicity of the vaccine. Adjuvants were used to enhance immunogenicity further, 
and novel adjuvants were found to be more immunogenic than alum (Gordon et al. 1995). 
Most studies in humans have used the proprietary adjuvant AS02. This is an oil-in-water 
emulsion containing the two immunostimulants QS21 and MPL, following relatively 
small studies to compare alternative formulations of the adjuvant (Stoute et al. 1997). A 
subsequent field trial was conducted in The Gambia, using asymptomatic parasitaemia in 
6 
adults as a marker of efficacy. (Bojang et al. 2001) 71 % protection against infection was 
observed in the first 2 months (although this did not persist beyond 2 months), and this 
has encouraged further studies in children. 30% efficacy against disease has been 
demonstrated in 1 to 4 year old children in Mozambique. This was originally documented 
during the first 6 months of follow up (Alonso et al. 2004), but now efficacy has been 
seen up until 18 months (Alonso et al. 2005). 
1.4.5 Other pre-erythrocytic vaccinations. 
A protein particulate vaccine was prepared comprising CS repeats expressed with 
the hepatitis B core protein, given with the adjuvant Montanide (Birkett et al. 2002), but 
this vaccine did not protect volunteers in infective challenge studies (Walther et al. 
2005a). 
1.5 Why T cells Inducing Vaccinations in Malaria? 
The HLA-B*53 allele was associated with protection against severe malaria in a 
large case-control study of Gambian children, suggesting a role for CD8 positive T cells 
(Hill et al. 1991). It was subsequently confirmed that T cells are induced by natural 
-infection. Adults in endemic areas develop HLA-B*53 restricted T cells recognising a 
conserved nonamer peptide from liver-stage antigen-l (Hill et al. 1992), and a peptide-
based approach using allele-specific motifs identified fourteen other class I epitopes in six 
pre-erythrocytic P. Jalciparum antigens (Hill 1999). 
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1.5.1 Cultured and Ex vivo ELISpots. 
The Ex vivo ELI Spot assay is well established as a measure of vaccine immunology 
(Scheibenbogen et al. 2000). This assay enumerates cells producing interferon gamma 
after overnight stimulation with antigen. However, other older assays used a period of 
culture with antigen (or cytokines) before measuring cytotoxic activity (Jerome et al. 
2003) or proliferation (Harrop et al. 2004), and a culture step using antigen and Il-2 can 
similarly be used before conducting an ELI Spot assay. This is referred to as the "cultured 
ELISpot". These two assays do not correlate with each other (Flanagan et al. 2001) in 
individuals naturally exposed to malaria. Further, although the numbers of immediate 
effector T cells responsive to pre-erythrocytic antigen did not correlate with protection 
against mild malaria in children in Kilifi (Flanagan et al. 2003), cultured ELISpots 
correlated with protection against natural infection in semi-immune adults (Reece et al. 
2004). 
Persistent responses are documented to influenza peptides in the absence of recent 
exposure (Scheibenbogen et al. 2000). However, after vaccination ex vivo responses are 
not necessarily persistent (McConkey et al. 2003). However, responses identified by the 
cultured ELlS pot appear to be persistent, and the long term cultured response is 
proportional to the initial ex'vivo response (Keating et al. 2005). These durable responses 
were called memory responses. Memory was originally used to describe the protection 
afforded by vaccination or previous infection, but has since been used as a term to 
describe secondary antibody or T cell responses (Zinkernagel & Hengartner 2006). 
Further descriptions of memory T cells have been in terms of markers, homing patterns 
and proliferative capacity, allowing a division into central and effector memory (Sallusto 
et al. 1999). Limited evidence suggests that central memory cells are detected in the 
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cultured ELISpot assay (Godkin et al. 2002). Since these cells are persistent, and require 
culture in order to be detected, I have used the term "resting memory" in this thesis. 
1.6 T cells in Animal Models 
1.6.1 Sporozoite immunization 
Multiple immunizations of both mIce and human volunteers with irradiated 
sporozoites induce sterilizing immunity. Immunity does not correlate with antibody titres 
against sporozoites, and is not generated by sporozoites that are incapable of invading 
hepatocytes because of over-irradiation (Herrington et al. 1991). In mice, T cell clones 
from irradiated sporozoite immunized mice transfer protective immunity to live 
sporozoite challenge (Mellouk et al. 1990). These clones recognized circumsporozoite 
protein derived peptides on infected hepatocytes leading to cell lysis and parasite death 
(Weiss et al. 1990). Furthermore, gene knock out mouse experiments demonstrated that 
protection is dependent on interferon gamma production (Doolan & Hoffman 1997). 
1.6.2 Sub-unit vaccinations: DNA 
Preparing large numbers of irradiated sporozoites is laborious, and it would be 
impractical to deliver them in the field. Further pre-clinical development of sub-unit T 
cell inducing vaccines was conducted in mice. Mice can be infected with the malaria 
species Plasmodium berghei and Plasmodium yoelii, for pre-clinical testing of the 
efficacy of vaccinations. The BALB/c and C57BLl6 strains of mice have been most 
commonly used. These mice recognise a pre-erythrocytic malaria epitope (Pb9) from the 
circumsporozoite protein (CSP). Early studies of T cell inducing vaccines used DNA 
expressing Plasmodium yoelii CSP (Sedegah et al. 1994). Only limited protection was 
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achieved in the mouse model, and DNA alone is poorly immunogenic in humans (Wang 
et al. 2001). Although the route, method and schedule of DNA administration has been 
varied (Leitner et al. 1997), it has not been possible to obtain consistent protection with 
DNA vaccinations alone. 
1.6.3 Sub-unit vaccinations: Poxviruses 
Poxviruses can be made recombinant for malaria antigen (Satchidanandam et al. 
1991). They are not effective when used alone, but are effective when used after other 
vectors. In the mouse model, vaccinia virus recombinant for the circumsporozoite antigen 
was found to be highly effective in protecting against malaria in combination with a 
recombinant influenza virus vector (Li et al. 1993). The order of vaccination was 
important. Vaccinia successfully boosted after priming with influenza virus vaccinations, 
but regimens that primed with vaccinia were not successfully boosted by influenza 
vaccination. Vaccinia is quite reactogenic in humans (Casey et al. 2005), but prime-boost 
vaccinations using naked DNA encoding the TRAP antigen to prime and an attenuated 
vaccinia virus to boost (modified vaccinia virus Ankara) achieved complete protection 
against malaria challenge (Schneider et al. 1998). Again, the sequence of vaccination was 
critical, since MV A alone or followed by DNA was not protective. A second pox virus, 
the attenuated fowlpox strain FP9, can also be used as a priming vector. In mouse studies, 
sequential immunization with FP9 and recombinant modified vaccinia virus Ankara 
(MV A) recombinant for malaria antigen was more immunogenic and protective than 
DNA/MV A prime boost immunization (Anderson et al. 2004). Better protection was not 
achieved by sequential (triple) immunization with a DNA vaccine, FP9, and MVA. 
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It is unclear why heterologous prime-boost vaccination should be so highly 
effective, in contrast to homologous repeated immunisations using viral vectors. It is 
suggested that the more strongly immunogenic virus, such as MV A, induces a strong 
immunological response to the vector rather than recombinant antigen when given alone. 
However, when a modest, but specific expansion of T cells reactive to the recombinant 
antigen has recently been achieved by a priming vaccination, these T cells have a 
selective advantage, and are preferentially expanded by the boosting vaccination (Moore 
& Hill 2004). Further pre-clinical studies confirmed that sequential DNA then MV A 
vaccinations were immunogenic (although not protective) in Pan troglodytes 
chimpanzees (Schneider et al. 2001) and sequential DNA then NYVAC vaccinations 
(another attenuated vaccinia virus vector) were protective in rhesus macaques (Rogers et 
al. 2002). Most pre-clinical development had concerned the pre-erythrocytic antigens, 
thrombospondin related adhesion protein (TRAP, (Robson et al. 1988)) and the 
circumsporozoite protein (CS). Both are well characterised antigens, and protection was 
seen with vaccination regimens based on either antigen. 
1.7 T cell Inducing Vaccinations in Human volunteers 
These recombinant vectors were then used to vaccinate human volunteers with a 
common pre-erythrocytic antigen construct, ME-TRAP, comprising multiple pre-
erythrocytic stage epitopes (ME) and the whole pre-erythrocytic stage antigen 
Thrombospondin Related Adhesion Protein (TRAP). TRAP was chosen, rather than the 
circum sporozoite antigen, since it appears to be less polymorphic (Flanagan et al. 1999), 
as well as being abundantly expressed by pre-erythrocytic parasites (Robson et al. 1988). 
The string of multiple epitopes was defined by reverse immunogenetics (selecting 
epitopes based on HLA binding) (Gilbert et al. 1997). Multiple DNA priming followed 
11 
by intradermal MV A boosting (i.e. heterologous prime-boost vaccination) induced 10-
fold higher T cell responses than previously achieved with homologous immunisations. 
Partial protection against experimental malaria was seen as a 2 day delay in time to 
parasitaemia after experimental malaria sporozoite challenge in a non-endemic area 
(McConkey et al. 2003). The regimen DNA ME-TRAP followed by boosting with MV A 
ME-TRAP was then subjected to Phase I and II trials in The Gambia. 300 semi-immune 
adults were immunised and followed weekly for asymptomatic parasitaemia. The 
vaccination was safe, immunogenic, but not significantly protective (Moorthy et al. 
2004b). 
Since the protection in mice was greater from FP9 primed regimens compared 
with DNA primed regimens, 17 volunteers were immunized with two sequential FP9 
immunizations followed by MV A once. This was equally immunogenic, but more 
protective (Webster et al. 2005). Two volunteers were completely protected after 
sporozoite challenge in Oxford, and the overall delay to parasitaemia was 2.5 days 
(p=0.32 for comparison with DNNMV A combinations, p=0.0022 with unvaccinated 
controls). One of these two volunteers was protected on re-challenge at 6 months and 20 
months. As in the mouse model, sequential priming with DNA then FP9 before using 
MV A did not improve protection. 
1.7.1 Modified Vaccinia Ankara (MVA) 
MV A is much safer than vaccinia because it fails to replicate in vivo. During the 
smallpox eradication campaign vaccinia administration was associated with significant 
side effects. The most comprehensi"ve data come from a 10 state survey of the USA in 
1968: there were 2.8 cases per million of post-vaccinia encephalitis, 0.9 cases of 
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progressive vaCCInIa, 10.4 cases of eczema vaccinatum, 23.4 cases of generalised 
vaccinia and 25.4 cases of accidental infection per million primary vaccinations with non-
attenuated vaccinia (Gurvich 1992). In an attempt to reduce these side effects several 
attenuated strains of vaccinia were developed. The most widely used of these was MV A, 
derived by multiple serial passage of vaccinia strain Ankara through chick embryo 
fibroblasts. MV A caused no serious side effects when given by intramuscular, 
subcutaneous and intradermal routes to 120,000 individuals in southern Germany and 
Turkey (Mayr et al. 1978). MV A was safe when administered to neonatal mice by 
intracerebral and intraperitoneal routes, and did not disseminate . . In mIce 
immunosuppressed by irradiation (Mayr et al. 1985). It appears to be attenuated as a 
consequence of genetic deletions, with a unique cytokine receptor profile (Blanchard et 
al. 1998). 
The safety data acquired during 100 immunisations with prime boost regimes in healthy 
volunteers in Oxford and over 200 immunisations with MV A in The Gambia has been 
favourable (Moorthy et al. 2004a; Moorthy et al. 2004b; Moorthy et al. 2003b; Webster et 
al. 2005). Local reactions occurred in 70% of subjects, limited to discolouration, 
blistering and itching, typically resolving over one week. 25% had a mild flu-like illness 
for not more than 24 hours after the first dose of MV A. Stocks of MV A encoding ME-
TRAP are produced to GMP standard by Impfstoffwerk Dessau-Tomau, Roslau, 
Germany. 
1.7.2 The Attenuated Fowlpox Strain, FP9. 
Fowlpox is an avian poxvirus which causes disease in chickens but not mammals. 
Recombinant attenuated fowlpox has been used as a rabies vaccine in mammals. FP9 was 
derived from wild type fowl pox by 400 passages in tissue culture, leading to marked 
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attenuation and loss of pathogenicity in chickens, including one-day old chicks (Taylor & 
Paoletti 1988; Taylor et al. 1988). In the UK a clone of FP9 has been developed and 
characterised in detail at the Institute for Animal Health in Compton (Laidlaw & Skinner 
2004). The stock ofFP9 from which FP9 ME-TRAP was manufactured was derived from 
a sample obtained of this clone. Like all avipoxviruses, FP9 and the recombinant FP9 
ME-TRAP cannot replicate in mammalian cells. Attenuated strains of fowlpox virus and 
other avipoxviruses have been used safely as recombinant viral vaccines in many human 
clinical trials and have been demonstrated to be non-virulent in human volunteers 
(Cavacini et al. 2002; Moorthy et al. 2003b; Rosenberg et al. 2003; Webster et al. 2005). 
40 volunteers have been immunised on 1-2 occasions with FP9 ME-TRAP in Oxford and 
16 with 2 immunisations in The Gambia. As for MV A, GMP standard production is by 
Impfstoffwerk Dessau-Tornau, Roslau, Germany. 
1.7.3 A1~-1'~J> 
The malaria DNA sequences cloned into FP9 ME-TRAP and MV A ME-TRAP are 
derived from a number of different genes. 
The single largest part of the synthetic protein ME-TRAP consists of the entire amino-
acid sequence of thrombospondin-related adhesive protein (TRAP) from the human 
parasite P. Jalciparum strain T9/96. 
The remainder of the synthetic protein ME-TRAP is made up of a multiple epitope (ME) 
string, containing a total of 20 short peptide sequences. Of these, 17 are derived from 
previously-defined immunogenic regions of six human malaria antigens (Gilbert et al. 
1997) while one (pb9 in cassette C) is derived from the mouse malarial parasite P. 
berghei (Romero et al. 1989). 
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Pb9 was included to allow evaluation of immunogenicity in mice. The remaining two 
epitopes, BCG and TT, are non-malarial T cell helper (universal) epitopes for CD4 T 
cells, from tetanus toxin and BCG vaccine respectively. and were included to help 
promote a strong cellular immune response. The TT epitope has a single amino acid 
change (tyrosine to phenylalanine at position two of the peptide sequence to attempt to 
broaden further the range of HLA class II molecules for which it will act as an epitope. 
A complete list of the gene cassettes containing the epitopes included in the ME.TRAP 
construct is given in appendix 9.1.3. 
1.7.4 Semi-immune adults: Time to asymptomatic parasitaemia. 
A field trial in Gambian semi-immune adults had already assessed two DNA and one 
MV A:ME-TRAP immunisations and observed an efficacy of only 10% (P=0.49) in 
reducing rates of asymptomatic parasitaemia. However, efficacy of FP9-MVA is likely 
to be higher than DNA-MV A vaccination (see 1.6.3). Furthermore, the efficacy against 
disease in children should also be higher than efficacy against parasitaemia in adults. 
The reasons for this are described below. 
• Early acquisition rates of parasitisation are much lower than expected from 
calculations of entomological inoculation rates (Appawu et al. 2004). If there was 
no significant contribution of host immunity to infection rates, it would be 
expected that adults become parasitaemic at the rate they are bitten by infective 
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mosquitoes. Since the acquisition rate of parasitaemia is much lower than 
expected, this suggests that studies of asymptomatic parasitaemia in adults are 
strongly influenced by pre-existing host immunity. 
• Parasite incidence rates should be corrected for frequency of mosquito biting; 
evidence suggests this is proportional to surface area, and so lower for children 
than adults(Smith et al. 2004). Reanalysis correcting for surface area would then 
suggest lower infection rates in adults. 
• In both the field study of DNA:ME-TRAP prime, MV A ME-TRAP boost and the 
study of RTS,S (a particulate protein vaccine that encodes the circumsporozoite 
antigen) conducted in The Gambia, gradually increasing protection against 
asymptomatic parasitaemia was seen when comparing older with younger age 
groups (Bojang et al. 200 I). 
• Recent work suggests that blood stage immunity to a merozoite antigen protects 
against parasitisation in a longitudinal study of adults after curative chemotherapy 
(John et al. 2004). This is further evidence that incidence studies in semi-immune 
adults are complicated by naturally acquired immunity. This immunity would act 
after parasites emerge from the liver, but before they reach sufficient numbers to 
be seen by microscopy. 
Furthermore, in endemic areas infection rates of adults are so high that it is very hard to 
observe efficacy against infection, in effect the experimental model is "saturated". When 
studies following parasitaemia clearing chemotherapy have been conducted in areas at 
approximately ten fold different transmission rates (Northern Ghana (Owusu-Agyei et al. 
2001) and Mali (Sagara et at. 2002», the rate of acquisition of parasitaemia during 
follow-up was very similar. 
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Finally, there is evidence that other measures reducing pre-erythrocytic parasites do 
reduce clinical disease despite a limited action on parasitaemia rates. 
• Extensive clinical trials on insecticide treated nets (lINs) have been perfonned, 
and the data subjected to meta-analysis recently. Limited impact on parasitisation 
rates per se is demonstrated (10%), albeit studied in cross-sectional surveys rather 
than longitudinal cohort studies after radical cure. Efficacy is harder to 
demonstrate in areas at higher transmission rates. Nevertheless, 40-60% efficacy 
against mild malaria in young children is described, as well as efficacy against 
anaemia and severe disease in larger studies (Lengeler 2004). 
• During both the RTS,S study and the DNAlMVA:ME-TRAP study in The 
Gambia, although use of bed nets was not randomised, bed net use was not 
associated with any lower incidence of malaria parasitisation (Bojang et a1. 2001). 
• In observational studies, although the prevalence of parasitisation changes little 
according to season (relative risk of 1.5 for the rainy season) the risk of clinical 
disease changes dramatically (relative risk of 4.4) (Baird et al. 2002). 
Importantly, a field trial in The Gambia demonstrated an overall 34% efficacy of RTS,S 
against asymptomatic parasitaemia in adults; 70% in the first 9 weeks, and none 
thereafter. However, phase I trials of RTS,S in non-endemic areas demonstrate long lived 
partial efficacy against experimental challenge with a large inoculum of sporozoites, with 
a delay to parasitaemia following sporozoite challenge still seen 6 months after 
vaccination (Stoute et a1. 1998). The discrepancy between the duration of efficacy in 
these studies may reflect the limitations of studying time to asymptomatic parasitaemia in 
adults, and the protection seen against disease in children may be greater than that seen 
for asymptomatic semi-immune adults. 
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In summary the incidence rate of parasitaemia in semi-immune adults is a measure that 
appears to be insensitive to a ten fold reduction in malaria challenge rate, with between-
individual variation determined heavily by blood stage immunity, and this incidence rate 
is poorly predictive of the potential protection afforded against disease in children, the 
main group requiring protection by a vaccine. 
1.7.5 Objectives. 
The objective of further studies in humans was to develop vaccinations using FP9 
and MY A vectors to deliver the antigen construct ME-TRAP, with the aim of conducting 
an efficacy trial in children in a malaria endemic area. I conducted a preliminary analysis 
of efficacy in sporozoite challenge studies of volunteers in a non-endemic area, phase 1 
safety and immunogenicity studies in adults and then children in a malaria endemic area, 
and finally a large phase 2b efficacy trial on children. 
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2 Sporozoite Challenge • In the UK: An 
Analysis of PCR Data 
(Calculation of Liver-to-Blood Inocula, Parasite Growth 
Rates and Pre-Erythrocytic Vaccine Efficacy from Serial 
Quantitative PCR Studies of Malaria Sporozoite 
Challengees) 
2.1 Introduction 
Sporozoite challenge of human volunteers can assess efficacy of pre-erythrocytic 
vaccines before large field trials (Herrington et aI. 1988). Volunteers are exposed to the 
bites of Plasmodium Jalciparum infected mosquitoes, monitored with regular blood film 
examinations, and treated after the first positive blood film. Parasitaemia-free intervals 
after sporozoite inoculation are then analysed as a survival function. A longer 
parasitaemia-free interval for a vaccine group has been considered to represent a reduced 
inoculum of parasites seeding the blood from the liver (McConkey et al. 2003; Witney et 
al. 2001). PCR detects lower parasite numbers than detected by blood smears. Blood 
films detect between twenty and fifty thousand parasites per ml, but PCR can detect 20 
parasites per mL (Andrews et al. 2005). Analysis of these data allowed us to test if 
vaccine induced immunity reduced parasite numbers emerging from the liver or 
subsequent growth rates. 
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Several immunization regimens were examined. Five used the pre-erythrocytic 
antigen ME-TRAP (malaria epitope-thrombospondin-related adhesion protein), encoded 
by three vectors; FP9, an attenuated strain of fowlpox, modified vaccinia virus Ankara 
(MV A) or plasmid DNA. A second pre-erythrocytic antigen, the circumsporozoite 
protein, was delivered by recombinant MVA and RTS,S/AS02, a particulate vaccine 
fusing most of the circumsporozoite protein to hepatitis B surface antigen with a 
proprietary adjuvant (Stoute et al. 1997). The particulate Apovia vaccine, ICC-1132, 
comprises the hepatitis B core antigen containing T and B cell epitopes from the 
circumsporozoite protein, with Montanide ISA 720 adjuvant (Birkett et al. 2002; Walther 
et al. 2005a). 
Heterologous prime-boost regimes using DNA and MV A encoding ME-TRAP 
were associated with significant delays in time to parasitaemia by blood film, but pre-date 
quantitative PCR (McConkey et al. 2003). A similar regimen (two sequential DNA 
immunizations followed by MV A and then FP9, designated "DDMF"), among others, has 
been assessed here. Two FP9 immunisations followed by MV A ("FFM"), and two prime-
boost regimes of RTS,SI AS02A and MV A encoding the circumsporozoite protein 
protected some volunteers and significantly delayed parasitaemia in others (Dunachie et 
al. 2006; Webster et al. 2005). Other ME-TRAP-based regimes, two DNA immunizations 
followed by FP9 then MV A ("DDFM"), a single FP9 before MV A ("FM") and MV A 
before FP9 ("MF") did not delay onset of parasitaemia by blood film (Webster et al. 
2005). The protection data available from blood film studies are summarized in table 2.1. 
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Table 2.1 Summary of vaccination reeimes, numbers of volunteers and efficacy by 
blood film data. 
Vaccine N Delay to parasitaemia Fully 
(days) protected 
DDDMM 0 2.2* 0 
DDMF 4 1.7* 0 
FFM 17 2.S* 2 
DDFM 3 0 0 
FM 4 0.6 0 
MF 4 0.4 0 
ICC-I132 11 0 0 
RRMlMRR 12 3* 4 
Vaccine abbreviations are; D - DNA expressing ME-TRAP, M- MVA expressing ME-
TRAP, F- attenuated fowlpox strain FP9 expressing ME-TRAP, R- the particulate 
vaccine RTS,S/AS02 encoding most of the circumsporozoite protein. ICC-l132 is a 
hepatitis B core-based circumsporozoite vaccine. M appearing in regimes with 
RTS,S/AS02 denotes MVA expressing the circumsporozoite proteiI?-' * indicates 
significance (p<O.OS) by log rank survival analysis. 
Parasites first emerge from the liver 6.S days after inoculation of sporozoites by 
mosquitoes (Daubersies et al. 2000; Hermsen et al. 2001). Parasite numbers in peripheral 
blood then depend on multiplication rates and sequestration of parasites in blood vessels. 
Parasites sequester in the second half of their 48 hour life cycle; the progeny of 
sequestered parasites then appear in peripheral blood until they too sequester. If perfectly 
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synchronous, parasites would be absent from peripheral blood on alternate days. 
However, partial synchrony is usual, with marked periodic fluctuations in parasitaemia. 
Fluctuations in blood film parasitaemia, measured in P. Jalciparum treated neurosyphilis 
patients, have been modelled using a sine wave function for sequestration and a 
logarithmic function for growth (Simpson et al. 2002). Another approach splits parasites 
into broods depending on the time of sampling, and was applied to volunteers receiving 
identical blood stage inocula to calculate growth rates (Cheng et al. 1997). I adapted both 
these models to determine growth rates and liver-to-blood inocula, and thereby protective 
efficacy, resulting from various immunisation strategies. 
2.2 Methods 
2.2.1 Challenge Studies 
Vaccinated and unvaccinated volunteers were exposed to the bites of 5 P. 
Jalciparum (strain 307) infected Anopheles stephensi mosquitoes. Twice daily blood 
smears and PCR measurements were made from the 6th until the 14th day and then once 
daily until the 21 st day. These vaccination and challenge trials are reported in full 
elsewhere (Dunachie et al. 2006; Walther et al. 2005a; Webster et al. 2005). Visualizing a 
single parasite by blood film examination prompted immediate treatment with standard 
doses of chloroquine over 3 days, and defined the study endpoint. Volunteers were 
considered fully protected if not parasitaemic by 21 days. Neither managing clinicians 
nor microscopists were aware of PCR data during the trial. The PCR method is described 
elsewhere (Andrews et al. 2005). Briefly, EDTA anticoagulated blood samples were 
filtered to remove leukocytes, DNA purified from 0.5ml filtered blood, and eluted into 
50~1. A portion of the multicopy 18S (small subunit) ribosomal RNA genes of P. 
Jalciparum was amplified by PCR and the increase in PCR product detected by binding 
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the fluorescent dye SYBR green using the Rotor-Gene Real-Time PCR machine (Corbett 
Research), using 5JlI extracted DNA in duplicate. All volunteers gave infonned consent 
for immunisations, challenge studies, and blood sampling. Procedures were reviewed by 
OXREC, the local ethics committee. 
2.2.2 Modelling 
2.2.2.1 Individual modelling using the sine wave function 
Volunteers with less than six PCR readings and those completely protected were 
excluded. Of 80 volunteers, six volunteers were completely protected and six volunteers 
had less than six points. Data for the logarithm of each PCR result, described by time as a 
continuous variable and volunteer were analysed using Stata STM (Timberlake). Non 
linear regression to detennine best fit by least squares was used, using the model; log (P) 
= tm+a+c sin(nt+k); P is the number of parasites per ml, t is time minus 6.5 days after 
sporozoite inoculation, m (gradient) is the logarithm of the daily multiplication rate, a 
(intercept) the logarithm of the starting parasite population per ml of peripheral blood. c 
(the sine wave amplitude) is the logarithm of the sequestered parasites and k (phase shift) 
the time between day 7 and the first peak. Hence, 10[c+a] approximated the first peak of 
parasites per ml as the number emerging from the liver after day 6.5. A 5 litre blood 
volume was assumed to calculate total parasite numbers. 95% confidence intervals were 
calculated using the root mean square of the standard error of each parameter, derived by 
asymptotic approximation. Day 6.5 readings were excluded, since the change between 
days 6.S and day 7 is generated by parasites emerging from the liver, rather than growth 
or sequestration. Samples taken before the first detection of parasites were excluded from 
analysis. Where parasites were undetected but previous timepoints had detected parasites, 
the lower limit of parasite detection was used (20 parasites per ml). 
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The line was fitted by non-linear least squares regression and checked by visual 
inspection. Alternative models, including linear regression, other sine functions (e.g. sin2 
or sin3 based functions and Fourier transformations) and using the sine function without 
log transforming peR results were considered. These strategies were no better, judged by 
least squares and r squared values (without increasing the number of parameters). 
Volunteers with more observations generated parameter estimates with lower standard 
errors (p<O.0005). An example of the line fit is shown in figure 1. Most individuals' data 
were well represented by the modelling strategy: the distribution of r squared values is 
shown in figure 2. 
I assessed methods for estimating the liver burden from these parameters by using 
a step function simulation of parasites emerging from the liver with a 10 fold 
multiplication rate in each 48 hour life cycle and 24 hour patent, non sequestered period. I 
simulated 12 hourly sampling over 4 days, and found 10[c+a] to be an accurate 
approximation for total liver burden, with a 10% average error. 
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Figure 2. t Example of line fit by individual sine wave modelling approach. 
Volunteer 184 received FP9 followed by MV A expressing the antigen ME-TRAP, and 
became blood film positive on day 11. The line drawn here is given by log(PCR)=0.56 
time+ 1.54+0.57sin(7t time - 1.02) 
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Figure 2.2 R squared values for line fit by individual sine wave modeJling. 
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Group modelling using the sine function. 
A mixed effects model, applied separately to each group, allows individuals with 
fewer than four peR readings to be included in analysis. Mixed effects models were used 
for groups with eight or more individuals. A group mean and each volunteer's deviation 
from the mean were calculated, assuming normal distributions for the group. Parameters 
m, c, a and k are analogous to those in individual fits, where mO represents the mean 
value for the group, and mi the separate factor for each individual., i.e. 
10g(P)=t(mO+mi)+aO+ai+(cO+ci)sin[7rt+(kO+ki)]. Mixed effects modelling methodology 
has previously been described in detail (Burton et al. 1998). Extensions of this model 
allowed us to examme periodicity for the overall group, I.e. 
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10g(P)=t(mO+mi)+aO+ai+(cO+ci)sin[7rt(p+pO)+(kO+ki)], and change in growth over time, 
10g(P)=t( mO+mi)exp( vO+v 1 )+aO+ai+( cO+ci)sin[ 1tt(p+pO)+(kO+ki)]. 
A Bayesian Markov Chain Monte Carlo method (WinBUGS ™ Version 1.4, August 
2002, MRC Biostatistics Unit, and Imperial College, London) was used. Fully protected 
individuals were excluded, and day 6.5 values and undetectable values treated as above. 
2.2.2.3 Group modelling using divided parasite populations. 
An alternative model links the peaks, troughs and midpoints of the oscillations 
(assuming 48 hours periodicity) by a logarithmic growth function. The volunteers in these 
trials have four blood tests in each 48 hour period, so are considered as infected by four 
partially overlapping populations of parasites. For example, parasites observed in 
peripheral blood on day 9 are the progeny of those observed on day 7. Few individuals 
would have sufficient time points to allow modelling of four different parasite broods, but 
mixed effects modelling allows analysis of a group of volunteers, each with four broods. 
Normal distributions are assumed for parameters and WinBUGS ™ Version 1.4 used for 
analysis. 
2.2.3 Statistical comparisons 
Liver-to-blood inocula and growth rates for individuals were compared with those 
from unvaccinated individuals by non-parametric testing (Stata 8™). Kruskal-WaIlis, non 
parametric testing compared vaccination regimes within the individual modelling. 
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2.3 Results 
2.3.1 Individual modelling using sine wave function 
The numbers of parasites emerging from the liver are displayed by individual 
grouped into different vaccination groups. (Figure 2.3, below). There were no significant 
differences between the control group and ICC-1132, DDFM, FM or MF. DDMF was 
associated with an 86% decrease in liver parasite burden (p=0.074). The FFM and 
RRMlMRR groups showed 92% and 97% reductions in liver-to-blood inocula compared 
with the control group (Kruskal Wallis p=0.004 and p=O.OOI,). Growth rates were similar 
between groups (fig. 2.4, below), with an average multiplication of 14.4 fold (95% 
confidence interval II fold to 19 fold) in 48 hours. There were no differences between 
groups for sequestration of parasites or time to parasites emerging from the liver. 
Estimates of the reduction in liver stage parasite numbers corresponded with blood film 
estimates of vaccine efficacy. Correlating liver burden estimate with time to blood film 
patency gave r=-0.552, p<0.0005. No correlation was seen with growth rate. 
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Figure 2.3: Estimated liver parasite load on day 6.5 plotted by volunteer with 95% 
confidence intervals. Grouped according to vaccine, and ordered according to liver 
burden. Groups are ordered according to efficacy (significant delay to parasitaemia by 
blood film data). A dashed horizontal line marks the average liver burden for controls. 
Vaccine abbreviations are; D - DNA expressing ME-TRAP, M- MVA expressing ME-
TRAP, F- attenuated fowlpox strain FP9 expressing ME-TRAP, R- the particulate 
vaccine RTS,S/AS02 encoding most of the circumsporozoite protein. ICC-1132 is a 
hepatitis B core-based circumsporozoite vaccine. M appearing in regimes with 
R TS,SI AS02 denotes MV A expressing the circumsporozoite protein. 
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Figure 2.4: Growth rates with 95% error bars, Volunteers are grouped according to 
immunization and ordered according to growth rate. A dashed horizontal line marks the 
average growth rate. Vaccine abbreviations as above (Fig 2.3). 
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2.3.2 Group modelling using the sine/unction 
I 
RRMlMRR 
A group model allowed inclusion of individuals whose data had too few points for 
individual modelling. The reduction in parasite load was 89% for RRMlMRR and 82% 
for FFM. (fig 2.5). By weighted means including completely protected individuals the 
reductions are 93% and 85% for RRMlMRR and FFM respectively. The mean 48 hour 
multiplication rate was 11.5 fold (95% CI 6.6-20.9). Growth rates were not significantly 
different by vaccination; control 12.3 fold (95% CI 8.3-16.6), ICC-I132 23 (95% CI 11-
60), FFM 9.6 fold (CI 8-23), RRMlMRR 15.8 fold (CI 8.7-30). In models examining 
periodicity, a cycle of 2.2 days was found (CI 1.5-2.9 days). There was no change in 
growth rate over time (change in rate of 0.97 fold per day, CI 0.7-1.3). 
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2.3.3 Group modelling using divided parasite populations. 
Assuming a 48 hour life cycle, it was possible to fit a logarithmic growth pattern 
for observations taken 48 hours apart for each volunteer. A mixed effects model for 4 
different broods per volunteer showed a reduction in parasite load of 95% for RRMlMRR 
and 86% for FFM (Fig 2.5). The overall growth rate was 11.5 fold (95% CI 5.8-22.9), by 
group growth rates were; control 10.5 fold (95% CI 4.7-23), ICC-I 132 23 fold (95% CI 
8-60 fold) FFM 10.5 fold (5.2-20), RRMlMRR 15.9 fold (7.9-31 fold). 
31 
Figure 2.5: Comparison of estimates for liver burden by different modelling 
strategies. Vaccine abbreviations are as for figure 2.3 above. 
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In all 3 models, reduced numbers of parasites emerging from the liver were found for 
vaccinations associated with protection by conventional blood film assessments, 
(RRM/MRR, FFM and DDMF, fig 2.3). In contrast, no differences in growth rates were 
seen (fig 2.4)_ Estimated liver inoculums from the individual sine wave model (model I) 
correlated closely with the time until blood film patent infection (r=-0.552, p<O.OOOI), 
but no correlation was seen with growth rate. 
Estimating 4 parameters from 6-16 (mean ten) points per individual gave large 
standard errors. (figs 2.3,2.4)_ Parameters are fitted as log values, amplifying standard 
errors when described in linear terms. This contributes to the large range of values 
returned. Nevertheless, the efficacy of immunization with FFM and RRMlMRR is clear 
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and attributable to a reduction in parasites emerging from the liver rather than reduced 
blood stage growth rates. The mixed effects models (models 2 and 3) gave equally large 
standard errors. I used group models to avoid bias from excluding those with few points 
from individual modelling, and have not selected volunteers whose data best fits the 
model to reduce standard errors, as done previously (Simpson et al. 2002). Results were 
similar to the individual model using a sine wave function (fig 2.3); I have therefore 
emphasized the more parsimonious individual model in presentation and discussion. 
Morphological studies suggest twenty thousand merozoites are released by a 
single schizont, (Meis et al. 1984; Meis 1986) an estimated eleven sporozoites (range 3-
17) are injected by a single mosquito bite (Beier et al. 1992), and the challenge model 
uses five infective bites. Fifty five sporozoites would therefore theoretically produce over 
one million merozoites, three times the PCR-based estimate, if every sporozoite reaches a 
hepatocyte. However, the average unvaccinated subject was blood film positive on day 
11. Assuming parasites emerged from the liver on day 6.5, grew in a blood volume of 
five litres at a rate of ten fold in 48 hours and were seen by blood film microscopy at ten 
parasites per microlitre, then the initial inoculum from the liver-to-blood would be 280 
thousand, very similar to the PCR derived estimate. (Fig 2.6) This suggests that only a 
fraction of sporozoites successfully invade liver cells. 
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Figure 2.6: Schema relating sporozoite inoculum, initial merozoite release, 
multiplication rate and blood film diagnosis. 
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The average liver-to-blood inoculum in the RRMlMRR group was in the ten to 
thirty thousand range, suggesting that these volunteers have only one infected hepatocyte. 
Individuals clearing 13 out of 14 hepatocytes might have had similar immunity to those 
clearing all 14, perhaps explaining difficulties in correlating individual immunity with 
protection (Stoute et a1. 1998). There are several caveats in this calculation, however; 
estimates of nascent merozoites within a single schizont are not precise and do not allow 
for inter-schizont variation in vivo, only a fraction of the 20 thousand merozoites will 
invade red cells, and it is possible that schizonts may be damaged but not killed by 
vaccine effects, so releasing reduced parasite numbers. Delay in schizonts releasing 
merozoites rather than reduction in numbers of released merozoites would also reduce the 
intercept. However, there was no difference in the timing of the first peak (as determined 
by modelling) between FFM vaccinees and controls (p=O,61) or between RTS,S 
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vaccinees and controls (p=0.7S), and similarly no difference in timing of the first PCR 
positive result (p=0.45 and 0.52 respectively). It is therefore unlikely these results reflect 
prolonged hepatic schizogony in vaccinees rather than killing of parasites. 
If schizonts are not partially injured by vaccine effects, (Le. either they escape 
completely or are killed), FFM vaccinees and R TS,S regimen vaccinees should have 2.2 
and 0.9 infected hepatocytes on average, respectively. A Poisson distribution would then 
predict that 13% FFM and 40% RTS,S regimen vaccinees would be completely 
protected, close to the actual results of 12% FFM and 33% RTS,S regimen vaccinees. 
This supports the view that these vaccines are working by affecting hepatocyte parasite 
yield in an all-or-none manner rather than quantitatively affecting the parasite yield of 
individual parasitized hepatocytes. 
I considered that chance sampling of parasites present in the volume of blood 
drawn and gene copies in the DNA eluted might be a source of variability in our data. 
Estimates from the Poisson distribution, the volume of blood sampled and the fraction of 
DNA analysed suggest that parasites were reliably sampled (i.e. with greater than 95% 
chance) above 10 parasites per ml, and that quantitation was accurate to within 20% at 
250 per ml. 
Growth rates here were slightly higher than the 8 fold previously calculated using 
blood film data (Simpson et al. 2002), but similar to the higher growth rates (ranging 
from 12 to 25 fold) estimated using PCR after inoculation of low numbers of blood stage 
parasites (Cheng et al. 1997; Pombo et al. 2002). PCR examines lower parasite densities, 
suggesting that at lower densities growth may be more rapid. However, in mixed effects 
model variation in growth rates over time did not occur during the monitoring period. It is 
possible that growth begins to slow at higher densities. 
The protective vaccine regimes assessed here are shown to act by reduction of 
liver parasite load rather than altered growth patterns or time of emerging from the liver. 
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This is an important endpoint of phase IIa malaria vaccine trials and complements data 
obtained by the traditional blood film microscopy endpoint. The substantial effect 
quantified here on parasite liver burden of each of the two partially protective vaccination 
regimes (FFM and RRMlMRR) suggests that relatively minor improvements of either of 
these pre-erythrocytic vaccination approaches could lead to a major increase in sterile 
protection rates. 
The combination with RTS,S and MVA was not more protective than RTS,S 
given alone (Dunachie et al. 2006), and so RTS,S alone is being developed in GSK 
sponsored trials elsewhere (Alonso et al. 2005; Alonso et al. 2004). I therefore went on to 
conduct further field trials using FP9 and MV A vectored vaccinations to deliver the 
antigen construct ME-TRAP. 
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3 Phase 1 in Kenya: Safety 
The safety profile of viral vectors FP9 and MV A 
recombinant for either of two pre-erythrocytic 
malaria antigens, ME-TRAP or CS, in children and in 
HIV positive and negative adults in Kenya. 
3.1 Background 
This section describes the first immunisation of adults in East Africa with FP9 and 
MVA, the first immunisations of children with FP9 ME-TRAP and MVA ME-TRAP, 
and the first immunisations of HIV positive adults with attenuated pox viruses in a 
malaria endemic area. The aims were to establish whether adverse events in this series of 
Phase I trials would support further testing, and to describe how reactogenicity varies by 
sequence of immunization, dose and antigen insert. Immunogenicity will be described 
later (section 4). 
3.2 Methods and volunteers. 
3.2.1 Location 
The study was carried at the Kenya Medical Research Institute, Centre for Geographic 
Medicine Research (Coast), located in Kilifi, Kenya (KEMRI, CGMR-C). Kilifi is 
37 
malaria endemic, with all year round transmission and two high transmission seasons 
(Mwangi et al. 2005). 
3.2.2 Study Design 
The study was open label. If safety data for component vaccinations of a regimen were 
not already available, vaccinations began with half then full doses of the individual 
component vaccines. These results were reviewed by safety monitors before the complete 
regimen was used. The safety monitors reviewed all serious adverse events, and their 
approval was required before further subjects were immunised. Two Safety Monitors 
worked in Kilifi, the third in western Kenya. Ethical approval was obtained from the 
Kenyan Medical Research Institute National Ethics Committee, and the Oxford 
University Tropical Research Ethics Committee. Research was conducted in accordance 
with the Helsinki Declaration of 1975 (revised 1983). 
3.2.3 Volunteers 
The adults worked on local sisal and dairy plantations, were male (to avoid unsuspected 
pregnancy) and aged 18-45 years. Children were from the families of workers, aged 1-6 
years and of both sexes. After public meetings and detailed individual discussions, 
consent was sought and a screening date suggested. Subjects were immunized no sooner 
than one week after signing consent. 
Volunteers were screened by history, examination and blood tests (full blood count, 
creatinine, alanine transaminase, malaria slide and HIV serology). SUbjects with 
clinically significant illness were excluded. Subjects with haemoglobin below 100 gil 
(adults) or 80 gil (children) were also excluded. Subjects with parasitaemia were treated 
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with Sulfadoxine-Pyrimethamine before immunisation. DetermineTR HIV rapid tests were 
used, confirmed by the SerozymeTR ELISA. Pre-test HIV counselling was offered. 
Individuals testing positive were referred to an HIV clinic and offered vaccination at a 
later date, excluding those with stage 3 disease. Pre-vaccination viral loads ranged from 
600 to 500,000 per ml, and CD4 counts from 1 to 644x103 per ml. Only HIV negative 
children were immunised. 
3.2.4 Vaccines 
The antigen inserts used were TRAP Goined to a multiple epitope (ME) string from six P. 
Jalciparum pre-erythrocytic antigens (Gilbert et al. 1997)) and CS. The ME string 
contains 14 pre-erythrocytic MHC class I epitopes, three class II epitopes, two pre-
erythrocytic B cell epitopes and pb9 (a Plasmodium berghei T-cell epitope that allows 
pre-clinical potency and stability testing). CS is coupled to the P. Jalciparum class I 
epitope Is6 (from Liver Stage Antigen 1) and pb9. 
The vectors used were an attenuated fowlpox virus, FP9, and modified vaccinia virus 
Ankara. Recombinant vaccine stock was supplied to contract manufacturer IDT (Rosslau, 
Germany), who produced clinical lots under GMP conditions. 
Two different batches of FP9 ME-TRAP were used. Batch 020602 was used for 33 adult 
immunisations, and 040803 for 18 adult immunisations and all the children. Single 
batches of FP9 CS (010703), MVA CS (020703) and MVA ME-TRAP (031099) were 
used. 
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Vaccines were stored at -80°C, and transported in cool boxes for use within 6 hours. 
Vaccines were given intradermally over the deltoid area of the non-dominant arm, using a 
27 gauge needle to raise a visible intradermal bleb. Volunteers were observed for 1 hour 
with advanced resuscitation facilities available. Children received vitamin A 
supplements, as per Government of Kenya guidelines. The immunization regimes used 
are shown in Table 3.1. 
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Table 3.1. Vaccination Reeimens used in Phase 1 trials 
Regimen Insert Number of 
volunteers 
HIV negative adults 
FFM METRAP 10 
FM METRAP 13 
FMF METRAP 5 
MFM METRAP 5 
M METRAP 3 
F CS 3 
F CS 3 
M CS 3 
M CS 3 
FFM CS 6 
FM CS 6 
FM CS 6 
HIV positive adults 
F METRAP 2 
M METRAP 2 
F METRAP 1 
M METRAP 2 
Children 
fm METRAP 2 
FM METRAP 2 
ffm METRAP 6 
ffM METRAP 6 
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FFM METRAP 6 
The following abbreviations are used: 
f half dose FP9 immunisation, i.e. 5xl07 plaque forming units (pfu) for FP9 ME-
TRAP and FP9 CS 
m half dose MVA immunisation, i.e. 7.5xl07 pfu for MVA ME-TRAP or 5x107 pfu 
forMVA CS 
F full dose FP9 immunisation, i.e. lxl08 pfu FP9 ME-TRAP and FP9 CS 
M full dose MV A immunisation, i.e. 1.5x 1 08 pfu MV A ME-TRAP or 1 xl 08 pfu for 
MVACS 
These abbreviations are then used to describe the sequence of vaccinations in each 
regimen, so that ffM refers to 2 half doses of FP9 (given sequentially) followed by a full 
dose of MV A. Vaccination intervals were 3 weeks for ME-TRAP insert using regimes, 4 
weeks for those using CS. The underscore U refers to an 8 week interval between 
immunisations. 
3.2.5 Assessment of safety. 
The same two field workers made observations throughout the study. They saw 
subjects daily for three days aftcr vaccination, supervised by a medically qualified 
investigator for the first 50 visits. Unsupervised observations were checked by digital 
photographs taken in the field. The investigator also saw subjects at one week and 2-3 
months after vaccination. Solicited adverse events were recorded, and the diameters of 
skin discolouration, and blistering measured. Loss of the epidermis or upper part of the 
dermis was described as a deroofed blister. Unplanned assessments could be requested, 
and further weekly visits were made until resolution of persistent side effects. 
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Symptoms were graded according to the impact on activities of daily living, i.e. 
"mild" if without impact, "moderate" if an activity could only be completed with 
difficulty, and "severe" if an activity of daily living was prevented. Events were 
considered serious if they were life threatening, caused serious disability, or required 
hospital admission. 
Repeat blood tests were taken 7 days after every immunisation, and 2 months and 
9 months after the final immunisation. For HIV positive subjects, viral loads and CD4 
counts were measured before, 1 week after and 4 weeks after immunisation. 
3.2.6 Electron Microscopy o/vaccine 
Samples of FP ME-TRAP batches 020602 and 040803 were examined by 
transmission electron microscopy after negative staining. Formvar carbon grids were 
glow discharged for 30 seconds before applying the vaccine diluted 1 :50 in Tris buffer 
(O.lM, pH6.8). They were then stained with 2% phosphotungstic acid pH 7.0 and 
examined with an FEI F30 microscope at 300kV. 
3.2.7 Statistical analysis. 
Frequencies of side effects were compared using Fishers exact test. Blistering was 
described by frequency, and the mean diameter among those with blistering. The 
diameter contributed by each subject was the maximum recorded during the 7 days 
follow up. A non parametric test (Kruskal-Wallis) was used to compare diameters. Log 
transformed ELISpot data were analysed by regression models. 
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3.3 Results 
Eighty nine adults and 23 children were screened. Five adults (with active 
pulmonary tuberculosis, chronic renal failure, orchitis and two with anaemia) and one 
child (relapsing nephrotic syndrome) were excluded. Sixty six HIV negative adults were 
randomly selected and offered immunisation. Six withdrew consent, and were replaced. 
Of the ten HIV positive adults, 7 opted for immunisation. All 22 children continued with 
vaccination, and all vaccinees completed the immunisation regimes scheduled. 
3.3.1 Serious adverse events (SAE) 
An HIV positive volunteer was immunized with FP9 ME-TRAP, and admitted to 
hospital 22 days later with a swollen, painful left leg. Doppler Ultrasound scanning 
confirmed ileo-femoral deep venous thrombosis. He recovered after treatment with 
intravenous heparin and warfarin. 
A 4 year old girl developed fever 10 days after immunization with MV A ME-
TRAP, and was admitted with acidosis and a 24% Plasmodium Jalciparum parasitaemia. 
There were no unusual features of the illness, and she was discharged after 5 days. There 
were no other severe adverse events. 
3.3.2 Moderate adverse events 
One adult experienced a headache lasting 3 days after being immunised with 
MV A ME-TRAP, and had difficulty working. One child developed persistent vomiting 2 
days after receiving fowlpox ME-TRAP. A heavy trichuris infection was concurrently 
identified and treated, and the vomiting resolved after 4 days. 
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3.3.3 Laboratory safety analysis 
There were no clinically significant abnormalities in full blood count or 
biochemistry during the trial. In HIV positive subjects, the median viral load was 1.1 x 
105 RNA copies per ml before vaccination (95% CI 1.0-3.8 x 105 ), 1.4 x 105 RNA copies 
one week after (95% CI 0.7-5.8 x 105) and 1.8 x 105 (CI 0.6-6.3 x 105) at one month. 
Mean CD4 counts were 231 x 103 per ml (95% CI 60-400) before, 194 x 103 per ml (CI 
56-330) at one week and 127 x 103 per ml (CI 50-320) at one month. Viral load and CD4 
count did not change significantly over time (p=O.2 to 0.5 by signed rank test for the 
various possible comparisons). 
3.3.4 Mild adverse events: Local reactions 
All vaccinations caused local skin discolouration. Erythema and slight cutaneous 
swelling began within 24 hours, and faded to leave a slightly hyperpigmented area after 
4-7 days. In some volunteers, blistering began on day 2 or 3 and deroofed blisters were 
seen on day 3 or 4 (median duration of 2 days for both). Deroofed blisters were shallow, 
with sloping edges, and deroofed and intact blisters were strongly associated (p<0.0005, 
Fisher's exact). The presence of either intact or deroofed blisters was not significantly 
associated with pain or itching (p=O.2, 0.3, 0.1 and 0.26). Hypertrophic scars or keloid 
reactions were not observed. 
The largest deroofed blister was 1 cm diameter, and lasted 4 days (occurring after 
MV A CS, without a priming immunisation), but was not painful. Most of these lesions 
healed rapidly. Seventeen deroofed blisters lasted one day only, and 16 healed within five 
days, but two deroofed blisters persisted for 14 days. All local side effects were graded 
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mild. Thirty four subjects experienced pain for one day, 15 subjects for two days and 3 
subjects for 3 days. 
3.3.5 Mild adverse events: Systemic reactions 
Febrile symptoms were frequent (12% of adults, 21 % of children), but a measured 
temperature above 37.5°C was less frequent (2.5% and 10%, respectively). The highest 
recorded temperature was 37.8°C in adults, and 38.1°C in children. 15% of adults 
experienced a headache of 1 days duration, 5% had a headache of 2 or 3 days duration. 2 
adults had mild headaches lasting one week (after FP9 CS and FP9 ME-TRAP). 
Gastrointestinal symptoms were rare in all groups (5.6%), and limitation of arm 
movement for one day occurred on three occasions only. 
3.3.6 Variations in reactogenicity by subject group and vaccine. 
Mild adverse events varied by subject group and vaccine. The different vector antigen 
combinations caused similar systemic symptoms, but significantly different local 
reactions (Table 3.2). There was more widespread discolouration after MY A ME-TRAP 
(p=O.OO 15), but MV A CS caused more deroofed (p=O.025) and intact (p=O.052) blisters. 
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Table 3.2. The distribution of mild adverse events by subject z::roup and vaccination 
given. 
Adults Children HIV+ 
adult 
Vaccine FCS FTRAP MCS MTRAP FTRAP MTRAP FIM 
TRAP 
N 30 51 24 45 40 22 7 
Temp. 0(0%) 2 (3%) 0(0%) 2 (4%) ((2%) 5 (22%) 0(0%) 
Fever 3 (10%) 10 (19%) 1 (4%) 4 (8%) 9 (22%) 4 (18%) 0(0%) 
Vomiting 0(0%) 5 (9%) 2-(8%) 2 (4%) 4 (10%) 0(0%) 1 (14%) 
Head-ache 6 (20%) 20 (39%) 2 (8%) 12 (26%) 
- -
1 (14%) 
Pain 13 (43%) 17 (33%) 5 (20%) 17 (37%) 10 (25%) 5 (22%) 0(0%) 
Itch 10 (33%) 26 (50%) 10 (41 %) 20 (44%) 4 (10%) 2(9%) 3(42%) 
Disc. 0.65 0.67 0.7 0.88 0.36 0.85 0.63 
Diameter 
95% CI for 0.57-0.73 0.62-0.73 0.60-0.82 0.78-1.00 0.29-0.44 0.38-1.31 0.44-0.90 
Disc. 
Intact 8 (26%) 9 (17%) 4 (16%) 2(4%) 8 (20%) 5 (22%) 1 (14%) 
blister 
(freq) 
Intact 0.25 0.21 0.3 0.2 0.23 0.24 0.2 
blister 
diameter 
Deroofed 7 (23%) 9 (17%) 6 (25%) 1 (2%) 9 (22%) 3 (13%) 0(0%) 
blister 
(freq) 
Deroofed 0.25 0.36 0.3 0.2 0.27 0.26 0 
blister 
diameter 
Limited 1 (3%) 1 (1%) 1 (4%) 0(0%) 0% 0% 0(0%) 
ann 
motion 
Table footnote: Each vaccination is considered separately; N refers to the numbers of 
vaccinations within each category. F CS refers to FP9 encoding CS, M CS to MV A 
encoding CS, F TRAP to FP9 encoding ME-TRAP and M TRAP to MV A encoding ME-
TRAP. 
Temp. refers to the number of subjects with a temperature measured above 37.5 degrees 
centigrade when assessed. High temperatures were only recorded the day after 
immunisation. Fever refers to the percentage subjectively reporting febrile symptoms, but 
not necessarily with a recorded temperature on measurement. Numbers of pain or itching 
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refer to the immunisation site only. Disc diameter refers to the mean diameter of 
discolouration. Blister diameter describes the mean diameter among those that had 
blisters. Headache is not recorded for children. 
3.3.7 Subject group 
Side effect profiles in adults and children were similar, except that children more 
frequently had a measured fever (p=O.008, only after MV A), less itching (p=O.004) and 
less skin discolouration (p=O.OOOI). There were no differences in local or systemic 
reactogenicity between HIV infected and uninfected subjects, excepting a trend for less 
frequent pain (p=O.047). 
3.3.8 Sequence o/immunisation 
When MV A was given without pnor FP9 immunisation, there was more 
widespread discolouration (p=O.03), intact blisters (p=O.OI5) and deroofed blisters 
(p=O.04). MV A without prior FP9 immunisation caused a 1 em diameter deroofed blister 
in one subject. The largest such blister following MV A primed by FP9 was O.3cm. These 
deroofed blisters healed after 1 or 2 days, but those following MV A alone persisted for 
14 days in two subjects. Similarly, when FP9 immunisation was given without prior FP9 
or MV A discolouration was greater (p=O.O 18), although other differences were marginal 
(p=O.04 for more frequent pain after F alone, p=O.087 for deroofed blisters) or of little 
significance (p=O.24 for itch). 
Systemic effects were independent of sequence of immunisation. FP9 after MV A 
caused more frequent headache than F after F or F alone (p=O.024), but this was not 
corroborated by other systemic symptoms. In children, fever was less commonly reported 
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after the second fowlpox immunisation than after the first (p=O.02). Full details of 
reactogenicity by sequence of vaccination are given in table 3.3. 
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Table 3.3. The distribution of mild adverse events by sequence of vaccination. 
Adults Children 
Sequence of F FF FM M MF F FF 
vectors 
N 53 16 10 18 38 22 18 
Temp. 1 (1%) 1 (6%) 0(0%) 0(0%) 1 (2%) 1 (4%) 0(0%) 
Fever 8 (15%) 2 (12%) 3 (30%) 2(11%) 2 (5%) 8 (36%) 1 (5%) 
Vomiting 4 (7%) 0(0%) 1 (10%) 1 (5%) 2 (5%) 3 (13%) 1 (5%) 
Headache 15 (28%) 4 (25%) 7 (70%) 5 (27%) 6 (15%) 0(0%) 0(0%) 
Pain 25 (47%) 4 (25%) 1 (10%) 9 (50%) 5 (13%) 8 (36%) 2 (11%) 
Itch 25 (47%) 4 (25%) 3 (30%) 11 (61%) 13 (34%) 4 (18%) 0(0%) 
Disc. 0.7 0.58 0.63 0.99 0.75 0.37 0.31 
Diameter 
95% CI for 0.64 0.50 0.51 0.79 0.66 0.27 0.24 
Disc. -0.77 -0.65 -0.79 -1.26 -0.86 -0045 -0040 
Intact 12 (22%) 5 (31%) 0(0%) 4 (22%) 1 (2%) 3 (13%) 5 (27%) 
Blister 
(frequency) 
Intact 0.24 0.24 - 0.3 0.2 0.18 0.26 
Blister 
Diameter 
Deroofed 14 (26%) 1 (6%) 1 (10%) 4 (22%) 2 (5%) 2 (9%) 7 (38%) 
Blister 
(frequency) 
Deroofed 004 0.2 0.3 004 0.2 0.3 0.26 
Blister 
Diameter 
Limited ann 0% 0% 0% 0% 0% 0% 0% 
motion 
Table 3.3 Footnote: Sequence is described left to right; F indicates the first FP9 
vaccination received by a volunteer, and FF refers to the second FP9 vaccination. FM 
indicates the safety profile of an MV A vaccination, given after Fowlpox. Abbreviations 
for adverse event descriptions are as for table 3.2 
3.3.9 Adverse events varied by dose a/vaccine. 
Since vaccination sequence modified reactions, comparisons of adverse events by 
dose were restricted to the first vaccination. Systemic symptoms were reduced at half 
doses in adults (p=O.04 for headache, p=O.18 for fever), but local reactions were similar. 
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In children, high dose MVA METRAP was followed by a temperature >37.5 degrees in 5 
of 14 children the next day, but none of 8 children after half dose (p=O.076). Skin 
discolouration was greater after high dose compared to low dose (p=O.004 for FP9, 
p=O.06 for MV A), but the frequency and extent of blisters was similar. Full details of 
adverse events according to vaccine dose are given in Table 3.4. 
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Table 3.4. The distribution of mild adverse events by subject l!roup and dose. 
Children Adults 
f F m M F F M M 
N 14 8 8 14 5 50 5 8 
Temp. 1 (7%) 0(0%) 0(0%) 5 (35%) 0(0%) 1 (2%) 0(0%) 0(0%) 
Fever 4 (28%) 4 (50%) 2 (25%) 2 (14%) 0(0%) 8 (16%) 0(0%) 1 (12%) 
Vomiting 2 (14%) 1 (12%) 0(0%) 0(0%) 0(0%) 4 (8%) 1 (20%) 0(0%) 
Headache - - - - 0(0%) 15 (30%) 0(0%) 3 (37%) 
Pain 7 (50%) 1 (12%) 2 (25%) 3 (21%) 0(0%) 25 (50%) 2 (40%) 4 (50%) 
Itch 3 (21%) 1 (12%) 2 (25%) 0(0%) 3 (60%) 25 (50%) 3 (60%) 4 (50%) 
Disc 0.24 0.53 0.39 0.7 0.68 0.74 1 1.23 
Diameter 
95% CI for 0.17 0.32 0.23 0.43 0.3 0.67 0.5 0.5 
Disc. -0.32 -0.85 -0.66 -1.14 -1.0 -0.81 -1.4 -2.1 
Intact 3 (21%) 0(0%) 1 (12%) 4 (28%) 0(0%) 12 (24%) 1 (20%) 3 (37%) 
Blister 
(frequency) 
Intact 0.2 - OJ 0.225 - 0.24 0.4 0.27 
Blister 
diameter 
Deroofed 2 (14%) 0(0%) 2 (25%) 1 (7%) 0(0%) 14 (28%) 2 (40%) 2 (25%) 
Blister 
(frequency) 
Deroofed 0.2 - 0.3 0.2 - 0.2 0.2 0.15 
Blister 
diameter 
Table 3.4 Footnote: f refers to half dose FP9 vaccinations, F to full dose. Similarly, m 
refers to half dose MV A vaccination, M to full dose. Abbreviations for adverse event 
descriptions are as for table 3.2. 
3.3.10 Batches ofFP9 ME-TRAP had different reactogenicity 
Batch 020602 of FP9 ME-TRAP caused less discolouration (p=0.0078), intact 
blisters (p=0.036) and deroofed blisters (p=0.0019) than batch 040803. By transmission 
electron microscopy, both batches contained discrete viral particles and smaller fragments 
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of membrane, but there were no clear differences between batches. Full details of 
reactogenicity according to batch are shown in Table 3.5. 
Table 3.5. The distribution of mild adverse events by batch of FP9 ME-TRAP (data 
from adults only; 020602 not used in children). 
Batch 040803 020602 
N 18 33 
Temp 0(0%) 2 (6%) 
Fever 3 (16%) 7 (21%) 
Vomiting 1 (5%) 4 (12%) 
Headache 8 (44%) 12 (36%) 
Pain 4 (22%) 13 (39%) 
Itch 6 (33%) 20 (60%) 
Disc Diameter 0.8 0.61 
95% CI for Disc. 0.66-0.95 0.56-0.66 
Blister (frequency) 6 (33%) 3 (9%) 
Blister diameter 0.22 0.23 
Deroofed Blister 7 (38%) 2 (6%) 
(frequency) 
Deroofed Blister 0.58 0.1 
diameter 
Table 3.5 footnote. Abbreviations for adverse event descriptions are as for table 3.2. 
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3.3.11 Pre-vaccination immunity to the antigen insert reduced local 
reactogenicity. 
There was no association between subsequent immune response to the vector or 
insert and local cutaneous reactions (immunogenicity will be described in full elsewhere). 
However, the pre-vaccination response to the insert antigen was associated with less 
blistering (Figure 3.1). The geometric mean response was 30 (95%CI 23-39) interferon 
gamma producing cells per million PBMC among subjects who went on to develop 
blisters, compared with 17 (95%CI 11-25) among those who did not develop blisters 
(p=0.022 by t-test). There was no difference among responses to the vector prior to 
immunisation. 
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Figure 3.1. Individual pre-vaccination responses to the TRAP antigen, by sequence 
of immunisation and presence/absence of blistering. On the category axis, subjects are 
divided first into immunisation category, then into "-ve" or "+ve", i.e. negative or 
positive for blistering. The y axis plots the summed T cell response to the antigen insert, 
TRAP. 
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The difference in insert response was seen only in ME-TRAP vaccmees 
(p=O.0052) rather than CS vaccinees (p=O.4). When using a regression model to adjust 
for the sequence of immunisation (a possible confounder) the response was found to be 
2.3 times greater among those without blistering (p=O.018). Detailed results on 
immunogenicity are presented in section 4.3. 
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Local adverse events tended to recur in individual subjects. 
73 subjects were immunised more than once. Table 3.6 describes the frequency 
with which adverse events recurred. Systemic symptoms were randomly distributed, but 
if blistering occurred after the first immunisation, it was more likely to recur after the 
second. (p=O.Ol for intact blisters and 0.005 for deroofed blisters) 
Table 3.6: The frequency of adverse events by occurrence following a single 
immunisation, or with subsequent immunisations. 
Comparing first and second Comparing second and third 
immunisations (n=73) immunisations (n=44) 
Freq on Freq on Freq on Freq on 
first second Freq on second second Freq on 
vaccine vaccine both vaccme vaccme both 
only only vaccmes only only vaccmes 
Temp. 2 2 1 2 1 0 
Headache 13 7 6 7 6 3 
Vomiting 4 3 1 4 2 0 
Fever 11 7 3 7 5 0 
Deroofed 
Blister 
(Freq) 14 2 5· 5 4 0 
Intact 
Blister 
(Freq) 11 2 5· 2 8 1 
Itching 15 12 11 7 5 6 
Pain 21 10 9 9 9 1 
Table 3.6 Footnote: Temp. refers to the number of subjects with a temperature measured 
above 37.5 degrees centigrade when assessed. Fever refers to the number subjectively 
reporting febrile symptoms, but not necessarily with a recorded temperature on 
measurement. Pain or itching refers to the immunisation site only. The frequencies of 
subjects with blistering are given. • indicates p<0.05 for a greater than expected frequency 
of subjects experiencing a reaction to both vaccinations. 
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3.4 Discussion 
There was mild subjective discomfort for the majority ofvaccinees, but no serious 
reactogenicity. There was no plausible link between the two serious adverse events and 
immunisation, and the safety monitors considered these events unrelated to vaccination. 
Both were isolated events, and not unusual in the respective subject groups. Deep venous 
thrombosis is associated with HIV infection (Saber et al. 2001). 
At this preliminary stage, FP9 ME-TRAP and MV A ME-TRAP appear safe in 
adults with HIV and there was no evidence that viral load or CD4 count was adversely 
affected by vaccination. This is critical, since in many populations large scale HIV testing 
prior to immunisations will be problematic, and a transient rise in viral load and fall in 
CD4 count has been seen after pneumococcal and influenza vaccines (Brichacek et al. 
1996; Staprans et al. 1995). There was no evidence that adverse events were more 
frequent or more severe in individuals with lower CD4 counts and higher viral load, 
although there were few adverse events recorded in this group. Compared with adults, 
children showed only minor differences in local skin discolouration. There was some 
evidence of more frequent objective fever but less frequent symptomatic fever. 
MV A CS had a different side effect profile to MVA ME-TRAP, causing less 
extensive skin discolouration, but more frequent blistering. MV A CS was higher titre 
(lx109pfulml compared to 3x108 pfulml for MVA ME-TRAP). Blistering had a smaller 
average diameter (0.34 cm) than the discolouration (0.72 cm). Virus given in a larger 
volume might disperse more following immunisation, causing more extensive skin 
discolouration, but resulting in less concentrated virus, so causing less frequent blistering. 
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3.4.1 Dose and sequence 
Systemic and local reactogenicity was less at lower doses, although few adult 
subjects were immunized at lower doses. However, the local reactogenicity of MV A was 
markedly lower if FP9 was given first. Therefore, where the intention is to use MV A as a 
boosting agent after FP9 in the final regimen, single dose immunisations should not be 
assessed first. The dose titration should start with the complete regimen at half dose, then 
move to full dose if reactogenicity is acceptable. Such an approach was taken for 
paediatric vaccinations here. 
There was evidence of variable subject susceptibility to cutaneous reactions. 
Those with blistering after the first immunisation were likely to experience a similar 
reaction for the second. These host factors might differ by population. If so, this would 
support conducting phase I studies in new populations before larger scale trials. 
3.4.2 Batch 
Unexpectedly, two batches of the same vaccine (FP9 ME-TRAP) had different 
local reactogenicity. Batches are prepared from the same master seed lot under GMP 
conditions, and GMP sterility tests, repeated potency tests and titrations were performed. 
The FP9 supplied for the original recombination to generate FP9 ME-TRAP was clonal, 
having been plaque purified. Differential gene loss during the short growth required to 
"bulk up" virus during manufacture seems unlikely. The batches were of different titre 
(4x108 pfu per ml for 040803, compared with Ixl08 pfu per ml for 020602). As for the 
comparison between MVA CS and MVA ME-TRAP, the more concentrated vaccine 
caused more frequent blistering. However, the less reactogenic FP9 ME-TRAP batch 
(020602) was also more immunogenic (results presented elsewhere), and this suggests a 
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more fundamental difference. Since the two batches looked similar by electron 
microscopy, the different reactogenicity was not due to differences in chick fibroblast 
debris or viral particle aggregation. 
3.4.3 Immune response 
After BCG local cutaneous reactions have been associated with immunogenicity 
(Roth et al. 2005), but this was not the case here. However, prior immunity to the malaria 
antigen insert protected against blistering (p=0.0052). This was only seen among the sub-
group receiving FP9 ME-TRAP, probably because CS containing vaccines were less 
immunogenic (see 4.3.1), and blistering was rare after MVA ME-TRAP. The effect was 
robust to adjustment for sequence (p=0.018, 2.3 fold difference, Figure 3.l). Following 
natural exposure, TRAP peptides induce interleukin 10 (Flanagan et al. 2006), and MV A 
induces T regulatory responses (Fletcher et aI, submitted). It is thus possible that TRAP 
specific responses down regulate local inflammation following vaccination. 
In conclusion, the vaccine regimes employed here were safe, the data presented 
details the determinants of reactogenicity and informs the conduct of future Phase I 
studies. 
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4 Phase 1 in Kenya: Immunogenicity. 
4.1 Background 
The direct, or ex vivo ELISpot identifies T cells that produce IFN-gamma after 
overnight incubation with antigen. The cultured ELlS pot assay uses a 10 day pre culture 
with first antigen then interleukin 2, in order to identify resting memory cells (Godkin et 
a1. 2002). The cell populations identified by these two assays are different. A study of 
naturally acquired immunity to CS protein demonstrated no correlation between cultured 
ELISpot and ex vivo ELI Spot results (Flanagan et a1. 2001). The cells identified by 
cultured ELI Spot persist for at least six months after vaccination of naIve subjects, 
despite waning of cells detected by ex vivo ELI Spot (Keating et a1. 2005). The cells 
detected by cultured ELI Spot are here referred to as resting memory cells. 
Mean effector T cell responses among vaccination groups predicted protection 
from sporozoite challenge (Webster et a1. 2005), but did not predict the inter-individual 
variation in protection seen within vaccination groups. However, cultured ELI Spot results 
predicted inter-individual variability in sporozoite challenge (Keating et a1. 2005), and 
cultured ELISpot assays using a particular peptide predicted protection against both 
parasitaemia and febrile malaria in a field study following vaccination with R TS,S (Reece 
et a1. 2004). In contrast to the RTS,S field study, the cultured ELISpot data from 
sporozoite challenge studies were analysed quantitatively (Keating et a1. 2005), as are the 
data presented here. 
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I conducted ELISpots using pools of up to 17 peptides, so as to cover the full 
length of the antigen used for vaccinations, even where limited cells were available. 
Other studies have used individual epitopes (Godkin et al. 2002). However, my aim was 
to detennine vaccine immunogenicity rather than track the kinetics of individual epitope 
specific respomses. Protection is most likely to be related to overall immunogenicity 
(McConkey et al. 2003; Webster et al. 2005). Since the critical interaction is between 
reactive T cells and infected hepatocytes rather than peptides in solution, protection is 
likely to be a function of the total number of potentially protective T cells in circulation, 
rather than of individual epitope responses. I have therefore presented results by summing 
responses to the whole antigen tested, except where strain cross-reactivity for specific 
pools of variant peptides is examined for. 
Vaccines with preliminary evidence of efficacy require immunogenicity data from 
adults in endemic areas before moving to immunise children. This offers a further 
opportunity to optimise the regimen for immunogenicity and study the acquisition of 
immunity. I compare prime boost regimens, single dose vaccinations and novel 
alternating vector regimes in a malaria endemic area, and compare CS and ME-TRAP 
inserts. 
4.2 Methods. 
The study design, subject groups and vaccination regimens have been described in 
section 3.2. Table 3.1 gives the numbers of subjects immunised with each vaccination 
regimen. Comparisons are made between the time course of responses following 
alternating vector vaccinations and prime boost vaccinations. Of the 23 subjects given 
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prime boost vaccinations, 19 were immunised 12 months before the alternating vector 
vaccinations, and 4 concurrently. 
4.2.1 ~L1j1J7ots 
PBMC incubations were in RPMI (Sigma-Aldrich) with 10% Human AB serum. 
ELISpots used Millipore MAIP S45 plates and MabTech antibodies according to 
manufacturer's instructions. 4 x lOs per well of freshly isolated peripheral blood 
mononuclear cells (PBMCs) were incubated in 100JlI with 10 Jlg/ml peptides for 18-20 
hours before developing. Individual 8 to 17 residue epitopes were pooled for the ME 
string. 20 residue peptides overlapping by 10 residues were used for TRAP. TRAP 
peptides were pooled first according to whether they were T996 variant specific (the 
vaccine strain), 307 specific or synonymous, and then according to region. CS was 
represented by 15 residue peptides, overlapping by 10 residues. The TH2R and TH3R 
polymorphic regions were pooled separately for 307 (vaccine strain) and 7G8 derived 
peptides. 20 Jlg/ml Phytohaemaglutinin (Sigma-Aldrich) was used as positive control, 
and PBMC cultured in media alone as negative control. Spot forming cell numbers were 
counted by ELISPOT plate reader (Autoimmun Diagnostika, version 3.0). 
For cultured ELISPOTs, Ixl06 PBMe were incubated in 0.5mls of 
IOJlglmllpeptide of pooled TRAP or CS pep tides in a 24-well plate. On days 3 and 7, 
250JlI of culture supernatant was replaced with 250JlI culture medium containing 20 
IU/ml recombinant IL 2. On day 9 the cells were washed three times and left overnight 
before the standard ELISpot assay. 
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4.2.2 Analysis. 
ELlS pot wells were assayed in duplicate. The mean was taken, and the negative 
control well result subtracted from each peptide well. Assays were considered failed if the 
positive control well was less than 50 spots, or the negative control greater than 20 spots 
for ex vivo ELISpots, or greater than 40 spots for cultured ELISpots. Pools were summed 
to calculate total responses. Results are then presented as number of spots per million 
incubated PBMC throughout. 
Data were log transformed to normalize distributions. Geometric means with 95% 
confidence intervals (by Stata 8™, Stata coorp) are used to describe groups. To avoid 
multiple comparisons, ANDV A was performed to test for heterogeneity of results. Where 
ANDV A results showed p<0.05, factorized linear regression was used to identify 
significantly different groups. 
In examining for either cross reactivity between different effector responses, or 
correlations between memory and effector responses, results were paired according to the 
region of CS/TRAP and volunteer. Each individual contributes 3 points, leading to an 
overestimate of significance. The cluster subcommand of Stata 8™ (Stata coorp) was 
therefore used to adjust p values upwards. 
4.3 Results 
The peak effector responses seen on ex vivo ELISpot were compared, using samples 
taken one week after each vaccination. 
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4.3.1 ME-TRAP was more immunogenic than CS 
Single vaccination with FP9 ME-TRAP raised T cell responses significantly above 
baseline (p<0.0005), to a geometric mean of 57 spots (95% CI 28-112) from a mean of 8 
spots at baseline (95% CI 4-14). FP9 CS alone was not significantly immunogenic. 
Geometric mean responses after FP9 CS were 40 spots per million (95% CI 15-100) 
compared to 17 spots per million (95% CI 7-48) at baseline, p=O.II. 
However, for regimes encoding both ME-TRAP and CS, the "boosting" immunisation 
with MV A expanded T cell responses further. Geometric mean responses to ME-TRAP 
were 185 spots per million PBMC after FM, and 389 spots after FFM. Responses to CS 
were 72 spots per million after vaccination with FM and 204 spots per million after FFM. 
The expansion was significant for FFM ME-TRAP (p<0.005), FM ME-TRAP (p<0.0005) 
and FFM CS (p=O.014) but not FM CS (p=O.2). 
Thus, for each vector combination, regImens encoding ME-TRAP were of greater 
immunogenicity than regimens encoding CS. An estimate of overall significance was 
made using a linear model to compare CS encoding regimens with ME-TRAP regimens, 
adjusting for the sequence of vectors. Immunogenicity was higher for ME-TRAP 
(p=O.OOI), and further study focused on ME-TRAP regimens. Median responses for each 
regimen are plotted in Figure 4.1. 
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Fhwre 4.1. Peak effector (ex vivo ELISpot) responses. 
Results are shown for ex vivo ELISpot assays taken one week after the vaccination 
regimen displayed on the category axis. Spot numbers per million PBMC are plotted 
along the y axis (log scale). F is used for FP9, and M for MVA. 2 or 3 dose regimes are 
described by the sequence of vaccinations. For instance, FFM refers to two sequential 
FP9 vaccinations followed by a single MV A vaccination. Boxes show the distribution of 
results, the resting line indicating median response, upper and lower box boundaries 
showing 25th and 75th centiIes, and the whiskers show adjacent values. The circles show 
outlier results. Single vector immunizations were immunogenic for ME-TRAP 
(p<O.0005) but not for CS. Overall, immunogenicity was higher for ME-TRAP than for 
CS (p=O.OO 1), and FFM was significantly more immunogenic than both M and FM 
(p=O.018). 
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4.3.2 Multiple Priming enhances immunogenicity 
The responses following MV A ME-TRAP given without priming (M) were compared 
with single priming (FM) and double priming (FFM). The geometric mean response after 
single dose MVA ME-TRAP was 150 spots per million PBMC (95% CI 45-510). This 
compares with 185 spots, (95% CI 96-360) when previously primed once (Le. FM ME-
TRAP), and 389 spots per million (95% CI 190-800) if primed twice (Le. FFM ME-
TRAP). MV A CS was not used alone, but responses were higher when primed twice 
(responses after FFM CS were 204 spots, CI 75-325) than when primed once, whether the 
interval between vaccinations was 4 weeks (responses were 50 spots per million, CI 30-
78, after FM CS) or eight weeks (40 spots, CI 12-130, after F _M CS). 
A second linear model was then used to compare M, FM and FFM, adjusting for the two 
different antigen inserts. There was significant variation by ANOV A (Le. FFM, FM and 
M raised significantly different responses), p=0.037. By individual analysis, FFM was 
significantly more immunogenic than both M and FM (p=O.O 18). 
Peak responses following alternating vector vaccinations (MFM or FMF ME-TRAP) 
were similar to Malone (l05 spots per million, 95% CI 23-470 and 110 spots, 95% CI 
38-316 respectively). 
4.3.3 Alternating vector vaccinations generate more memory then Prime Boost 
Whereas the response after prime boost (FFM or FM ME-TRAP) fell to 5% of the peak 
response after 270 days (fig 4.2), alternating vectors (MFM or FMF) maintained 84% of 
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the peak response after 270 days. Thus, although the alternating vector responses were 
significantly lower than prime boost (FFM or FM), p=0.04, at 7 days and similar at 56 
days (p=0.3), alternating vector responses were higher (p<0.0005) at 270 days. 4 prime 
boost vaccinees were immunised concurrently with alternating vector vaccinees. The 
geometric mean response at 56 days among prime boost vaccinees one year previously 
was 123 spots per million PBMe (range 0-500). Of the 4 prime boost vaccinees that were 
concurrent with alternating vector vaccinations, one response was above the mean (295 
spots), one response below the mean (18 spots) and two were non-responders (0 spots). 
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Figure 4.2. Timecourse of effector (ex vivo ELISpot) responses. 
The durability of effector cells was measured by ex vivo ELISpots on blood samples 
drawn at 7, 56 and 270 days after the final immunization. This is indicated on the 
category axis, grouped according to vaccination regimen. Prime Boost describes both FM 
and FFM immunisations, Alternating vector describes FMF and MFM immunisations. 
Subjects receiving MV A ME-TRAP immunisation without priming or FP9 ME-TRAP 
went on to complete full vaccination regimes (MFM or FMlFFMlFMF), and so time 
course data is not available. The response to prime boost immunization fell to 5% of the 
peak response at 270 days, but alternating vectors (MFM or FMF) maintained 84% of 
their peak response . 
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A similar pattern was seen for cultured ELISpot responses, which detect resting memory 
cells. Prime Boost TRAP encoding regimes provoked an 8 fold rise in geometric mean 
resting memory cell responses (Fig 4.3, p=0.02), from 120 spots (95% CI 55-255) to 810 
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spots per million (CI 470-1150), and Prime Boost CS regimes provoked only a 2 fold rise 
of borderline significance, from 230 spots (95% CI 80-685) to 633 (CI 250-1580), 
p=O.08. However, the mean resting memory response was 1580 spots (CI 1000-2488) 
after alternating vectors, considerably higher than for prime boost (FFM or FM) 
(p<O.0005). The resting memory population generated by prime boost vaccination fell to 
33% of the peak over 270 days, but the resting memory generated by alternating vectors 
did not diminish. 
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Figure 4.3 Timecourse of resting memory (cultured ELISpot) responses. 
The durability of resting memory cells was measured by cultured ELISpot. The resting 
memory was measured by cultured ELiSpot on blood samples drawn 7, 56 and 270 days 
after the final immunization. This is indicated on the category axis, grouped according to 
vaccination regimen. Prime Boost describes both FM and FFM immunisations. 
Alternating vector describes FMF and MFM immunisations. The induction of resting 
memory cells was significant after prime boost TRAP encoding regimes (p=0.02), but not 
after prime boost CS regimes (p=0.08). Alternating vector regimes induced more resting 
memory responses than prime boost (p<0.0005), and the response was sustained. 
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4.3.4 TRAP and CS responses to vaccination are not limited to the vaccination 
strain 
TRAP responses at baseline appeared cross-reactive (r=0.46, p=O.OOOI, figure 4.4), and 
those raised by immunisation were more so (r=0.75, p<0.0005). However, T cell 
responses to CS at baseline were reactive to either 3D7 strain or 7G8 strain, but not both 
(excepting one response out of 14). However, immunisation with either FP9 CS or MVA 
CS produced cross reactive responses (r=0.54, p=O.OOI or r=0.75, p<0.0005 
respectively). There was a bias towards responses against the vaccine strain after 
vaccination. Responses to the vaccine strain were 3 fold higher (95% CI 1.5-6 fold) after 
MV A CS, and 1.3 fold higher (95% CI 1-1.7 fold) after MV A ME-TRAP. 
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Fieure 4.4 Strain cross reactivity. 
Results from ex vivo ELISpots 7 days after vaccination are plotted. The numbers of cells 
per million PBMC responding to the vaccine strain are on the x axis, against numbers 
responding to variant peptides on the y axis. A point in the far right corner of a graph 
would then represent a high response to both the vaccine strain peptides and the variant 
peptides, suggesting cross reactivity. Points closer to either axis represent responses 
specific to either the vaccine strain (if close to the x axis) or specific to variant peptides 
(close to the y axis). The top three panels demonstrate TRAP responses, the lower three 
CS responses. For each peptide group, the left panel shows responses prior to 
vaccination, the central panel after FP9, the right panel responses after MY A. TRAP 
responses appeared cross-reactive at baseline (r=0.46, p=O.OOOl) and after immunisation 
(r=0.75, p<0.0005). Responses to CS at baseline were not cross reactive at baseline 
(r=0.04), but were after vaccination (r=0.75, p<0.0005). 
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4.3.5 Batches ofFP9 ME-TRAP have different immunogenicity (Figure 4.5) 
Two different batches of FP9 ME-TRAP were used. In most cases, this did not vary 
within regimen (i.e. batch 040803 for FFM, batch 020602 for FMFIMFM), but among the 
FM regimen, eight subjects received batch 040803, and eight 020602. One MV A ME-
TRAP batch was used throughout. Batch 020602 FP9 ME-TRAP was immunogenic 
given alone (p=0.002, 120 spots per million), but responses after batch 040803 were not 
different to those present at baseline (p=0,45). Similarly, batch 020602 was more 
effective at priming the subsequent MV A ME-TRAP vaccination. Geometric mean 
responses were 331 spots per million after batch 020602, compared to 110 after batch 
040803, p=0.0054. Responses were also more long lived using batch 020602. Mean 
responses were 64 spots per million at 56 days, compared to 17 spots with batch 040803 
(p=0.037). However, the anti-vector immunity raised by the two FP9 ME-TRAP batches 
were similar, at 22 spots (CI 13-45) for 020602 and 20 (CI 5-62) for 040803. 
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Figure 4.5 Comparison of FP9 ME-TRAP batches (ex vivo ELISpot). 
Subjects who received FM vaccination regimes were divided according to the batch of 
FP9 ME-TRAP vaccination they received (all received the same MVA ME-TRAP batch). 
Responses are shown before immunization (baseline) and then 7 days after the first FP9 
ME-TRAP vaccination (F + 7). 14 days after the FP9 ME-TRAP vaccination, MV A ME-
TRAP was given. Then responses after a further 7 days (FM+7) and 56 days (FM+56) are 
displayed. At each timepoint, responses are split by the batch of FP9 ME-TRAP used in 
the overall vaccination regimen. Batch 020602 FP9 ME-TRAP was immunogenic given 
alone (p=0.002), as priming the later MV A ME-TRAP vaccination (p=0.0054), and 
generated more long-lived responses (p=0.037) . 
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4.3.6 Pre-vaccination memory predicts post-vaccination response for single 
vector immunisations 
The resting memory responses present before vaccination predicted the post vaccination 
effector response (r=0.21, p=0.021, Figure 4.6). This correlation was entirely due to 
subjects receiving single immunisations encoding TRAP (i.e. F or M alone). When this 
group was analysed alone, r=0.49, p=0.0003, but for the other prime boost regimes, 
r=0.02, p=0.8. This could be better expressed by testing for an interaction between pre-
vaccination memory and vaccination regimen in predicted outcome (i.e. effector response 
to vaccination). A model allowing this interaction between vaccination group (single 
vaccination or multiple vaccinations) and pre-existing resting memory was significantly 
better (p=O.Oll) than a model without interaction. This further confirms that the 
correlation between prevaccination memory and post vaccination response was specific to 
one vaccination group (single dose vaccination). 
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Figure 4.6 Resting Memory responses pre-vaccination against effector responses 
post-vaccination. 
The cultured ELI Spot responses found prior to vaccination are plotted at the x axis. The 
subsequent ex vivo ELI Spot result 7 days after vaccination is plotted on the y axis. The 
left graph shows responses following prime boost vaccination regimes. The right graph 
shows responses following single vaccinations (i.e. either FP9 ME-TRAP or MV A ME-
TRAP alone). Prior resting memory responses predicted post vaccination response 
(r=0.21, p=0.021). For single immunisations encoding TRAP (i.e. For Malone), r=0.49, 
p=0.0003, but r=0.02 for prime boost regimes. This suggests that for single vaccinations 
(but not for prime boost regimes) immunogenicity depends on prior memory responses. 
Pre-vaccination effector responses were not significantly above background (p=0.17), and 
so were not analysed here. 
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Concurrent ex-vivo effector responses and resting memory cells after vaccination were 
quite strongly associated (r=0.41, p=0.003), although there was no correlation prior to 
vaccination (r=-0.12 p=0.56). 
4.3.7 Anti Vector Immunity 
When Modified Vaccinia Ankara was used to infect PBMC in the ELI Spot assay, high 
levels of reactivity were seen in all samples, whether immunised or not (data not shown). 
However, non specific reactivity was not seen with wild type vaccinia (WR), and so 
responses to wild type vaccinia are presented here, since the non-specific reactivity seen 
with MV A was not considered infonnative. Responses to vaccinia averaged 7 spots per 
million at baseline (ranging from 2.5 to 144), but were higher after FP9 ME-TRAP, at 20 
spots per million (range 2.5 to 450), p=0.002. 
Since there was a wide range of anti-vector specific immunity, and there appeared to be 
cross-reactivity between FP9 and MV A, the potential for these responses to impair 
subsequent immunogenicity was compared. The anti vector immunity measured by ex 
vivo ELISpot responses to vaccinia at baseline was plotted against the subsequent 
response to FP9 ME-TRAP, and the anti vector immunity detected one week after FP9 
ME-TRAP was plotted against the subsequent response to MV A ME-TRAP (Figure 4.7). 
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Figure 4.7. Pre vaccination anti-vector immunity against post vaccination insert 
response in adults. 
The ex vivo response to vaccinia found before vaccination is plotted on the x axis. The 
subsequent ex vivo response to the antigen insert is shown on the y axis. Responses are 
split into two graphs. The left panel relates vector responses at screening to antigen insert 
responses immediately after FP9 vaccination, the right panel relates vector responses after 
FP9 vaccination to antigen insert responses immediately after MY A vaccination. 
Negative correlations of r=-0.35, p=0.09 for FP9 ME-TRAP and r=-0.59 p=0.0058 for 
MY A ME-TRAP were seen. 
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Negative correlations of r=-0.35, p=O.09 for FP9 ME-TRAP and r=-0.59 p=0.0058 for 
MY A ME-TRAP were seen. This gave a negative correlation of r=-0.32, p=0.03 overall, 
and a coefficient of -0.5, p=0.002 when adjusted for vaccination. The least squares 
regression line was positioned differently for FP9 and MY A. This was expected, since 
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MV A was more immunogenic than FP9, and was given after FP9, when anti-vector 
responses had already been induced. This suggests that even a weak anti-vaccinia 
response prior to either FP9 ME-TRAP or MV A ME-TRAP immunization attenuates the 
response induced to the insert. 
4.3.8 Immunisation of children 
The first four children to be immunised received only single priming immunisations with 
FP9 ME-TRAP followed by MVA ME-TRAP, but subsequently children were 
immunised with two priming vaccinations with FP9 ME-TRAP, followed by boosting 
with MV A ME-TRAP. Different doses of FP9 ME-TRAP were compared, to examine 
whether a lower dose would result in less anti-vector immunity, and so improve the 
immunogenicity of the final vaccination with MVA ME-TRAP. Different doses ofMVA 
ME-TRAP were also compared to examine whether the full dose was required for strong 
immunogenicity. 
4.3.9 FP9 ME-TRAP and MVA ME-TRAP were immunogenic in children 
Both the first FP9 ME-TRAP vaccination and the final vaccination with MV A ME-TRAP 
raised responses above baseline (Figure 4.8). On ex vivo ELI Spot, the geometric mean 
response was 6 spots per million at baseline (95% CI 2-12), rising to 13 (95% CI 8-21) 
spots per million (p=0.10) after FP9 ME-TRAP, and rising further to 113 per million 
(p<0.0005) after MV A ME-TRAP. By cultured ELI Spot, geometric mean resting 
memory responses were 35 per million at baseline, 245 per million after FP9 ME-TRAP 
(p=0.006), and 780 per million after MV A ME-TRAP (p<0.0005). Ex vivo responses 
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after the second FP9 ME-TRAP vaccination were not higher than baseline (p=0.82), and 
cultured responses were not measured. Responses 3 months post vaccination were still 
elevated above baseline for both ex vivo (17 spots, p=0.014) and cultured ELISpot (150 
spots, p=0.014). 
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Figure 4.8. ex vivo and cultured ELISpot responses in children over time. 
Samples were drawn at screening, one week after each vaccination, and 90 days after 
completing the regimen. Spot numbers per million PBMC are plotted (log scale) on the y 
axis. The time points are described by the sequence of vaccinations. For instance, FF+7 
refers to the timepoint one week after the second of two sequential FP9 vaccinations. 
Boxes show the distribution of results, the resting line indicating median response, upper 
and lower box boundaries showing 25th and 75th centiles, and the whiskers show 5th and 
95th centiles where there are outliers, or minimum and maximum results where there are 
no outliers. The circles show outlier results. Both the first FP9 ME-TRAP vaccination 
and the final vaccination with MV A ME-TRAP raised responses above baseline. 
Responses above baseline were seen after FP9 ME-TRAP (p=O.1 for ex vivo, p=0.006 for 
cultured ELI Spot), after MVA ME-TRAP (p<0.0005 for both assays) and at 90 days 
(p=O.O 14 for ex vivo, and 0.014 for cultured). n= 18 at all time points. 
0 
0 
0_ 
0 
~ 
u 
:! 
O'l 
a.. 0 
c:::: 0 
~ 0_ ~ 
"E 
o 
o 
o 
o 
Baseline F+7 FFM+7 FFM+90 
Cuttured ELiSpot 
o 
o B 
o 
Baseline F+7 FF+7 FFM+7 FFM+90 
Ex vivo ELiSpot 
81 
4.3.10 Halfdose FP9 ME-TRAP priming was more immunogenic thanfull dose. 
After the regimen using full dose FP9 and full dose MV A, the geometric mean response 
on ex vivo ELI Spot was 70 (95% CI 20-260). Geometric mean responses were higher for 
the regimes that used half dose FP9, at 197 eCI 164-240) spots per million for half dose 
FP9 then full dose MV A and at 94 spots (el 23-320) for half dose FP9 then half dose 
MV A, p=0.034 (Figure 4.9). 
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Figure 4.9. Ex vivo and cultured ELISpot responses in children hy vaccination 
regimen. 
Responses for cultured and ex vivo ELlS pots seven days after final vaccination are shown 
by regimen, which vary according to the doses of component vaccinations used. f refers 
to a half dose FP9 immunisation, i.e. 5xl07 plaque fonning units (pfu) FP9 ME-TRAP. m 
refers to half dose MVA immunisation, i.e. 7.5xl07 pfu MVA ME-TRAP, F to full dose 
FP9 immunisation, i.e. lx108 pfu FP9 ME-TRAP and M refers to full dose MVA 
immunisation, i.e. 1.5x108 pfu MVA ME-TRAP. These abbreviations are then used to 
describe the sequence of vaccinations in each regimen, so that fiM refers to 2 half doses 
of FP9 (given sequentially) followed by a full dose of MV A. Means according to FP9 
dose are shown by the dotted lines. The very first immunisations given to children only 
used a single FP9 dose. 2 children received fm and 2 children FM. These data are also 
shown. Immunogenicity was lower with full dose FP9, both for ex vivo (p=O.034) and 
cultured ELiSpot (p=O.058). 
0 
0 
u o. 
:! 0 .... 
III 
a.. 0 
c 0 0 0 ~ 0 0 o. 0 8 0 
's ..-- 0 8 
... 
00 ·········· .. 0·· 00 
cD 0 0 Q. 0 0 88 
.!!! 
.. 'W' "" 'w' ... ' ._ ..... 'W_" 0 
0 o 0 (j) 0 0 ' ........ ,_, ....... , ..... , .. ,.,_, 'w"''''''_' 
U 0 0 0°0 
C) 0 ...... _ .. _ .... _w. .. 0 .. 
c: 0 0 :;:; 0 0 cD 
... 
u 
cD 
II') 0 0 
I'll .... 
E 
E 
I'll 
C) 
z 
!!:: ..... 0 0 
FM FFM fm ffM ffm FM FFM fm ffM ffm 
Cultured ELiSpot Ex vivo ELiSpot 
83 
A similar pattern was seen on cultured ELI Spot. After full dose FP9, then full dose MVA 
the geometric mean response was 246 (CI 61-980). However, when half dose FP9 was 
used to prime the later MVA vaccination, mean responses were 755, CI 335-1700 (after 
full dose MVA) and 1220, CI 300-2100 (after half dose MVA), p=0.058. 
4.3.11 Half dose MVA ME-TRAP compared with full dose. 
Although MV A dose made no difference to responses seen on ex vivo ELI Spot (p=0.46), 
half doses appeared to be more immunogenic by cultured ELI Spot. The geometric mean 
response of all those given half dose MVA (i.e. ffm and fm) was 1110 (CI 650-1900), 
compared to 410 (CI 200-830) after full dose MV A (i.e. FFM, FM and ffM), p=0.05. 
However, half dose FP9 had been shown to be more immunogenic than full dose. When 
only half dose FP9 regimens were compared (i.e. ffm and fm compared with ffM), the 
responses were 1096 spots per million at low dose MV A (95% CI 630-2000) compared 
with 741 (95% CI 320-1600) at high dose, p=O.l6. 
4.3.12 There was no relationship between pre-vaccination anti-vector immunity 
and immunogenicity in children. 
Less PBMC were available for study in children, and anti-vector immunity was only 
measured seven days after the second FP9 vaccination. No correlation was found between 
pre-vaccination anti-vector immunity and the immunogenicity of the boosting vaccination 
with MV A ME-TRAP (r=0, after excluding the single outlying result, Figure 4.10). 
However, there was very little anti vector response evident after the second FP9 
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immunisation. The geometric mean was 2.5 spots per million, and the highest response 
18 spots per million. It appeared that in children, vaccination with FP9 did not induce 
cross reactive responses to vaccinia. 
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Figure 4.10 Pre vaccination anti-vector immunity against post vaccination insert 
response in children. 
The ex vivo response to vaccinia found before vaccination with MV A ME-TRAP is 
plotted on the x axis. The subsequent ex vivo response to the antigen insert is shown on 
the y axis. No correlation is seen (r=0 after excluding the single outlier). 
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4.3.13 To further examine the determinants of vector cross reactivity, adult 
responses were analysed by prior smallpox vaccination status. 
Responses at baseline to vaccinia virus were higher in those adults with scars suggestive 
of prior smallpox immunization. Geometric means were 4.5 (95% CI 2-10) without a 
scar, but 10 (CI 5-25) with a scar, p=O.OI (Figure 4.11). FP9 immunisations did not 
provoke a rise in vaccinia reactivity in subjects without previous smallpox 
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immunisations, among whom the geometric mean was 6 spots per million PBMC (CI 3-
10). However, in subjects with scars, FP9 induced a significant response, with a 
geometric mean of 45 spots per million (CI 18-122). This was significantly higher than 
baseline responses to vaccinia (p=O.021) and significantly higher than responses to 
vaccinia after FP9 in subjects without scars (p=O.027). Following subsequent 
immunisation with MVA, both subjects with and without scars had similar anti-vaccinia 
responses, at 94 spots (CI 35-225) with prior smallpox immunisation, and 89 (CI 42-176) 
without. 
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Figure 4.11 Comparison of anti-vector response by smallpox vaccination scar status 
(ex vivo ELlS pot). 
Ex vivo ELISpots using vaccinia rather than peptides representing the antigen insert were 
conducted. Responses are shown before immunization (baseline) and then 7 days after the 
first FP9 ME-TRAP or FP9 CS vaccination (F), or 7 days after MV A ME-TRAP or 
MV A CS was given (M). At each timepoint, responses are split according to the presence 
or absence of a scar from previous smallpox vaccination. Subjects with smallpox 
vaccination scars had higher responses at baseline (p=O.O 1) and after FP9 (p=O.OOO 1). 
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4.4 Discussion 
Alternating vector regimes (MFM or FMF) generated more persistent T cell 
responses than heterologous prime boost regimes (FFM or FM). Over 270 days the 
effector T cell response to alternating vector regimes was well sustained (84% of the peak 
response), but fell to pre-vaccination levels after heterologous prime boost vaccinations. 
The alternating vector regimes also raised stronger resting memory T cell responses, 
which did not fall over 270 days, whereas resting memory T cell responses to prime boost 
immunizations (FFM or FM) decayed to 33% of peak levels. 
Results from cultured ELI Spot assay may not have a linear relationship with the 
numbers of resting memory cells at the start of the assay. Culture conditions may 
disproportionately limit the proliferation of very high numbers of cells. It is possible that 
the limited proliferation of very high cell numbers masked a loss of resting memory cells 
following alternating vector immunization. However, if analysis was restricted to 
responses below 1500 cells per million, there was still no detectable fall in resting 
memory responses over 270 days. The mean response for this restricted analysis was very 
similar to that following prime boost vaccination (790 vs. 720 spots), for which a fall in 
responses over time was seen. 
This is an important finding in vaccine development for two reasons. Firstly the 
longevity of response is critical to efficacy in the field, and such sustained effector 
responses have not been previously described for T cell inducing vaccinations. Secondly, 
in both sporozoite challenge studies in non-endemic areas (Keating et al. 2005) and field 
trials in endemic areas (Reece et aI. 2004), the resting memory population of T cells 
correlated with protection against malaria. 
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4.4.1 Heterologous versus homologous boosting. 
Previous phase 1 studies in non-endemic areas demonstrated that multiple priming 
(i.e. two sequential FP9 ME-TRAP or DNA ME-TRAP immunizations before boosting 
with MV A ME-TRAP rather than one FP9 ME-TRAP or DNA ME-TRAP) increases the 
immunogenicity of viral vector vaccination regimes. However, neither multiple priming 
nor multiple boosting resulted in similarly maintained effector responses (McConkey et 
al. 2003). Memory cells begin to differentiate following the initial expansion of peak 
effector cells. In mouse models, T cell contraction is governed by early inflammation 
(Badovinac et al. 2004), but accelerated by dendritic cell stimulation (Badovinac et al. 
2005), perhaps by prolonged contact with the antigen. Repeated homologous vector 
boosting may not deliver the antigen because of significant anti vector immunity. 
However, alternating the vector might allow effective antigen delivery and expand the 
memory population, provided that strong anti-vector immunity is relatively short lived (as 
suggested in studies of MVA re-boosting in West Africa (Moorthy et al. 2004a». The 
effector population may be refractory to further stimulation at this stage (Corbin & Harty 
2005), and alternating vectors seems to improve memory but not increase the peak 
effector response. 
4.4.2 Pre-vaccination resting memory 
The responsiveness of the resting memory population pnor to vaccination 
correlated with in vivo effector response generated after single dose regimes (FP9 ME-
TRAP or MV A ME-TRAP), suggesting that the resting memory population are the pool 
of cells from which effector cells differentiate in vivo following a second antigen 
exposure, and this probably underlies the correlations seen with protection (Keating et al. 
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2005; Reece et al. 2004). Similar memory populations are not identified in malaria naive 
subjects (Keating et al. 2005), for whom single dose regimes are not immunogenic. 
However, primed boost regimes do not depend on pre-vaccination resting memory 
populations. There was no correlation between prior resting memory and effector 
response when considering prime boost regimes in this study, and those regimes were 
immunogenic in naIve subjects in previous studies (Webster et al. 2005). This was 
unlikely to represent a chance finding of subgroup analysis. A model with pre-
vaccination memory and vaccination group as interacting terms explaining post 
vaccination response was significantly better than a model without the interaction. 
4.4.3 CS vaccinations were less immunogenic 
It is unclear why CS vaccinations should be less immunogenic. It is unlikely that 
the lower immunogenicity is caused by natural exposure, since immunogenicity was also 
low in non-endemic areas (Walther M et aI, in preparation). It is possible that the GPI 
anchor motif included in the CS insert is responsible for this reduced immunogenicity 
(Bruna-Romero et al. 2004), although both immunogenicity and efficacy was observed 
when CS was delivered by the adjuvanted protein particulate vaccine RTS,S (Alonso et 
al. 2004; Lalvani et al. 1999). 
FFM was identified as more immunogenic than FM, and spacing prime and boost 
by 8 weeks instcad of 4 did not confer an advantage. Findings with DNA prime and 
MV A boost in naive subjects were similar (McConkey et al. 2003). Antibody responses 
have often been higher when longer intervals between vaccinations were used (Pittman et 
al. 2000). This may not be the case for T cell inducing vaccinations. 
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4.4.4 Batch variability 
Surprisingly, different batches of the same vaccine produced different 
immunogenicity. Both batches were prepared by GMP from the same master seed virus. 
FP9 ME-TRAP batch 020602 was more immunogenic as a single immunization and as 
priming for boosting with MV A. Repeated titrations of plaque forming units excluded an 
error in dosing, and titrations of viable virus from vials stored in Kilifi confirmed 
stability. Potency testing in mice was satisfactory for both batches. 
The less immunogenic batch (040803) was used in half the FM immunizations, 
and all the alternating vector immunizations. Although less inflammation has been 
associated with lower effector responses and stronger memory responses (Badovinac et 
al. 2004), this was not the case here, since the less immunogenic batch for effector 
responses (040803) was associated with greater cutaneous inflammation (see section 
3.3.1 0). Furthermore, this cannot explain the increased longevity seen with alternating 
vectors, since similar longevity was not a feature of prime boost FM immunizations using 
batch 040803. However, the use of batch 040803 for alternating vectors might well 
explain the lower peak effector response. 
4.4.5 Strain Cross-reactivity 
T cell responses to the insert after both vaccinations were crossreactive (figure 
4.4). This was demonstrable by pooling variant and synonymous peptides separately. Had 
they been pooled together, it would have been difficult to distinguish cross reactivity 
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because of responses to shared peptides from cross reactivity between polymorphic 
peptides. 
Responses to the circumsporozoite protein raised by natural exposure were almost 
entirely strain specific, but following immunisation marked strain cross reactivity was 
generated (figure 4.4). Responses at baseline favored 3D7. However 3D7 and 7G8 
responses were similar after MVA CS, despite the vaccine encoding 3D7 strain CS. 
Altered peptide ligands have been identified among the polymorphic regions of CS, and 
can render T cells capable of responding to one variant only (Good et a1. 1993). Repeated 
contact with various altered peptide ligands during natural exposure might "switch off' 
the T cell response to some peptides, and avoid repeated boosting of responses. The 
cytokine milieu following vaccination with viral vectors may reverse that process, and 
produce cross-reactive responses. Responses were strain specific after immunizations 
with RTS,S (Dunachie et a1. 2006; Lalvani et a1. 1999). Further studies are required to 
assess whether strain cross reactivity is a particular feature of delivery with viral vectors. 
These data from a malaria endemic area provide evidence that alternating vector 
regimes enhance memory over multiple boosting or multiple priming regimes, possibly 
by prolonging antigen exposure in the host. Increasing numbers of heterologous prime 
boost regimes are being developed to vaccinate against infectious pathogens such as HIV, 
HBV and M. tuberculosis and to treat chronic infections and cancer. These data suggest 
that alternating vector regimes should be assessed in the clinical development of such 
products. 
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4.4.6 Vaccination o/children 
Vaccination regimes that primed with FP9 ME-TRAP and boosted with MV A 
ME-TRAP were immunogenic in children. Responses were still evident 3 months after 
immunisation. Both immediate effector (seen on ex vivo ELISpot) and resting memory 
(seen by cultured ELISpot) T cells were significantly induced. However, the 
immunogenicity was slightly lower in children compared to adults. On ex vivo ELlS pot, 
the geometric mean responses after FFM ME-TRAP were 113 spots per million (CI 70-
180) among the children compared to 389 spots per million (95% CI 190-800) in adults. 
By cultured ELISpot, mean responses were 623 spots per million (390-1000) in children, 
compared with 810 spots per million (el 470-1150) among adults. 
4.4.7 Vector cross-reactivity 
The data from adult vaccinations suggested that FP9 induces some cross reactive 
anti-vector immunity against MV A in subjects who had previously received smallpox 
vaccination, and that this anti-vector immunity impairs the immunogenicity of subsequent 
vaccination with MV A ME-TRAP. This suggests that strategies to reduce the anti-vector 
responses raised by the priming might enhance the immunogenicity of the overall 
regImen. 
Immunisations of children were designed to compare regimes using half or full 
doses of FP9. Half dose priming with FP9 was associated with a marginal trend towards 
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increased immunogenicity for the malaria insert (p=0.035). The varying immunogenicity 
with FP9 and MY A doses should be interpreted with caution at this stage, since the 
sample size was relatively small (22 children), the spread of results quite wide, and little 
anti-vector immunity was identified after FP9 vaccination in children. However, cultured 
ELlS pot responses to the vector were not measured, and these might have explained the 
lower immunogenicity seen with full dose FP9 priming. 
In adults, anti-vector immunity was measured after the first FP9 ME-TRAP 
immunization. In children limited PBMC were available, so anti-vector immunity was 
only measured after the second FP9 ME-TRAP. However, since only infrequent anti-
vaccinia responses were seen after the second FP9 ME-TRAP vaccination in children, 
this is unlikely to represent a critical difference. 
4.4.8 Smallpox vaccination 
T cell responses to vaccinia virus were higher among those adults previously 
given smallpox vaccine, even though smallpox vaccinations were given more than 20 
years ago. Smallpox vaccination ceased in Kenya in 1980, and so none of the children 
could have been immunised. FP9 provoked cross reactive anti-vaccinia responses in 
adults volunteers with scars suggestive of previous smallpox vaccine, but anti-vaccinia 
responses were absent in adult volunteers without scars. This suggests an "original 
antigenic sin", i.e. prior memory cell populations reactive to vaccinia differentiate to 
effector phenotype specific to vaccinia on exposure to FP9. However, those without prior 
immunization develop primary responses to FP9, which do not cross react with vaccinia. 
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Original antigenic sin has also been observed in humans for T cell responses in 
chronic HIV and hepatitis B infection, when virus mutants emerge in vivo with variant T 
cell epitopes (Bertoletti et al. 1994). The subsequent host response may continue to be 
directed against the initial epitope rather than the new variant, allowing the virus to evade 
host immunity. The data presented here relate to a defined exposure and demonstrate the 
skewing of responses consequent on prior exposure to smallpox virus, despite the long 
time intervals involved. Since FP9 and MV A are highly attenuated, host immunity is not 
required to limit viral replication (Carroll & Moss 1997). No greater reactogenicity was 
observed in subjects with vaccinia scars, or the immunosuppressed subjects with HIV 
infection who received single dose immunizations to assess safety, described in section 
3.3.6. 
Prime boost regImes should ideally use vectors with minimal pre-existing 
immunity and vector cross reactivity. The former has particular relevance for adenovirus 
vectors. Recombinant adenovirus immunizations are increasingly being developed as 
vaccines in humans to induce strong T cell responses, and immunity against many 
serotypes is widespread. Natural exposure to adenovirus is high, particularly in malaria 
endemic areas. The data here suggest anti-vector immunity does limit immunogenicity in 
adults, and so efforts to genetically modify human adenovirus, or identify adenovirus 
from another species to limit anti-vector immunity are important. Similarly, cross-
reactive immunity between different pox virus vectors chosen in prime boost 
combinations may limit the immunogenicity of the boosting vector, and these data 
suggest vectors with less cross-reactivity will be more immunogenic. 
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4.4.9 Vaccine Dose 
Higher doses of MV A have been associated with greater immunogenicity by ex 
vivo ELI Spot (Moorthy et al. 2003a), but this was not so here (p=0.46). Unexpectedly, 
half dose MV A was instead associated with higher cultured ELISpot responses (p=0.05). 
Higher doses of MVA cause a greater local inflammatory reaction (section 3.3.9) and in 
mouse models this has been associated with greater contraction of T cells post 
vaccination (Badovinac et al. 2004). The lesser inflammatory reaction from half dose 
MV A may have resulted in less T cell contraction, and therefore the higher resting 
memory responses seen here. 
This work emphasizes the need for dose-finding studies in children with new 
vectored vaccines, and the potential for enhanced immunogenicity with half doses of 
priming vectors warrants further investigation. Since heterologous prime boost 
immunization regimes using FP9 ME-TRAP and MV A ME-TRAP were immunogenic in 
children, larger studies to determine protection against malaria were conducted. 
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5 Phase 2 in Kenya: Efficacy. 
A Randomized Controlled Trial to Measure Efficacy 
of the Candidate Malaria Vaccines FP9 ME-TRAP 
and MV A ME-TRAP in Children Aged 1-6 Years 
Old in a Malaria Endemic Area. 
Immunogenicity and safety data were acquired for adults and then children in Phase 1 
studies in Kenya before a Phase 2 study was undertaken (sections 3 and 4), including the 
FFM ME-TRAP regimen (i.e. two sequential FP9 ME-TRAP vaccinations followed by 
MV A ME-TRAP). Although single vector immunisations and alternating vector regimens 
were compared in phase 1 studies in adults, the FFM ME-TRAP regimen had 
demonstrated the greatest peak responses, and there was evidence of protection for this 
regimen in sporozoite challenge in naIve volunteers (Webster et al. 2005). The aim of the 
Phase 2b trial was to evaluate safety, immunogenicity and efficacy of the vaccination in 
the target population (i.e. children in a malaria endemic area), using mild febrile malaria 
as an endpoint. 
5.1 Methods. 
5.1.1 Study Design 
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The study was randomised, controlled and double blind. Ethical approval was 
obtained from the Kenyan Medical Research Institute National Ethics Committee, the 
Central Oxford Research Ethics Committee, and the London School of Hygiene and 
Tropical Medicine Ethics Committee. An independent Data Safety Monitoring Board and 
a Local Safety Monitor were appointed. The DSMB reviewed all serious adverse events 
as they occurred, approved the selection of vaccine dose based on previous phase 1 
studies, and reviewed the analysis plan. Research was conducted in accordance with the 
Helsinki Declaration of 1975 (revised 1983). The trial was conducted according to Good 
Clinical Practice. Oxford University, acting as trial sponsor, arranged external monitoring 
and oversaw the conduct of the trial. 
405 children were immunised with at least one dose of vaccine. Blood tests for 
immunology, safety, and cross-sectional assessments of malaria parasitaemia were 
conducted pre-vaccination, at screening, one week after the third vaccination, then at 3 
months and at 9 months. Monitoring for solicited adverse events was conducted for one 
week after each vaccination. Unsolicited adverse events and episodes of malaria were 
monitored throughout the 1 year study duration. Children were screened in February 
2005, immunised between March 2005 and May 2005, and followed up until February 
2006. Monitoring is continuing in a further study. 
5.1.2 Location 
The study was carried out in Junju sublocation in Kilifi District, on the Kenyan 
coast. Junju contains a group of 5 closely related villages within the Chonyi area of Kilifi 
district. Junju lies between Kilifi and Mombasa, 14 km inland from the coastal road. 
Kilifi is malaria endemic, with all year round transmission and two high transmission 
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seasons (Mwangi et al. 2005). The transmission intensity is 22-53 infective bites per year 
(Mbogo et al. 2003). Junju is served by a local government dispensary, which has an 
active ITN distribution programme. Inpatient care is provided at Kilifi District Hospital. 
5.1.3 Study Participants 
The participatin~ children were aged 1-6 years old (inclusive), healthy, and 
resident in the study area. After a series of public meetings and individual discussions, a 
screening date was set at which study information was repeated, and consent was sought 
before proceeding. Subjects were not immunized until at least one week after their 
parents signed consent, to allow the parents time to consider their decision. 
Children were screened by history, examination and blood tests (full blood count, 
creatinine, alanine transaminase). Subjects with clinically significant illness were 
excluded. Clinically evident immunsuppression was one of the criteria for exclusion, but 
no children were excluded on this basis. HIV testing was not conducted. Abnormal 
alanine transaminase or creatinine levels were exclusion criteria, but anaemia without 
clinically significant signs and symptoms was not (although iron supplementation was 
given). Recent blood transfusions (2 months), current participation in another clinical 
trial, or receipt of another experimental vaccine were also exclusion criteria. Eligible 
children were invited to attend vaccination in the order in which they were screened. 
5.1.4 Vaccines 
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The antigen insert used was TRAP, joined to a multiple epitope (ME) string from 
six P. Jalciparum pre-erythrocytic antigens (Gilbert et al. 1997). The ME string contains 
14 pre-erythrocytic MHC class I epitopes from six P Jalciparum pre-erythrocytic 
antigens, three class II epitopes, two pre-erythrocytic B cell epitopes and pb9 (a 
Plasmodium berghei T-cell epitope that allows pre-clinical potency and stability testing). 
The vectors used were an attenuated fowlpox virus, FP9, and modified vaccinia 
virus Ankara. Recombinant vaccine stock was supplied to contract manufacturer IDT 
(Rosslau, Germany), who produced clinical lots under GMP conditions. Single batches of 
FP9 ME-TRAP and MV A ME-TRAP were used throughout (both batch 051204). 
The trial vaccination regimen was two sequential FP9 ME-TRAP vaccinations 
(5x107 plaque forming units) followed by MVA ME-TRAP vaccination (1.5x108 plaque 
forming units), given intradermally. The control was rabies vaccine (Aventis Pasteur, 
WIST AR strain), administered according to the same timings. Rabies was also given 
intradermally, at 0.25 IV. Vaccinations were spaced 4 weeks apart (acceptable range 3-5 
weeks). 
5.1.5 Randomization and Vaccination 
Vaccines were shipped to Kenya on dry ice with logged temperature monitoring, 
stored at -80°C, and transported to the field in cool boxes for use within 6 hours. 
Vaccines were given intradermally over the deltoid area of the non-dominant arm, using a 
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27 gauge needle to raise a visible intradermal bleb. Volunteers were observed for 1 hour 
with resuscitation facilities available for advanced life support. Children received vitamin 
A supplements with each vaccination, as per Government of Kenya guidelines, and 
parents were given two doses of paracetamol syrup for use if the child developed fever at 
night. 
Eligible children were assigned a randomization number, and vaccine group 
allocated using restricted randomization in blocks of 10 after sorting the list of eligible 
subjects by age and village. Randomization envelopes were prepared and sealed in the 
UK, without the involvement of any investigators involved in enrolling or assessing 
children at the study site. Each child was assigned the sealed opaque envelope bearing 
their study number, which was opened when they attended for the first vaccination. The 
nurses who administered vaccinations did not take part in any other trial related 
procedure, and were subsequently based in Kilifi District Hospital rather than the trial 
site. They drew up vaccinations according to the instructions in the randomisation 
envelope, and documented the vaccination in notes that were not available to the 
investigators until after unblinding, after follow up was completed for all children. The 
randomisation envelopes were re-sealed after each vaccination, and stored in a locked 
office for re-use at subsequent vaccinations. Neither parents nor investigators were told of 
the vaccination allocation, and the investigators did not enter the vaccination room while 
vaccinations were conducted. 
5.1.6 Assessment of safety. 
Field workers visited subjects daily for the first three days after vaccination and at 
one week after vaccination. Solicited adverse events were recorded, and the diameters of 
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skin discolouration, and blistering measured. Loss of the epidermis or upper part of the 
dermis was described as a deroofed blister. If unsolicited adverse events were reported, 
these were assessed and documented by a medically qualified investigator. Blood tests for 
routine biochemistry (plasma alanine transaminase and creatinine) and haematology (full 
blood counts) were conducted 7 days after the final vaccination, then at 3 months and 9 
months. 
5.1.7 ELISpots 
ELISpots were conducted and analysed as described previously (section 4.2.1 and 4.2.2) 
5.1.8 Monitoring/or malaria episodes. 
The primary endpoint was a clinical episode of malaria, defined as an axillary 
temperature greater than 37.5 degrees centigrade, with a Plasmodium falciparum 
parasitaemia greater than 2,500 parasites per Jll. The presence of any faIciparum 
parasitaemia with fever above 37.5 degrees was a secondary endpoint. 
Estimating a 50% incidence of malaria, the study was designed to detect 35% 
efficacy with 80% power by enrolling 400 children. In fact there was less malaria 
transmission than expected (as in most of East Africa in 2005) and only a 25% incidence 
was recorded, and so the actual trial was only powered to detect 50% efficacy. 
Asymptomatic parasitaemia is common in children under endemic conditions 
(70% of children in this study). If a child with asymptomatic parasitaemia is evaluated 
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during an unrelated viral illness, they will be wrongly ascertained as a case of febrile 
malaria (Schellenberg et aI. 1994). An endpoint with low specificity leads to a misleading 
estimate of efficacy (Scott et al. 2005), and I therefore sought to minimise the effect of 
asymptomatic, chronic parasitaemia in three ways. A previously defined threshold 
parasitaemia was used for the diagnosis of malaria (Mwangi et al. 2005), all children 
received curative treatment for malaria before monitoring began, and only children where 
fever was confirmed by measurement (rather than simply reported) had blood films made. 
This latter measure is important since subjective reporting of fever by parents is not 
specific for objective fever (Mwangi et al. 2003). 
The curative treatment was given one week after the final vaccination, using 7 
days of directly observed dihydroartemisinin monotherapy (2mg per kg on the first day, 
followed by lmg per kg for 6 days). Blood films were taken to confirm children were 
parasite-negative one week after the end of treatment. 
Children were then visited every week by fieldworkers. The mother was asked 
whether she thought the child was hot, and the axillary temperature was also measured. 
When the temperature was greater than 37.5 degrees, a blood film was made and a rapid 
near-patient test for malaria conducted. The blood film was reviewed within 24-48 hours, 
but treatment decisions were based on the rapid test result. 
When the mother reported the child was hot, but an objectively elevated 
temperature was not identified, blood films and rapid testing was not performed, but the 
field worker returned to the child a further three times in the next 24 hours. Rapid testing 
and blood films were performed if the temperature was elevated on any of these visits. 
Parents could bring their children for assessment in between regular weekly visits if they 
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thought the child had developed fever, and the child was assessed as above. Field workers 
were recruited from the villages in which the study was conducted, and so were readily 
accessible to the parents. Treatment for episodes of malaria was with the Government of 
Kenya recommended first line treatment, artemether-Iumefantrine. 
During blood tests for safety and T cell response, blood films were made on all 
children. The results of this testing was not available for several weeks, during which 
monitoring of febrile illnesses continued. Asymptomatic parasitaemia was therefore not 
treated unless the child developed a fever. All blood films (from well children and febrile 
children) were counted in duplicate by two microscopists, and a third count conducted if 
they were discrepant. 
5.1.9 Analysis 
No interim analyses were planned or conducted, and the analysis plan was 
approved by the DSMB before unblinding. The primary analysis was a log rank test 
comparing the time to the first or only episode of malaria (defined as fever with 
parasitaemia above 250011lL) between the vaccination groups, stratified by age group, 
ITN (insecticide treated net) use and village, for both ATP and ITT subjects. The hazard 
ratio and 95% confidence interval was estimate by Cox's regression adjusted for the same 
covariates. Age group was a categorical variable with three levels (1-2 years old, 2-5 
years old, 5-6 years old). Village had 5 levels. ITN use was defined as sleeping under a 
treated net every night, which had less than three holes into which a finger could 
comfortably fit. 
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Poisson regression was used to estimate the incidence rate ratio taking into 
account all malaria episodes, adjusted for the same covariates. A period of 28 days after 
each malaria episode was deducted from the person time at risk, since individuals were 
assumed not to be at risk of malaria during this period. In secondary analyses, malaria 
was defined as fever with parasitaemia at any density. ELISpot results were log 
transformed, substituting one spot per million for negative results (half the lower limit of 
detection), and then Students T tests used to compare results. To examine the effect of 
ELISpot results on episodes of malaria, the responses were divided into tertiles, and the 
terti Ie was then used as a categorical variable. 
The analysis plan specified that monitoring of malaria episodes would continue 
for a further 9 months, after which a second analysis of episodes would be conducted. 
5.2 Results. 
5.2.1 Trial profile 
530 children were screened. Eligible children were invited to attend for 
vaccination in the order in which they were screened. Vaccination continued until at least 
400 children were immunised (on the last day of vaccination, the total had reached 405). 
The trial participants were balanced between treatment allocation groups in both 
demographic characteristics at baseline and progress through the trial (Table 8). 275 of 
386 children (71%) were parasitaemic at baseline (data for parasitaemia was missing for 
one child at baseline). 73 children received anti-malarial treatment for intercurrent febrile 
malaria during vaccinations. Blood films were not taken on the days of vaccination, but 
179 of 374 children (52%) were parasitaemic one week following final vaccination, 
before receiving anti-malarials at the start of monitoring. 
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Table 5.1. Baseline covariates for children enrolled in the Phase 2b trial. 
Covariate 
Village 
Gongoni 
Junju 
Kolewa 
Mapawa 
Mwembe Tsungu 
Age Category (years) 
1-2 
2-5 
5-7 
ITN* (baseline) 
Without 
With 
ITN (end) 
FFM ME-
TRAP 
36 
50 
50 
39 
15 
36 
107 
47 
135 
54 
Rabies 
40 
50 
59 
32 
16 
41 
108 
48 
140 
54 
Without 75 70 
With 113 123 
Parasitaemia at screemng 134 141 
visit 
Without parasitaemia 55 56 
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* ITN use was defined as sleeping under an insecticide treated net every night with less 
than three holes that could comfortably admit a finger. ITN data is missing for 4 children 
at baseline and 6 at the end. Data on parasitaemia at screening was missing for 1 child. 
The Intention To Treat (ITT) cohort included all children who received any 
vaccinations where data was available for at least one week's surveillance for episodes of 
malaria. The According To Protocol (ATP) cohort included only children where 
immunisations and pre-monitoring anti-malarial therapy were given as planned. In total 
346 children were vaccinated According To Protocol, and an additional 41 children were 
included only in the Intention To Treat analyses (Figure 5.1). 15 of the original 405 
vaccinees did not complete all three vaccinations, and 1 child moved out of the area after 
the third vaccination but before monitoring for malaria episodes began. The 41 children 
included in ITT analysis but not ATP had received all three vaccinations, but 28 had not 
complied with observed anti-malarial therapy, and 17 had incorrect timings of 
vaccinations. Nevertheless, all subjects had received the correct doses of the correct 
vaccination. Of the 28 who had not complied with treatment, blood films were available 
from only 8, of whom 7 were positive for malaria parasites. The distribution of A TP and 
ITT groups by vaccination is given in Figure 5.1. After screening for eligibility, parents 
were invited to bring their children back to the dispensary for immunisation. Children 
were randomized on attending for vaccination. 
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Figure 5.1 The Trial Profile for phase 2b efficacy trial .. 
Trial Profile 
Assessed for eligibility 
(n=530) 
! I Randomized (n=405) I Excluded on eligibility (n=5) 
1 ~ Did not attend vaccination (n=120) 
Allocated to placebo (n=204) 
First Dose (n=204) 
Last Dose (n=198) 
Pre-surveillance treatment (n= 182) 
1 
At least one follow up visit (n=197) 
9 months follow up (n=192) 
! 
Analyzed ATP n=171 
Analyzed ITT n=197 
5.2.2 Safety 
r-------------------------~ 
Allocated to FFM ME-TRAP (n=201) 
First Dose n=201 
Last Dose n=190 
Pre-surveillance treatment (178) 
1 
At least one follow up visit n=190 
9 months follow up n=188 
1 
Analyzed ATP n=175 
Analyzed ITT n=190 
The vaccine was well tolerated. 10 serious adverse events occurred. 4 occurred 
after rabies vaccination (severe malaria, gastroenteritis, trauma and asthma) and 6 after 
FFM ME-TRAP (severe malaria, an abdominal skin infection distant to the vaccination 
site, trauma, gastroenteritis and multiple seizures). The serious adverse events identified 
were not unexpected events given the study population, were not closely related to 
vaccination in timing, and were judged unlikely to be linked to vaccination by the 
investigators and the Data Safety Monitoring Board. Local cutaneous discolouration was 
frequent (seen after 72% of FP9 ME-TRAP vaccinations and 64% of MVA ME-TRAP 
vaccinations). Cutaneous blistering occurred after 16% and 19% of FP9 and MVA 
vaccinations respectively, but blistering with a diameter greater than O.Scm occurred at a 
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rate of 1-4%. No blisters were greater than lcm in diameter, or associated with reports of 
marked pain. Marked pain was reported by the children's parents after 0.5% of 
vaccinations. Keloid formation or hypertrophic scars were not seen. Systemic adverse 
events and limitations of normal daily activities (such as appetite and play) were rare, and 
distributed evenly between the control (Rabies) vaccine recipients and the poxvirus 
vaccine recipients. (Table 5.1). 94% of those receiving a first vaccination returned to 
complete the course of 3 vaccinations. The range of routine haematology and 
biochemistry results, and frequency of abnormal results, was similar for the two groups. 
No abnormal laboratory results were attributed to vaccination. Very long term, passive 
follow up for safety is possible because of the Demographic Surveillance Study (DSS) 
well established in the area. 
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Table 5.2. Solicited adverse events: Frequencies of children experiencin2 the named 
adverse events at any time during the first week of monitorin2 after vaccinations 
given in the Phase 2b trial. 
Confidence 
Vaccination Adverse event Freq. Percent 
interval 
1 sl FP9 ME-TRAP Any blister 32 15.9% (10-20%) 
2nd FP9 ME-TRAP Any blister 31 16.1% (10-21%) 
MVAME-TRAP Any blister 36 19.0% (13-24%) 
Rabies Any blister 13 2.2% (0-3%) 
1 sl FP9 ME-TRAP Blister >0.5 cm diameter 8 4.0% (1-6%) 
2nd FP9 ME-TRAP Blister >0.5 cm diameter 2 1.0% (0-2%) 
MVAME-TRAP Blister >0.5 cm diameter 7 3.7% (1-6%) 
Rabies Blister >0.5 cm diameter 2 0.3% (0-1 %) 
1 st FP9 ME-TRAP Marked local pain and reduced activities 0 0.0% (0-1 %) 
2nd FP9 ME-TRAP Marked local pain and reduced activities 0 0.0% (0-1 %) 
MVAME-TRAP Marked local pain and reduced activities 1 0.5% (0-1%) 
Rabies Marked local pain and reduced activities 0 0.0% (0-1%) 
Marked local pain without impact on 
1st FP9 ME-TRAP 1 0.5% (0-1%) 
activities 
Marked local pain without impact on 
2nd FP9 ME-TRAP 0 0.0% (0-1%) 
activities 
Marked local pain without impact on 
MVAME-TRAP 2 1.1% (0-2%) 
activities 
Marked local pain without impact on 
Rabies 0 0.0% (0-1%) 
activities 
112 
1st FP9 ME-TRAP Temp>39.0 degrees 2 1.0% (0-2%) 
2nd FP9 ME-TRAP Temp>39.0 degrees 0 0.0% (0-1%) 
MVAME-TRAP Temp>39.0 degrees 2 1.1% (0-2%) 
Rabies Temp>39.0 degrees 1 0.2% (0-1%) 
Freq. refers to the number of children experiencing the adverse event listed. 'Reduced 
activities' refers to children whose parents stated they were not eating or not playing after 
receiving the vaccine. 'Marked pain' refers to the report given by parents, who were 
offered the options 'none', "a little" or "a lot" of pain experienced by the child after 
vaccination (excluding the immunisation itself). Adverse events for rabies vaccinations 
are given by aggregate for all vaccinations. 
5.2.3 Immunogenicity 
The vaccine was immunogenic (Figure 5.2). T cell responses were measured using both 
the ex-vivo and the cultured ELISpot, and both assays detected a response to vaccination. 
This was significantly greater than the response measured pre-vaccination (p<0.0005), 
and greater in FFM ME-TRAP vaccinees than children receiving control vaccinations 
(p<0.0005). Ex vivo T cell responses rose from 30 spots per million before vaccination 
(95% confidence interval 21-40) to 107 spots per million (95% CI 88-127) after 
vaccination. Cultured responses rose from 123 spots at baseline (95% CI 104-142) to 407 
(95% CI 349-464). 9 months post vaccination, the mean response among FFM ME-
TRAP vaccinees remained above the control group for both ex vivo (44 spots among 
FFM ME-TRAP vaccines, 95% CI 32-57, compared with 27 spots among controls, 
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95%CI 21-32) and cultured ELISpot (464 spots, CI 371-557 compared with 206 spots, CI 
156-256), p=0.015 for ex vivo, p<0.0005 for cultured ELI Spot. 
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Figure 5.2. T cell responses to vaccination identified by both ex vivo and cultured 
ELISpot, are displayed by time. Median, 25th and 75th quartile, 5th and 95% quartile and 
outlying results are given by box and whisker plots. Data was available for 400 children 
at screening (i.e. pre-vaccination), for 379 seven days after the last vaccination, for 345 at 
three months and 304 at nine months. T cell numbers were similar at baseline for ex vivo 
(p=OA) and cultured (p=0.91) responses. Ex vivo responses were higher among FFM 
vaccinees at one week (p<0.00005), three months (p=0.27) and nine months (p=0.015), as 
were cultured responses (p<0.00005, p=0.0007 and p<0.00005 respectively). 
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5.2.4 Efficacy 
The cumulative incidence of malaria (fever with parasitaemia >2500/JlL) was 
52/190 children in the malaria vaccine group and 40/197 in the control group, (stratified 
log rank test -/=2.2, P=O.l4), with a hazard ratio of 1.5, 95% confidence interval 1.0 to 
2.3.346 children were vaccinated according to protocol and followed up, of these 40/175 
had malaria in the malaria vaccine group compared to 36/171 in the control group, 
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(stratified log rank test X 2=0.36, P=0.55; hazard ratio 1.3, 95%CI 0.83 to 2.1). Kaplan-
Meier plots are shown in figure 5.3. 
In a secondary analysis, the number of malaria cases (malaria defined as fever with 
parasitaemia at any density) was 69/190 in the malaria vaccine group and 54/197 in the 
controls, stratified 10grank test X 2=2.79, P=0.095, hazard ratio 1.5 (95%CI 1.0 to 2.1), 
and among those vaccinated according to protocol, 58/175 and 48/171 respectively, 
10grank test X 2= 1.26, P=0.26. 
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Figure 5.3. The probability of remaining free of clinical malaria is plotted over the 9 
months of monitoring (the primary analysis). Numbers of children at risk are given 
below the Kaplan Meier plots. Both plots use an endpoint of >2,500 parasites per 
microlitre and fever, plot a) describes the Intention To Treat (ITT) group, plot b) 
describes According To Protocol (ATP). P=0.55 for plot a), 0.14 for plot b). 
Kaplan Meier plots of the probability of remaining free of clinical malaria 
(fever plus parasitaemia >2,500 per ul). 
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Multiple episodes were modelled by Poisson regression, adjusted for the same covariates. 
There were 0.46 episodes of malaria (fever with parasitaemia >2500IJlL) per person year 
among the FFM ME-TRAP vaccinees, and 0.36 episodes per person year among the 
control group (incident rate ratio 1.6, 95%CI 1.1 to 2.3, P=O.O 17). Among those 
vaccinated according to protocol, the rate ratio was 1.4 (95%CI 0.89 to 2.1, P=0.16). 
When these analyses were repeated using malaria definition of fever with any 
parasitaemia, the rate ratios were 1.5 (1.1 to 2.0), P=O.O 13 (ITT) and 1.4 (0.96 to 1.9), 
P=0.08 (ATP). Incidence rate ratios are plotted in figure 5.4. 
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Only two episodes of malaria required hospital admission (one In each vaccination 
group), and neither of these met accepted criteria for severe malaria. 
5.2.5 Co variates 
Age, village and ITN use were specified as covariates. Older age was significantly 
protective on both Cox survival analysis for time of first episode (HR =0.24, CI 0.1-0.54, 
p=O.OOI) and poisson regression for number of episodes (Incidence Rate Ratio=O.2, CI 
0.09-0.42, p<0.0005). Village was a significant factor in both analyses (p=0.0093 in Cox, 
p=0.012 by poisson). There was a tendency towards a protective effect of Insecticide 
Treated Net use on Cox (HR=0.84, CI 0.47-1.48 p=0.55) and poisson regression for 
multiple episodes (IRR=0.6, CI 0.36-1.04, p=0.07). However, analysis of ITN use was 
complicated by the increased prevalence of use from 28% at baseline to 62% by the end 
of the study. 
5.2.6 Secondary Analysis by Sub-group 
The possibility that susceptibility might vary by T cell response to vaccination 
(either by ex vivo or cultured ELISpot) was considered. Vaccinees were divided into 
tertiles according to the ex-vivo or cultured ELI Spot responses measured one week after 
vaccination, and each tertile was compared with the control group (Fig 5.4). No clear 
trend for differential susceptibility according to immunogenicity was seen, and a log 
likelihood ratio test suggested the two models using immunogenicity (ex vivo and 
cultured) were not significantly better than using covariates alone (Log likelihood testing 
gave p=O.4 for ex vivo and p=0.24 for cultured). However, owing to the overall low 
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immunogenicity seen in this trial, the arithmetic mean was only 228 spots per million on 
ex vivo ELI Spot in the highest tertile. Exploratory analysis divided vaccinees into 7 
groups of 28 children per group (on average), according to ex vivo T cell response. The 
highest responders were at a mean of 325 spots per million, but still had more frequent 
episodes of malaria than the control group (Hazard Ratio=2.39, 9S% CI 1.1-S.9). The 
highest 27 responders by cultured ELI Spot were at mean response of 1,130 spots per 
million, and the Hazard Ratio was 1.76, 9S% CI 0.78-4 compared with controls. 
Cultured and ex vivo ELI Spots were also conducted at 3 months and 9 months 
post vaccination. Data for number of episodes of malaria were split into 3 three month 
blocks, and T cell responses related to each block divided into tertiles for comparison 
with control vaccinations as above. As with the survival analysis, there was no indication 
that immune response predicted susceptibility to malaria (p=0.4, p=0.29 for log 
likelihood). 
Other endpoints were haemoglobin and parasitaemia detected at cross-sectional 
surveys at 3 and 9 months. These were not different between vaccination groups, with the 
prevalence of parasitaemia at 29% and 26% at 3 months and 33% and 33% at 9 months 
for FFM ME-TRAP and the control group respectively. Mean haemoglobin was 11.1 g/dl 
before monitoring began, and 10.1 (9S% CI 9.8-10.S) in both the FFM ME-TRAP and 
control group. 
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Figure 5.4 The results from secondary analyses of malaria episodes are shown. 
These multiple analyses were generated by varying the case definition and statistical 
methodology, and are shown for both ATP and ITT. The more rigorous case definition 
(>2500 parasites per JlI and fever) is the first in each group of comparisons. Cox 
regression was used to estimate hazard ratios for time to first episode (panel a) and 
poisson regression was used to estimate incidence rate ratios for the frequency of 
episodes (panel b). Models were adjusted for age, village and ITN use. The two groups of 
3 points to the right of each panel show the hazard ratios and incidence rate ratios for 
subgroups FFM ME-TRAP vaccinated subjects. Subjects were divided into tertiles based 
on either ex vivo or cultured ELISpot responses. Hazard ratios and incidence rate ratios 
for each tertile relative to the control group are shown, using a case definition of 
parasitaemia >2500 and fever. 
Hazard ratios (a) and Incidence Rate Ratios (b) for the effect of vaccination 
according to population and endpoint, and for T cell responses by terti Ie. 
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5.3 Discussion. 
Apart from BeG trials, no other vaccines that primarily induce T cells responses 
have been studied for efficacy in children. I report here a phase 2b evaluation of one of 
very few vaccines shown to protect against malaria in challenge studies in human 
volunteers. 
FFM ME-TRAP was safe when given to 1-6 year old children in an endemic area. 
It was also immunogenic, but not as immunogenic as in malaria naive (Webster et al. 
2005) or semi-immune adults (Moorthy et al. 2004a), and was not protective against 
episodes of clinical malaria. Although more malaria episodes were observed in the 
malaria vaccine group, the difference was not significant by primary analysis. 
5.3.1 Blinding 
Intradennal poxvirus vaccinations are associated with skin discolouration and 
blistering (see 3.3.4). This was unlikely to have compromised blinding, since children 
were routinely assessed by fieldworkers who were unaware of an expected difference in 
local reactogenicity. Furthennore, 16% of intradennal rabies vaccinations in the trial 
were associated with skin discolouration. 
5.3.2 Adverse T cell responses 
It is theoretically possible that TRAP responses induced by vaccination might be 
anti-inflammatory, and so reduce naturally-acquired protective responses (Flanagan et al. 
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2006). Altered peptide ligand effects of vaccination could increase susceptibility to 
malaria (Gilbert et al. 1998), and high levels of TGF beta release after vaccination might 
promote parasite growth (Walther et al. 2005b). However, there was no indication in our 
study that higher T cell responses predicted greater susceptibility to malaria within the 
vaccination group (either cultured or ex vivo). Furthermore, naturally acquired responses 
were not associated with protection among the control group in this study (as in a 
previous study of natural immunity (Flanagan et a1. 2003». It therefore seems unlikely 
that vaccine induced responses could lead to greater susceptibility by suppressing 
naturally acquired responses. The DNA-MV A regimen tested in The Gambia induced 
stronger T cell responses to TRAP than seen here, but there was no evidence of enhanced 
susceptibility in vaccinees (Moorthy et al. 2004b). There is therefore no obvious 
hypothesis to link vaccine induced responses with enhanced susceptibility, and the 
significance testing by primary analysis suggests that this was a chance finding. 
5.3.3 Moderate immunogenicity. 
FFM ME-TRAP was only moderately immunogenic in this population, despite the 
strong immunogenicity observed previously. In particular, stronger immunogenicity was 
seen in previous phase 1 studies in adults and children in Kilifi. Arithmetic mean 
responses by ex vivo ELISpot were 610 spots per million PBMC in malaria naive adults 
(Webster et al. 2005) but 350 spots per million in semi-immune adults in The Gambia 
and 360 spots per million in Kenya (see 4.3.2). The arithmetic mean T cell response 
during phase 1 trials in children in Vipingo, Kilifi was 200 spots per million, and in the 
Phase 2b study in Junju reported here, arithmetic mean responses were 107 spots per 
million. Vipingo, the site of the earlier phase 1 trial (4.3.8), lies only 3-4km from the 
main coastal road and has an annual EIR of 1, compared to the EIR of 22-53 in Junju 
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(Mbogo et al. 2003). It seems that immunogenicity is moderately reduced for semi-
immune adults compared with malaria naive adults, and reduced further among children 
in a malaria endemic area. The children immunised in the phase 1 trials lived on a 
plantation in Kilifi, where there is slightly lower transmission intensity than among the 
children immunised in the phase 2b trial in Junju. 
5.3.4 Batch variability 
It has recently been shown that different batches of FP9 ME-TRAP can be 
associated with different immunogenicity (4.3.5), and work to assess factors that may 
underlie this variability is in progress. However, studies on semi-immune and naive 
adults used the same batch of vaccine, and preliminary studies in the same group of semi-
immune adults suggested that the batches used for phase 1 and phase 2b trials in children 
had similar immunogenicity. It is therefore unlikely that most of the observed variation in 
immunogenicity is accounted for by batch variation. 
5.3.5 Immunosuppression 
Several studies have shown dendritic cell function to be impaired by malaria and 
other chronic infections (Wilson et al. 2006), and placental malaria induces T regulatory 
responses at birth (Brustoski et al. 2006). The children in Junju had greater malaria 
exposure than the children from the plantation in phase 1 studies. Semi-immune adults 
have less frequent blood stage malaria infection than children, but more than naive 
volunteers. The association between poor immunogenicity and more frequent malaria 
might be causal. There may also be other relevant factors, such as infection with other 
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parasites (Nookala et a1. 2004; Sabin et a1. 1996) or nutrition, and these will be explored 
later (section 6.3). 
The ex vivo T cell responses previously associated with protection of naIve 
volunteers in sporozoite challenge were at a mean of over 500 per million PBMC. It has 
previously been demonstrated that the much lower responses (mean 44 spots per million 
PBMC) are not protective in the field (Flanagan et a1. 2003). In the trial presented here, 
the mean response to vaccination was 110 spots per million PBMC, and was not 
protective. Furthermore, the mean response in the upper terti Ie of responders was 230 
spots per million, and there was no tendency towards protection against episodes of 
malaria (HR 1.26, CI 0.68-2.33) although the confidence intervals in this analysis are 
now very wide. Similarly, in an exploratory analysis examining the 30 highest 
responders, among whom the mean response was 325 spots per million, the Hazard Ratio 
was 2.39 (CI 1.1-5.18). 
Data from sporozoite challenge studies suggests that cultured ELlS pot responses 
to examine resting memory T cells (Keating et a1. 2005) may be a better correlate of 
protection than ex vivo responses. The mean cultured response in the present study was 
407 spots per million, compared with previous studies showing 810 spots per million for 
adults and 880 per million for children in Kilifi (4.3.3 and 4.3.9), and 500 per million in 
adults in the UK (Keating et a1. 2005). The cultured responses in the present study were 
durable (Figure 5.1), but not associated with protection (Figure 5.3). 
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5.3.6 Conclusions 
There was thus no tendency towards protection with higher ex vivo or cultured 
ELISpot responses. This suggests that similar T cell inducing vaccinations designed for 
malaria endemic conditions should demonstrate considerably greater immunogenicity in 
phase 1 studies in the target population before progressing to phase 2 studies. However, it 
might be possible to induce qualitatively different T cell responses that are more 
protective in sporozoite challenge studies. For instance FP9 MV A regimes induce more 
CD8 responses than DNA MV A regimes, and these are more protective in animal models 
(Anderson et al. 2004). 
It is unclear whether similar reductions in liver parasites to those seen in 
sporozoite challenge (section 2.3.1) might have occurred in this trial without a reduction 
in clinical episodes, but these reductions might be expected among children with the 
highest T cell responses. These data, together with the Phase 2a and 2b data for 
RTS,SI AS02 (Alonso ct at. 2004; Stoute ct al. 1997) suggest that greater than 90% 
reductions in liver parasites are required for protection in the field. 
This trial reports a novel design for field trials of interventions against malaria. 
The method of monitoring described here identifies a clinically relevant endpoint (febrile 
malaria) with a uniform case definition, and without the unpredictable element of health 
seeking behaviour involved in passive case detection. This approach will be suitable for 
further phase 2b field trials without requiring the larger sample sizes involved in passive 
case detection studies. This trial also suggests a threshold of T cell responses that pre-
erythrocytic vaccines will need to exceed in order to provide measurable efficacy in 
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children, and raIses the possibility that T cell inducing vaccines may show lower 
immunogenicity in higher transmission settings. 
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6 Malaria and Immunosuppression: 
(The induction and persistence of T cell responses 
after natural exposure and vaccination is reduced by 
. prIor exposure to Plasmodium Jalciparum 
parasitaemia. ) 
6.1 Background 
The vaccination regimen FFM ME-TRAP was not protective among children in 
the field, and the immunogenicity of vaccination appeared lower than seen previously 
(5.2.3). Some epidemiological observations suggest that cellular responses may be 
suppressed in malaria endemic areas (Floyd et aI. 2002; Greenwood & Armstrong 1991; 
Greenwood et al. 1972), but it is not clear why. Malaria infected erythrocytes modulate 
dendritic cell function in vitro, inhibiting T helper cell induction (Urban et al. 1999; 
Wilson et al. 2006) and stimulating T regulatory cells (Riley et al. 2006), but the evidence 
that associates malaria with immunosuppression in vivo is limited. Routine childhood 
antibody inducing vaccinations appear to be effective in malaria endemic areas, and 
mostly unaffected by chemoprophylaxis (Bradley-Moore et aI. 1985). There may be a 
transient suppression of cellular responses during acute infection in Thai adults (Ho et al. 
1986; Walsh et al. 1995). Acute infection has also been associated with a loss of T cell 
inhibition of Epstein-Barr virus infected cells (Whittle et al. 1984), and there is a transient 
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suppression of vaccine induced antibody responses after inpatient treatment for malaria 
(Williamson & Greenwood 1978). However, when malaria naIve volunteers were 
exposed to very low parasitaemia, they rapidly acquired cellular responses (Pombo et al. 
2002), although subsequent data has suggested that a drug effect may have accounted for 
the protection against malaria seen in association with these responses (Edstein et al. 
2005). It may be that exposures of either longer duration or higher parasitaemia would 
instead suppress cellular responses. Longitudinal studies of the kinetics of cellular 
responses with individual data on malaria exposure are lacking. 
However, other factors might also suppress cellular responses in malaria endemic areas. 
Severely malnourished children have a suppressed cellular response to mycobacterial 
antigens (Liebe schuetz et al. 2004). Severe malnutrition is rare, but mild malnutrition is 
common in malaria endemic areas, and might also lead to depressed cellular immunity. 
Concurrent helminth infections suppress or alter T cell responses by inducing a TH2 
cytokine profile (Ramalingam et al. 2005). T cell responses to tetanus toxoid (Cooper et 
al. 1998; Nookala et al. 2004; Sabin et al. 1996) and BCG (Malhotra et al. 1999) may be 
inhibited by helminth infection. 
A further analysis was designed to examine factors that might influence natural or 
vaccine induced acquisition of T cell responses, and factors influencing the subsequent 
attrition of those responses. Responses to the pre-erythrocytic antigen TRAP were 
measured in both actively vaccinated and control groups. Exposure to malaria and other 
parasites was studied throughout the year of follow up. In order to account for the 
influence of prior exposure, the ELiSpot data was adjusted for ELlS pot results from 
earlier time points. 
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6.2 IVIethods 
6.2.1 Analysis. 
ELISpot wells were assayed in duplicate, taking the mean and subtracting the 
negative control well result. Assays were discounted if the positive control was less than 
50 spots, or the negative control greater than 20 spots for ex vivo ELISpots, or 40 spots 
for cultured ELISpots. Pools were summed to calculate total response. Results are 
presented per million incubated PBMe. Geometric means and 95% confidence intervals 
are reported, substituting 1 spot per well above background for blank wells (the lower 
limit of detection). T cell responses are compared using Students T test on log 
transformed results. 
Multiple regression analysis used log transformed spot numbers. Peptide pool, 
previous ELlSpot response, village and age as a categorical variable were first examined 
as explanatory variables. Where peptide pool, village and prior response were 
consistently significant predictors, all subsequent analysis of additional factors was 
adjusted by them. The additional factors nutritional status, gastrointestinal helminth 
infection, urinary schistosomiasis, eosinophilia (as a categorical variable with three 
levels), malaria parasitaemia (concurrent and previous) and episodes of febrile malaria 
(binary variables, present or absent) were examined. The coefficients derived from 
analysis of log transformed spot numbers were then multiplied by 100 to give the 
percentage change in response. 
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6.2.2 ELISpots and monitoring 
ELI Spot assays were described in 5.1.7, and monitoring for episodes of malaria was 
described in 5.1.8. 
6.3 Results 
6.3.1 Kinetics of responses 
Vaccination with FFM ME-TRAP induced both ex vivo ELI Spot measured responses 
(from a geometric mean of 9 spots per million, CI 7-11 to 55 per million, CI 45-67, 
p<0.0005) and cultured ELI Spot measured responses (from a geometric mean of 55 spots 
per million, CI 44-68 to 240 per million, CI 200-290, p<0.0005). These vaccine induced 
responses constitute the first data set analysed (Figure 6.1) 
There was also a significant rise in T cell responses during the malaria season among 
placebo vaccinees. Ex vivo responses rose from 10 spots per million (95% CI 8-12) 
before the malaria season (January 2005), to 23 spots per million (95% CI 18-28) in the 
malaria season (August 2005) p=0.0005. Resting memory (cultured) responses also rose 
significantly during the malaria season, from 53 per million (CI 42-66) in January 2005, 
to 97 per million (CI 79-120) in August 2005, p=O.OOOl. These naturally acquired 
responses make up the second data set. 
Responses that had been induced by vaccination then fell over the following 9 months. Ex 
vivo responses fell from a geometric mean of 55 spots per million (CI 43-66) in early 
May 2005 (one week after vaccination) to 19 spots per million (CI 16-24) in January 
2006 (9 months after vaccination), p<0.00005. However, resting memory responses were 
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preserved, from 234 spots per million in May 2005 (CI 194-281) to 213 (CI 169-269) in 
January 2006, p=O.51. The attrition of responses during the 9 months after vaccination is 
shown in Figure 6.1, data set 3. 
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Figure 6.1. T cell responses to vaccination identified by both ex vivo and cultured 
ELISpot, are displayed over time for each data set analysed. Median, 25th and 75th 
quartile, Sth and 9S% quartile and outlying results are given by box and whisker plots. 
Vaccination with FFM ME-TRAP induced ex vivo ELISpot and cultured responses 
(p<O.OOOS, p<O.OOOS, Data set 1). There was also a significant rise in T cell responses 
during the malaria season among placebo vaccinees (Data set 2, p<0.0005, p=O.OO 1 for ex 
vivo and cultured responses respectively). Vaccine induced ex vivo response fell over the 
next 9 months. (Data set 3, p< O.OOOS), but cultured responses were sustained (p=O.Sl). 
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6.3.2 Multiple regression models to determine factors associated with variation 
of responses. 
The responses at the second time point for each of the three data sets are modelled as 
outcomes, using the earlier T cell responses and blood film results at both time points as 
explanatory variables. The frequencies of other covariates in the population are given in 
Table 6.1, and the results of multiple regression models to identify explanatory variables 
for T cell responses are shown in Table 6.2(a-c). 
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Table 6.1: The frequencies of explanatory factors amon2 study subjects. Percentages 
are given within each variable. 
Data set 2 Data set 3 
Data set 1 (responses (responses 9 
(vaccine induced induced by months after 
Variable Factor responses) natural exposure) vaccination) 
Village Gongoni 34 (18%) 31 (18%) 35 (20%) 
Junju 47 (25%) 39 (23%) 40 (23%) 
Kolewa 51 (27%) 50 (30%) 44 (26%) 
Mapawa 37 (20%) 31 (18%) 35 (20%) 
Mwembe 
Tsungu 14 (7%) 15 (9%) 14 (8%) 
MUAC 151 terti Ie 44 (24%) 45 (27%) 38 (22%) 
2nd tertile 54 (29%) 62 (37%) 53 (31%) 
3rd tertile 85 (46%) 59 (35%) 77 (45%) 
GI worm Infected 34 (23%) 41 (29%) 32 (24%) 
Uninfected 111 (77%) 96 (71%) 103 (76%) 
Schist. Infected 12 (8%) 7 (5%) 10 (7%) 
Uninfected 127 (92%) 117 (95%) 119 (93%) 
Eosinophils Norm 88 (48%) 79 (47%) 81 (48%) 
Mod. 53 (28%) 48 (28%) 54 (32%) 
High 25 (13%) 33 (19%) 27 (16%) 
Febrile 
malaria ~1 Episode. 24 (11%) 30 (20%) 38 (25%) 
No Episodes 194 (89%) 120 (80%) 114 (75%) 
Previous 
blood film Positive 123 (70%) 79 (50%) 72 (43%) 
Negative 52 (30%) 79 (50%) 72 (57%) 
Current 
Blood film Positive 78 (43%) 38 (23%) 47 (28%) 
Negative 102 (57%) 123 (77%) 117 (72%) 
Abbreviations: Age cat.= age category; M. Tsungu = Mwembe Tsungu, MUAC = Mid 
Upper Arm Circumference, GI worm = Microscopy of Stool positive for helminth 
infection, Schist = Microscopy of urine positive for schistosomiasis, Mod.= eosinophil 
count above 0.5x106 per ml, High = above lxlO6 per ml. Prev film = thick film positive 
for malaria parasites previously, Current Film= thick film positive for malaria parasites 
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currently, Feb Mal = Febrile Malaria = at least one episode of febrile malaria during 
surveillance previously. 
6.3.3 Co variates 
The pool of TRAP peptides that were tested, the child's village and prior immunity were 
all significant factors in each data set. Neither vaccine induced nor naturally acquired 
responses examined in data sets 1 and 2 varied by age. 9 months after vaccination, ex vivo 
responses in data set 3 were significantly better sustained among older children (2-7 year 
olds) compared with 1-2 year old children, but cultured responses did not vary. 
The ex vivo T cell responses measured pnor to vaccination predicted the ex vivo 
responses after vaccination (p=O.012). Cultured responses 9 months after vaccination 
were predicted by cultured responses one week after vaccination (p<O.0005), and ex vivo 
responses 9 months after vaccination were predicted by ex vivo responses one week after 
vaccination (p=O.009). However, neither cultured nor ex vivo responses during the dry 
season predicted naturally acquired responses seen during the rainy season. 
Analysis for further factors was then adjusted for the covariates peptide pool, prior 
ELISpot results and village, but age category was not used as a covariate in further 
analysis. 
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6.3.4 Nutrition and helminth infection 
T cell responses did not vary by nutritional status (as determined by Mid Upper Arm 
Circumference in January 2005). Parasitic infection was determined by stool and urine 
microscopy, and peripheral blood eosinophil counts (conducted in January 2005). There 
were no associations between T cell responses and microscopy results for urinary 
schistosomiasis or gastro-intestinal helminth infections, but eosinophilia was strongly 
associated with a greater attrition of ex vivo ELI Spot responses, examined in data set 3 
(p=O.006 by log likelihood ratio testing, Table 6.2c). Responses in eosinophilic subjects 
were 69-79% of the magnitude of responses without eosinophilia, Table 6.2c. However, 
cultured responses did not vary by eosinophilia, and eosinophilia did not alter vaccine 
induction of responses (Table 6.2a) or naturally acquired responses (Table 6.2b), 
examined by data sets 1 and 2 respectively. 
6.3.5 Parasitaemia and malaria infection 
Asymptomatic malaria parasitaemia as vaccination began was associated with a reduction 
in post vaccination T cell responses (i.e. data set 1) to 85% of the magnitude of non-
parasitaemic children (p=0.09) by ex vivo assays and 79% (p=0.043) by cultured ELI Spot 
assays (Table 7.2a). Natural acquired responses (data set 2) were also suppressed by 
previous parasitaemia, to 75% (p<O.0005) by ex vivo assays and 75% {p=O.032} by 
cultured assays (Table 7.2b). However, parasitaemia at the time blood was drawn for 
ELI Spot assays did not reduce T cell responses for either vaccine induced or naturally 
acquired responses. 
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ex vivo responses to vaccination with FFM ME-TRAP were less well sustained among 
children previously parasitaemic (at 81 %, p=O.002), with concurrent parasitaemia (69%, 
p=O.OI4) and with episodes of febrile malaria prior to the ELI Spot assays (79% p=O.OI4). 
Cultured responses did not vary by asymptomatic parasitaemia, but were reduced to 72% 
by episodes of febrile malaria (p=O.04). 
Further sub-group analysis (data not shown) did not suggest that higher parasitaemias 
were associated with greater reductions in T cell responses. 
Figure 6.2 shows the frequencies of T cell responses by previous exposure to malaria 
parasitaemia, displayed for each peptide pool and for each data set studied. 
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Figure 6.2: Interferon gamma producing T cells are compared by prior exposure to 
malaria parasitaemia (paired box and whisker plots). Responses to each of the three 
peptide pools are shown within each panel. Ex vivo assay results are shown in the upper 
row, cultured assay results in the lower row. The left column displays immediate vaccine 
induced responses left, naturally acquired responses are centre and sustained vaccine 
induced responses right. Prior exposure to malaria parasitaemia was associated with 15% 
(p=O.09) and 21% (p=O.043) respective reductions in ex vivo and cultured ELISpot 
immediate responses to vaccination, 25% (p<O.0005) and 25% (p=O.032) reductions 
following natural exposure and 19% (p=O.OI8) and no reduction (p=0.48) in sustained 
responses after vaccination. 
Data set 1: Induction of responses by 
vaccination with FFM MENegTRAP 
Data set 2: Induction of responses by 
natural exNegure 
8 One week Post 
~ vaccination (Bleed 2) 
Fold change 
(Bleed 21 Bleed 1). 
8. Malaria season 
~ End (Bleed 3) 
Fold change 
(Bleed 31 Bleed 1) 
~~!t ,~~, fT ~.1 
x100 ~ 
x10 ~ 
x1 ~ 
~ Paras Neg Pas Neg Pas Neg Pas Neg Pas Paras. 
II) 
<J p=O.09 p=O.043 
gf Malaria film: Posative n=46. Negitive n=110 i Data set 3: Decay of responses after 
vaccination with FFM MENegTRAP § 9 months Post Fold change t ; V~"~~~~ (:'~4ffileM1) ':,7 
~ ~ !,++ ~', 
9 0 xO.01 
Paras Neg Pas Neg Pas Neg Pas Neg Pas 
p=0.018 p=0.48 
Malaria film: Posative n=80. Negitive n=61 
~~ 0 ,'00 S~ •••.•.• ~'.r1 ::'! r T ~'! 
Neg Pas Neg Pas Neg Pas Neg Plos 
p<0.0005 p=0.032 
Malaria film: Posative n=43. Negitive n=119 
I Ex vivo ~~;::~::~:::S:!:Ij Cultured ELiSpot 
1::::::;:;:;:/:::1 Ex vivo change 
1;88883 Cultured change 
1A 
XO.018. 
'" ~ 
138 
6.3.6 Combined multiple regression analysis for sustained ex vivo responses. 
In data sets 1 and 2, only one factor significantly altered responses after adjusting for 
peptide pool, previous ELI Spot results and village. However, several additional factors 
were predictors of the attrition of ex vivo responses after vaccination (Table 6.2c, data set 
3), and so were entered into a further multiple regression analysis. The effect of 
eosinophilia was still highly significant (p=O.0005, with reductions in response to 63% 
and 79% respectively for moderate and high eosinophilia). Concurrent parasitaemia 
(74%, p=O.OOI), previous parasitaemia (85%, p=O.048) and episodes of febrile malaria 
(81 %, p=O.033) were also independently associated with ex vivo ELI Spot results. 
6.3.7 Protection against episodes of malaria 
Vaccination with FFM ME-TRAP was not protective, and neither ex vivo nor cultured 
ELI Spot results predicted protection within FFM ME-TRAP vaccinees (5.2.4). The 
naturally acquired T cell responses were not protective, either for ex vivo (IRR=1.17 for 
each 10 fold rise in T cell numbers, 95% CI 0.7-2) or cultured ELI Spot (IRR=0.84, 95% 
CI 0.5-1.3, p=0.48). 
6.3.8 Relationship of ex vivo to cultured responses. 
Although both cultured and ex vivo responses did not correlate among unvaccinated 
children (r=-0.017, p=0.71), there was a significant association between cultured and ex 
vivo responses one week after vaccination, in May 2005 (r=O.l8, p<O.00005 unadjusted, 
coefficient=0.14 p=0.006 when adjusted for peptide pool and village). 
139 
Table 6.2a Results of multiple regression model to examine factors influ{'ncing the 
acquisition of T cell responses after vaccination (Data set 1). The average effect 
associated with each factor is given as a percentage relative to individuals without that 
factor for each variable. (For instance, responses to the middle region of the TRAP 
molecule are, on average, 60% of the responses seen to the N terminal portion). Where 
more than two options exist for a given factor, a log likelihood ratio test (LR test) is given 
for the overall significance of that factor in the model. 
Factor 
Peptides 
N terminal 
Middle 
C terminal 
Age cat. 
1-2 years 
2-5 years 
5-7 years 
Prevo ex vivo 
Ex vivo 
Coefficient 
100% 
60% (48-75%) 
91% (74-112%) 
100% 
109% (87-138%) 
125% (97-165%) 
p value 
<0.0005 
0.4 
0.41 
0.086 
(January 2005) 141%(108-189%) 0.012 
Prevo cult. 109% (89-134%) 0.362 
Village 
Gongoni 
Junju 
Kolewa 
Mapawa 
M. Tsungu 
MUAC 
1 st terti Ie 
2nd tertile 
3rd tertile 
Glworm 
Schist. 
Eosin. 
Normal 
Mod. 
High 
Prevo Film 
(January 2005) 
.Current film 
(May 2005) 
Febrile malaria 
(Jan-May 
2005) 
100% 
91 % (69-12%) 
72% (54-93%) 
72% (53-95%) 
104% (72-154%) 
100% 
109% (71-141 %) 
112% (89-141%) 
117% (57-151%) 
151% (103-218%) 
100% 
134% (99-181%) 
112% (85-147%) 
85% (69-102%) 
95% (79-112%) 
102% (77-134%) 
0.51 
0.013 
0.019 
0.8 
0.45 
0.32 
0.136 
0.03 
0.06 
0.39 
0.09 
0.57 
0.86 
Cultured 
LR test Coefficient 
<0.00005 100% 
50% (38-64%) 
74% (56-56%) 
0.2 100% 
79% (6-97%) 
97% (7-128%) 
p value LR test 
<0.0005 
0.016 
<0.076 
0.79 
<0.00005 
0.1 
75% (56-102%) 0.09 
0.01 
0.59 
0.12 
117% (91-147%) 0.22 
100% 
93% (69-127%) 
69% (51-95%) 
47% (34-67%) 
138% (91-213%) 
100% 
83% (63-109%) 
95% (74-123%) 
81 % (61-107%) 
85% (56-125%) 
100% 
114% (83-162%) 
12% (89-162%) 
79% (63-99%) 
99% (79-117%) 
99% (72-134%) 
0.66 
0.024 
0.0005 
0.123 
0.2 
0.73 
0.13 
0.42 
0.38 
0.23 
0.043 
0.7 
0.97 
<0.00005 
0.38 
0.48 
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Table 6.2b Results of multiple regression model to examine factors influencing the 
acquisition of T cell responses after natural exposure (Data set 2). The average 
response associated with each factor is given as a percentage relative to the comparison 
for each variable. Where more than two options exist for a given factor, a log likelihood 
ratio test (LR test) is given for the factors addition to the model. 
Ex vivo Cultured 
Factor Coefficient p value LR test Coefficient p value LR test 
Peptides 
N terminal 100% 0.0028 100% 0.11 
Middle 75% (63-91 %) 0.005 74% (57-98%) 0.038 
C terminal 125% (85-123%) 0.74 89% (67-115%) 0.357 
Age cat. 
1-2 years 100% 0.09 100% 0.88 
2-5 years 95% (79-119%) 0.73 98% (74-128%) 0.88 
5-7 years 79% (61-101 %) 0.064 93% (67-128%) 0.63 
Prevo ex 
vivo 
(January 
2005) 75% (56-102%) 0.09 117% (85-158%) 0.34 
Prevo cult. 117% (91-147%) 0.22 125% (97-162%) 0.079 
Village 
Gongoni 100% <0.00005 100% <0.00005 
Junju 75% (6-93%) 0.01 98% (74-131%) 0.89 
Kolewa 151% (123-19%) <0.0005 43% (32-58%) <0.0005 
Mapawa 141 % (109-181 %) 0.007 37% (26-51 %) <0.0005 
M. Tsungu 112% (83-151 %) 0.43 77% (5-12%) 0.255 
MUAC 
1 st tertile 100% 0.27 100% 0.11 
2nd tertile 109% (93-128%) 0.27 77% (58-99%) 0.046 
3rd terti Ie 97% (83-114%) 0.71 93% (7-121 %) 0.59 
GJ worm 98% (12-117%) 0.86 83% (64-107%) 0.16 
Schist. 109% (75-154%) 0.62 107% (64-173%) 0.78 
Eosinophils 
Normal 100% 100% 
Mod. 107% (85-134%) 0.53 0.81 89% (66-123%) 0.478 0.32 
High 128% (83-125%) 0.8 81% (61-107%) 0.14 
Prevo Film 
(May 
2005) 75% (64-87%) <0.0005 75% (57-97%) 0.032 
Current 
film 
(August 
2005) 95% (79-114%) 0.62 91 % (72-117%) 0.465 
Febrile 
malaria 
(May-Aug 
2005) 102% (83-125%) 0.828 91% (7-12%) 0.51 
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Table 6.2c Results of multiple regression model to examine factors influencing the 
attrition of T cell responses after vaccination (Data set 3). The average response 
associated with each factor is given as a percentage relative to the comparison for each 
variable. Where more than two options exist for a given factor, a log likelihood ratio test 
(LR test) is given for the factors addition to the model. 
Ex vivo Cultured 
p 
Factor Coefficient p value LR test Coefficient value LR test 
Peptides 
N tenninal 100% 100% 
Middle 66% (53-81 %) <0.0005 0.0003 69% (48-66%) 0.028 0.038 
C tenninal 21% (69-104%) 0.134 69% (48-64%) 0.027 
Age cat. 
1-2 years 100% 100% 
2-5 years 128% (91-144%) 0.198 0.12 169% (74-151 %) 0.775 0.019 
5-7 years 97% (74-123%) 0.776 165% (108-251 %) 0.02 
Prevo ex 
vivo (May 
2005) 138% (114-165%) <0.0005 154% (39-169%) 0.155 
Prevo Cult. 93% (81-108%) 0.384 141 % (109-181 %) 0.009 
Village 
Gongoni 100% 100% 
Junju 103% (14-129%) 0.78 <0.00005 151%(102-223%) 0.039 0.0006 
Kolewa 154% (123-198%) <0.0005 89% (57-134%) 0.59 
Mapawa 199% (157-263%) <0.0005 69% (44-102%) 0.075 
M. Tsungu 144% (104-199%) 0.025 74% (39-134%) 0.3 
MUAC 
1 st tertile 100% 100% 
2nd tertile 112%(89-141%) 0.31 0.5 114% (79-169%) 0.45 0.44 
3rd tertile 101 % (82-125%) 0.89 93% (66-128%) 0.67 
Glwonn 95% (77-117%) 0.66 113% (77-165%) 0.51 
Schist. 120% (89-165%) 0.228 77% (42-144%) 0.43 
Eosinophils 
Nonnal 100% 100% 
Mod. 69% (53-87%) 0.002 0.006 75% (50-120%) 0.26 0.337 
High 79% (63-99%) 0.043 70% (48-112%) 0.15 
Prevo Film 
(Aug 2005) 81 % (69-95%) 0.018 111 % (85-147%) 0.48 
Current 
film time 
assay (Jan 
2006) 69% (58-83%) <0.0005 112% (91-165%) 0.2 
Febrile 
malaria 
(May 
2005-Jan 
2006) 79% (66-95%) 0.014 72% (52-98%) 0.04 
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Peptides give the different peptide pools, grouped by region of TRAP from which they 
were derived. Abbreviations: Age cat.= age category; M. Tsungu = Mwembe Tsungu, 
MUAC = Mid Upper Arm Circumference, GI worm = Stool microscopy positive for 
helminth infection, Schist = Urine microscopy positive for schistosome ova, Mod.= 
eosinophil count above 0.5xl06 per ml, High = above lxl06 per ml. Prev film = thick film 
positive for malaria parasites previously, Current Film= thick film positive for malaria 
parasites currently, Febrile malaria = at least one episode of febrile malaria during 
surveillance previously, Prev ex vivo = T cell responses detected by ex vivo ELISpot on 
prior blood tests, Prev Cult = T cell responses detected by cultured ELISpot on prior 
blood test. 
6.4 Discussion 
Parasitaemia at the start of monitoring, but not parasitaemia at the time of the ELlS pot 
assay inhibited the acquisition of T cell responses in data set 1 (responses acquired after 
vaccination) and data set 2 (responses acquired after natural infection). The data sets are 
demonstrated in figure 6.1, and the effect of parasitaemia in figure 6.2. This might reflect 
an effect of parasitaemia per se at the time point immediately prior to vaccination, or 
simply that more highly exposed children are both parasitaemic and immunosuppressed. 
However, concurrent parasitaemia would be equally strongly linked to overall exposure, 
but did not influence T cell responses. Furthermore malaria episodes during the time of 
monitoring were not associated with lower T cell responses in data sets 1 and 2. 
143 
6.4.1 Potential mechanisms 
By what mechanism might early parasitaemia but not parasitaemia at the time of the 
assay for cellular responses influence T cell induction? Children received priming 
vaccinations 2 weeks after the earlier blood films, and boosting vaccinations one weck 
prior to the concurrent blood films. In the cohort studied for natural exposure, malaria 
transmission was high throughout the interval between blood film examinations. 
Parasitaemia might inhibit T cell priming (in both vaccination and natural exposure), but 
not the subsequent boosting or recall of responses. 
However, concurrent parasitaemia, earlier parasitaemia and episodes of febrile malaria 
were all independently associated with a more rapid attrition of ex vivo T cell responses 
(data set 3). Eosinophilia was not associated with altered vaccine immunogenicity or the 
acquisition of natural immunity, but was strongly associated with greater attrition of ex 
vivo ELISpot responses after vaccination (cultured ELI Spot responses were not altered). 
Furthermore, although village significantly influenced all three data sets, the effects were 
not in consistent directions for the induction (Data sets 1 and 2) and the attrition of 
responses (data set 3). Taken together, these data suggest that T cell priming and memory 
are suppressed by different factors. 
The priming of T cells responses depends on dendritic cells, whereas subsequent memory 
appears to be independent of dendritic cells (Kassiotis & Stockinger 2004), but is 
dependent on cytokines such as IL 7 and IL 15 (Geginat et al. 2001; Kaech et al. 2003). 
Previous parasitaemia may act on dendritic cells to inhibit T cell priming, but intercurrent 
febrile malaria, parasitaemia, and the TH2 responses associated with eosinophilia may 
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alter the cytokine milieu required to support memory cells. The inflammatory cytokine 
response during malaria infection in mice depletes memory cells (Xu et al. 2002). 
6.4.2 Accuracy of estimates 
The results are not due to confounding by T cell responses protecting against infection. 
Previous studies have demonstrated that the ex vivo responses to TRAP raised by natural 
infection are not associated with protection, and in this study neither cultured nor ex vivo 
detected responses were protective. Malaria exposure led to subsequently reduced T cell 
responses, but T cell responses were not prospectively associated with a lower malaria 
risk. 
The 15-30% reductions in T cell responses in parasitaemic children are likely to be an 
underestimate of the overall immunsuppression caused by malaria in endemic areas. 
Parasitacmia below the level of blood film detection is frequent in endemic areas (Ndao 
et al. 2004), and some children may have cleared their parasitaemia soon after the film 
was taken. It is likely that the majority of children in the study (film negative and 
positive) were exposed to malaria, but those with positive blood films had a greater 
suppression of cellular responses. 
The ELlSpot assay allows accurate, reproducible and high through-put measurement ofT 
cell responses (Tassignon ct aI. 2005). Many of the quite low frequencies of T cell 
identified in this study would not have been above background reactivity in standard 
intracellular cytokine staining assays for use with F ACS. Although I did not confirm the 
phenotype of responding cells, previous work has shown that both natural infection 
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(Flanagan et a1. 2003) and vaccination (Moorthy et a1. 2004a) induce primarily CD4 
responses. 
6.4.3 Helminth infections 
Neither gastrointestinal helminth infection nor urinary schistosomiasis was associated 
with altered cellular immunity. However, only single specimens of stool and urine were 
examined, and children with lower parasite burdens might have been identified by 
repeated specimens or concentration techniques. 50% of children had either moderate or 
high eosinophilia, compared with a prevalence of 7% for urinary schistosomiasis and 
25% for gastro-intestinal helminth infection. The higher prevalence may reflect infections 
missed by microscopy, but also could be due to filarial infection (night time blood films 
were not performed). The only common cause of eosinophilia among children in Africa is 
helminth infection, and eosinophilia may be a more discriminatory marker for altered 
immunity, since it is more closely associated with the TH2 cytokine responses than the 
presence of absence of parasites (Akdis et a1. 2003). Since eosinophilia was associated 
with greater attrition of cellular responses, it is very likely that helminths do playa role, 
and more intensive examination might identify the parasites involved. 
6.4.4 Conclusions 
Malaria parasitaemia and eosinophilia should be considered in assessmg the 
immunogenicity and efficacy of experimental and routine (i.e. BCG) T cell inducing 
vaccinations. T cell inducing vaccines are in development for diverse pathogens, 
including HIV (Mwau et a1. 2004) and TB (McShane et a1. 2004). Efficacy may vary 
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according to malaria endemicity, and clinical development plans should include trials in 
high transmission areas. Although vaccine efficacy was seen only in children not pre-
treated with anti-malarial drugs in one trial (Genton et al. 2002) , the influence of 
parasitaemia on efficacy in a particular trial design may not correlate with 
immunogenicity. I observed that the immunogenicity of prime-boost vaccination was 
lower in a population with more frequent blood stage malaria infection (5.2.3). The 
inhibition of T helper cells might also explain the poorly sustained antibody responses to 
blood stage antigens seen among children in malaria endemic areas (Kinyanjui et at. 
2003). Since Intermittent Presumptive Treatment with antimalarials in infants may 
become public health policy, the interaction between antimalarial use and vaccine 
immunogenicity and efficacy may soon be of practical importance. 
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7 Concluding Remarks 
Although there were encouraging indications that the vaccination regimen FFM 
ME-TRAP was partially protective in experimental studies of sporozoite challenge in the 
UK (section 2.3.1), and that it was safe and immunogenic in phase 1 studies in Kenya, the 
regimen did not subsequently protect 1-6 year old children against clinical disease. Since 
the immunogenicity of vaccination in the efficacy study was lower than that seen 
previously (5.2.3), it is unclear whether similar reductions in liver parasites to those seen 
in sporozoite challenge might have occurred without a reduction in clinical episodes, but 
similar reductions might have been expected among children with the highest T cell 
responses in the efficacy study. However, taking these findings together with data from 
comparable sporozoite challenge studies and field efficacy studies for RTS,S/AS02 
(Alonso et al. 2004; Stoute et al. 1997), it is probable that vaccines will need to achieve 
greater than 90% reductions in pre-erythrocytic parasites in order to see protection in the 
field. There is evidence that the reduction in pre-erythrocytic parasites in sporozoite 
challenge studies is proportional to immunogenicity (Webster et al. 2005). Given that 
90% reductions in pre-erythrocytic parasites have already been seen, it is possible that 
even modest increases in immunogenicity will result in more frequent fully protected 
volunteers. 
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7.1 Immunogenicity 
Immunogenicity also needs to be documented in the target population before 
conducting a larger trial to establish efficacy. The immunogenicity was lower among 
children in Kenya than had been seen in naIve volunteers, and the data presented in 
section 6.3.5 suggests that malaria infection may have contributed to this. In the 
development plan of future vaccination regimens, immunogenicity should be documented 
under different malaria transmission intensities, and in children with and without 
asymptomatic parasitaemia. 
In phase 1 trials, I showed that novel, alternating vector vaccinations result in 
greater memory responses than classic prime-boost vaccinations. The longevity of 
protection is critical to the utility of any vaccination. Since prime boost vaccinations are 
in clinical development for other pathogens such as TB (McShane et al. 2004), HIV 
(Mwau et a!. 2004) and malignancy (Greiner et al. 2002), further study should investigate 
whether the enhanced memory can be achieved with other vector and antigen 
combinations. 
7.2 Batch variability 
I showed a variation in immunogenicity and reactogenicity for one batch of FP9 
ME-TRAP. The reasons for variability were not related to vaccine titre or loss of potency 
over time. Further in vitro characterisation of pox virus preparations is underway. A 
single seed lot of virus had been used to generate the batches of FP9 ME-TRAP used in 
this study, and the growth time to produce the virus required in these studies was not of 
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sufficient length to allow significant genetic variation of the virus, as has been when very 
large scale production is conducted (Sauerbrei et al. 2006). Although electron microscopy 
studies did not identify significant differences in the batches of FP9 ME-TRAP used here, 
the technique examines only a few virus particles. Studies to measure virus particle 
agglutination using a novel adaption of flow cytometry will allow a more thorough 
characterisation. Clinically insignificant variation between lots of commercially licensed 
attenuated vaccines has been identified (Lieberman et al. 2006). There is no evidence of 
variable immunogenicity or reactogenicity by batch of MV A vaccines. Batch variability 
may be confined to FP9, but data are limited. The clinical development plans of new 
virally vectored vaccine regimens will need to consider the possibility of significant batch 
variability at an appropriate stage. 
7.3 Other pre-erythrocytic vaccinations in development 
7.3. J Adenovirus 
Similar viral vectored regimens have been used to induce T cells reactive to HIV 
antigens (Mwau et al. 2004). However, regimens using adenovirus appear to have 
induced the strongest T cell responses thus far (Duerr et al. 2006). Wild type adenovirus 
is pathogenic in humans. Instead of the multiple passage used to attenuate MV A, specific 
genes were deleted to render the virus replication defective (Santra et al. 2005). 
Adenovirus vectored regimens are more immunogenic when given after a DNA prime 
(Xin et al. 2005). 
However, immunity to adenovirus from natural exposure is common, particularly 
In Africa (Nwanegbo et at. 2004). Antibodies to adenovirus limit the vector's 
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immunogenicity in animal models (Lemckert et al. 2005), and I have presented data here 
showing the immunogenicity of recombinant MV A was reduced by prior anti-vector 
immunity. Studies in progress in humans using adenovirus vectored vaccinations have 
selected subjects with low antibody titres to the vector. However, there are a large 
number of simian adenoviruses, with varying degrees of sequence homology 
(Avvakumov et al. 2004). Commercial development of these vectors is underway. Since 
there is no evidence of cross-reactivity between adenovirus and MV A, these vectors 
would be suitable for prime boost vaccinations. This approach may further improve 
immunogenicity. 
7.3.2 RTS,S 
The other approach to pre-erythrocytic vaccination against malaria in field trials 
uses the adjuvanted particulate protein vaccine, RTS,S (GlaxoSmithKline Biologicals, 
Rixensart, Belgium). This comprises the carboxyl terminal (a.a. 207-395) of the 3D7 
circumsporozoite protein fused to the hepatitis B surface antigen, co-expressed in yeast 
with the non-fused hepatitis B surface antigen. When given with a proprietary adjuvant 
AS02A, an oil-in-water emulsion using the two immunostimulants QS21 and MPL, both 
antibody and cellular responses were induced (Lalvani et al. 1999). It is unclear whether 
antibodies, cellular responses, or both mediate protection in sporozoite challenge studies 
(Stoute et al. 1997; Sun et al. 2003). Field trials have demonstrated short-lived efficacy 
in adults (Bojang et al. 2001), and 30% efficacy against febrile malaria in children 
(Alonso et al. 2004). The efficacy appears to be durable (Alonso et al. 2005), and further 
studies are in progress to optimise the adjuvant used (Stewart et al. 2006). Further phase 
2b field trials with the new adjuvant are planned, and these are likely to follow similar 
methodology in defining cases of febrile malaria to that used in section 5.1.8. It is likely 
this wiI1lead to a phase 3 trial in the near future. 
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7.4 In conclusion 
Although the regimen FFM ME-TRAP that I tested was not protective against 
febrile malaria in children, the data acquired in the course of phase 1 and 2 studies will 
inform the development of the next generation of T cell inducing vaccinations against 
malaria. This is likely to involve more immunogenic vectors, studies examining batch 
variability, single vector and alternating vector regimens, and careful attention to the 
immunogenicity of vaccination in the field. 
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9 Appendices 
9.1 TRAP Peptides used in ELISpot assays 
9.1.1 TRAP peptides: T996 (vaccine strain) 
TI MNHLGNVKYLVIVFLIFFDL 
T2 VIVFLIFFDLFL VNGRDVQN 
T3 FL VNGRDVQNNIVDEIKYSE 
T4 NIVDEIKYSEEVCNDQVDL Y 
T5 EVCNDQVDL YLLMDCSGSIR 
T6 LLMDCSGSIRRHNWVNHA VP 
T7 RHNWVNHAVPLAMKLIQQLN 
T8 LAMKLIQQLNLNDNAIHL YV 
T9 LNDNAIHL YVNVFSNNAKEI 
TIO LNDNAIHL YVNVFSNNAKEI 
TIl IRLHSDASKNKEKALIIIRS 
TI2 KEKALIIIRSLLSTNLPYGR 
Tl3 LLSTNLPYGRTNLTDALLQV 
TI4 TNLTDALLQVRKHLNDRINR 
TI5 RKHLNDRINRENANQLVVIL 
TI6 ENANQLVVILTDGIPDSIQD 
TI7 TDGIPDSIQDSLKESRKLSD 
TI8 SLKESRKLSDRGVKIA VFGI 
TI9 RGVKIA VFGIGQGINV AFNR 
T20 GQGINV AFNRFLVGCHPSDG 
T21 FLVGCHPSDGKCNLYADSAW 
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T22 KCNL YADSA WENVKNVIGPF 
T23 ENVKNVIGPFMKA VCVEVEK 
T24 MKA VCVEVEKTASCGVWDEW 
T25 TASCGVWDEWSPCSVTCGKG 
T26 SPCSVTCGKGTRSRKREILH 
T27 TRSRKREILHEGCTSEIQEQ 
T28 EGCTSEIQEQCEEERCPPKW 
T29 CEEERCPPKWEPLDVPDEPE 
T30 EPLDVPDEPEDDQPRPRGDN 
T31 DDQPRPRGDNSSVQKPEENI 
T32 SSVQKPEENIIDNNPQEPSP 
T33 IDNNPQEPSPNPEEGKDENP 
T34 NPEEGKDENPNGFDLDENPE 
T35 NGFDLDENPENPPNPDIPEQ 
T36 NPPNPDIPEQKPNIPEDSEK 
T37 
T38 DIPEQKPNIPEDSEKEVPSD 
T39 EDSEKEVPSDVPKNPEDDRE 
T40 VPKNPEDDREENFDIPKKPE 
T41 ENFDIPKKPENKHDNQNNLP 
T42 NKHDNQNNLPNDKSDRNIPY 
T43 NDKSDRNIPYSPLPPKVLDN 
T44 SPLPPKVLDNERKQSDPQSQ 
T45 ERKQSDPQSQDNNGNRHVPN 
T46 DNNGNRHVPNSEDRETRPHG 
T47 SEDRETRPHGRNNENRSYNR 
T48 RNNENRSYNRKYNDTPKHPE 
T49 KYNDTPKHPEREEHEKPDNN 
T50 REEHEKPDNNKKKGESDNKY 
T51 KKKGESDNKYKIAGGIAGGL 
T52 KIAGGIAGGLALLACAGLA Y 
T53 ALLACAGLAYKFVVPGAATP 
T54 KFVVPGAATPYAGEPAPFDE 
T55 YAGEPAPFDETLGEEDKDLD 
T56 TLGEEDKDLDEPEQFRLPEE 
T57 EPEQFRLPEENEWN 
9.1.2 TRAP peptides: 3D7 strain 
(only the 20aa sequences that are variant to T996 are shown) 
D3 FL VNGRDVQNNIVDEIKYRE 
D4 NIVDElKYREEVCNDEVDL Y 
D5 EVCNDEVDL YLLMDCSGSIR 
D8 LAMKLIQQLNLNDNAIHL Y A 
D9 LNDNAIHL Y ASVFSNNAREI 
DIO SVFSNNAREIIRLHSDASKN 
D11 IRLHSDASKNKEKALIIIKS 
D12 KEKALIIIKSLLSTNLPYGK 
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D13 LLSTNLPYGKTNLTDALLQV 
D27 TRSRKREILHEGCTSELQEQ 
D28 EGCTSELQEQCEEERCLPKR 
D29 CEEERCLPKREPLDVPDEPE 
D31 DDQPRPRGDNFAVEKPNENI 
D32 FA VEKPNENIlDNNPQEPSP 
D33 IDNNPQEPSPNPEEGKGENP 
D34 NPEEGKGENPNGFDLDENPE 
D35 NGFDLDENPENPPNPPNPPN 
D36 NPPNPPNPPNPPNPPNPPNP 
D37 PPNPPNPPNPDIPEQKPNIP 
D38 DIPEQKPNIPEDSEKEVPSD 
D42 NKHDNQNNLPNDKSDRYIPY 
D43 NDKSDRYIPYSPLAPKVLDN 
D44 SPLAPKVLDNERKQSDPQSQ 
D48 RNNENRSYNRKHNNTPKHPE 
D49 KHNNTPKHPEREEHEKPDNN 
D50 REEHEKPDNNKKKAGSDNKY 
D51 KKKAGSDNKYKIAGGIAGGL 
D52 KIAGGIAGGLALLACAGLA Y 
D53 ALLACAGLAYKFVVPGAATP 
D54 KFVVPGAATPYAGEPAPFDE 
D55 YAGEPAPFDETLGEEDKDLD 
056 TLGEEDKDLDEPEj2FRLPEE 
D57 EPEQFRLPEENEWN 
9.1.3 Multiple Epitope peptides 
Sequence Epitope Antigen Type HLA restriction 
MINAYLDKL st8 PfSTARP CD8 A2.2 
ISKYEDEI Is50 PtLSA-I CD8 BI7 
SYIPSAEKI pb9 PbCSP CD8 mouse H2-Kd 
KPNDKSLY IsS PtLSA-l CD8 B35 
KPKDELDY cp26 PfCSP CD8 B35 
KPIVQYDNF Is6 PtLSA-l CDS B53 
ASKNKEKALII tr42/43 PffRAP CD8 BS 
GIAGGLALL tr39 PffRAP CD8 A2.1 
MNPNDPNRNV cp6 PfCSP CD8 B7 
HLGNVKYLV tr26 PfTRAP CD8 A2.1 
KSLYDEHI Is54 PtLSA-l CD8 B58 
LLMDCSGSI tr29 PfTRAP CD8 A2.2 
DPNANPNVDPNANPNV CSP PfCSP CD4 promiscuously binding 
IQVHFQPLPPA VVKL BCG BCG CD4 promiscuously binding 
IQFlKANSKFIGITE TT TT CD4 promiscuously bindin~ 
YLNKIQNSL cp39 PfCSP CD8 A2.1 
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MEKLKELEK la72 PfLSA-l CDS BS 
ATSVLAGL ex23 PfEXP-l CDS B5S 
NANPNANPNANPNANP NANP PfCSP B cell 
DEWSPCSVTCGKGTRSRKRE TRAP-AM PfTRAP Binding motif 
The multiple epitopes were pooled together in a single well. Synonymous TRAP peptides 
(i.e.!, 2, 6, 7, 14-26,30,39,40,41,45,46,47, and those available only for T996 (50, 51, 
52,53,54,55,56,57) were pooled across 3 wells. Variant peptides (i.e. 3, 4,5, S-13, 27-
29,31- 3S, 42- 44, 4S, 49 were pooled according to strain, in 2 pools ofT996 peptides 
and 2 pools of 3D7 peptides. The vaccine strain was T996. 
9.2 Circumsporozoite Antigen: Peptides used in ELlS pot assays 
Synonymous CSNTI-D MRKLAILSVSSFLFV 
rel!ions 
CSNT2-D ILSVSSFLFVEALFQ 
CSNT3-D SFLFVEALFQEYQCY 
CSNT4-D EALFQEYQCYGSSSN 
CSNT5-D EYQCYGSSSNTRVLN 
CSNT6-D GSSSNTRVLNELNYD 
CSNT7-D TRVLNELNYDNAGTN 
CSNTS-D ELNYDNAGTNLYNEL 
CSNT9-D NAGTNL YNELEMNYY 
CSNTIO-D L YNELEMNYYGKQEN 
CSNTII-D EMNYYGKQENWYSLK 
CSNTI2-D GKQENWYSLKKNSRS 
CSNT13-D WYSLKKNSRSLGEND 
CSNTI4-D KNSRSLGENDDGNNE 
CSNTI5-D LGENDDGNNEDNEKL 
CSNTI6-D DGNNEDNEKLRKPKH 
CSNTI7-D DNEKLRKPKHKKLKQ 
CSNTIS-D RKPKHKKLKQPADGN 
CSNTI9-D KKLKQPADGNPDPNA 
CSNT20-D PADGNPDPNANPNVD 
CSNT21-D PDPNANPNVDPNANP 
CSNT22-D NPNVDPNANPNVDPN 
CSI-D NANPNANPNANPNAN 
CS2-D ANPNANPNANPNKNNQ 
CS3-D NKNNQGNGQGHNMPN 
CS4-D NKNNQGNGQGHNMPN 
CS5-D GNGQGHNMPNDPNRN 
CS6-D HNMPNDPNRNVDENA 
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CS7-D DPNRNVDENANANSA 
CS8-D VDENANANSAVKNNN 
CS9-D NANSA VKNNNNEEPS 
TH2R region, CSlO-D VKNNNNEEPSDKHIK 
3D7 strain 
CSll-D NEEPSDKHIKEYLNK 
CS12-D DKHlKEYLNKIQNSL 
CS13-D EYLNKIQNSLSTEWS 
CS14-D IQNSLSTEWSPCSVT 
CS15-D STEWSPCSVTCGNGI 
TH3R region, CS16-D PCSVTCGNGIQVRIK 
3D7 strain 
CS17-D CGNGIQVRIKPGSAN 
CSlS-D QVRIKPGSANKPKDE 
CS19-D PGSANKPKDELDYAN 
CS20-D KPKDELDY ANDIEKK 
CS21:.D LDY ANDIEKKICKME 
Synonymous CS22-D DIEKKICKMEKCSSV 
re~ion 
CS23-D ICKMEKCSSVFNVVN 
CS24-D KCSSVFNVVNSSIGL 
CS25-D FNVVNSSI GLIMVLS 
CS26-D SSIGLIMVLSFLFLN 
TH2R region, CSlO-G VKNNNNEEPSDKHIE 
7G8 strain 
CSII-G NEEPSDKHIEQYLKK 
CS12-G DKHIEQYLKKIKNSI 
CS13-G QYLKKIKNSISTEWS 
CS14-G IKNSISTEWSPCSVT 
CS15-G STEWSPCSVTCGNGI 
TH3R region, CS16-G PCSVTCGNGIQVRIK 
7G8 strain 
CS17-G CGNGIQVRIKPGSAN 
CSlS-G QVRIKPGSANKPKDE 
CS19-G PGSANKPKDELDYEN 
CS20-G KPKDELDYENDIEKK 
CS21-G LDYENDIEKKICKME 
The synonymous regions were pooled across 3 peptide pools, and the TH2R and 
TH3R regions pooled according to strain, 2 pools of 3D7 peptides and 2 pools of 
7GS peptides. The vaccine strain was 3D7. 
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9.3 Standard Operating Procedures for ELISpot assays. 
9.3.1 Ex vivo ELISPOT 
• Make the coating solution by adding 10 III of catcher antibody (l-DIK for gamma, or capture Il2 
antibody for BD) per ml of ELISPOT coating buffer resulting in a concentration of 10 Ilg/ml. Record 
the lot number of the catcher antibody on the Standard record sheet. IFN gamma and 112 concentrations 
are the same. 
• Add 50 III per well of the coating solution to the ELISPOT plate. Keep at RT for 3-8 h or at +4°C for 
8-48 hours. 
• Flick off the coating solution, and wash the plates 6 times with 250 III sterile PBS using a multichannel 
pipette to dispense the PBS. Flick off the washing solution and blot onto absorbent paper. 
• Block the wells with 100 III RIO. Keep the plate at RT for 1-8 h or at +4°C for 8-48 h. 
• Flick offthe blocking solution, and add peptides and other stimulants to the wells by transferring 50 III 
of solution from the stimulant plate (see 3.10) to the corresponding wells on the ELISPOT plate. Add 
50 III of cell suspension (8x106 cells/ml in RNIO) to the appropriate wells on the plate. Prepare 
duplicate wells per each sample. Record the time of addition of cells to the plate on the Standard record 
sheet. 
• Incubate the plate for 18-20 h at +37°C 5%C02 in the TC incubator. 
• Flick off the cell suspension, and, using the plate washer, wash 6 times with PBS-Tween. Flick off the 
washing solution and blot onto absorbent paper. 
• Dilute the detector antibody (7-B6-1-Biotin for gamma, or Il2 detector antibody - BD) 1:1000 in PBS 
resulting in a concentration of Illg/ml, and add 50 III to each well. Record the time of addition of the 
detector antibody and the batch number ofthe antibody on the Standard record sheet. Concentrations 
are the same for 112 and IFNgamma. 
• 
• 
Incubate the plate for 2-4 h at RT or overnight at +4°C. 
Flick off the detector antibody and, using the plate washer, wash 6 times with PBS-Tween. Flick off 
the washing solution and blot onto absorbent paper. 
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• Dilute the SA-ALP 1: 1000 in PBS, and add 50 ).11 to each well. Record the time of addition of the SA-
ALP and the batch number of the SA-ALP to the Standard record sheet. 
• Incubate for 1-2 h at RT. 
• Flick off the SA-ALP and, using the plate washer, wash 6 times with PBS-Tween. Flick off the 
washing solution and blot onto absorbent paper. 
• Make up the development buffer from the AP Conjugate Substrate Kit: 
N umber of plates 1 2 3 4 5 6 7 8 
Vol Water Iml 4.8 9.6 14.4 19.2 24 28.8 33.6 38.4 
Vol25x Dev Buff Iml 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 
Vol Reagent A 1111 50 100 150 200 250 300 350 400 
Vol Reagent B 1111 50 100 150 200 250 300 350 400 
• Add 50 ).11 to each well. Record the time of addition of the buffer and the lot number of the kit to the 
Standard record sheet. 
• Develop for approximately 3-7 min at room temperature. 
9 
43.2 
1.8 
450 
450 
• Wash thoroughly with tap water and let soak over night. Record the time of washing to the Standard 
record sheet. 
• Dry in air for 1-2 days before counting with ELISPOT reader. 
9.3.2 Cultured ELISPOT 
• Spin 1 million PBMC at 1400 rpm for 7 minutes. 
Day 0 
• Add 250 ).11 RN 1 0 to the cell suspension, transfer to a well (= 2 xl 06 cells/well). Add 250ul of peptide 
pool. 
DAY 3 
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• Carefully take off250 fll of media. Add 250ul of RN 10 containing SOul ofrIl2 stock solution (50 
units). 
DAY 7 
• Carefully take off250 fll of media. Add 250ul ofRNlO containing SOul ofrIl2 stock solution (50 
units) 
DAY 9 
• Resuspend cells carefully and transfer them to a 15-rnl falcon tube. Wash 3 times with 1 mlofRPMI. 
Resuspend in 0.5 ml ofRNIO. Incubate at +37°C overnight. 
DAY 10 
• Prepare the ELISPOT plate as in ex vivo protocol. Add 25 fll of cultured cells (corresponds to 2.5 x 
104 of the initially plated cells) and 25 fll ofRNI0 to duplicate wells of an ELlS POT plate containing 
50 fll of stimulants transferred from the stimulant plate. Pipette RN I 0 cultured and stimulated cells as 
two separate samples. Use the remaining cells to calculate the cell number after at day 10 and possibly 
for ICS. Incubate at +37°C for 18-20 h. 
DAY 11 
• Develop the ELI SPOT plate as described in ex vivo protocol. 
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